[
  {
    "nctId": "NCT04513704",
    "statement": "Male or female, aged 18-64 years (both inclusive) at time of signing informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Body mass index (BMI) between 20.0 and 29.9 kg/m^2 (both inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Glycated haemoglobin (HbA1c) greater than or equal to 6.5% (48 mmol/mol) at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Use of tobacco and nicotine products, defined as any of the below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Smoking more than 5 cigarettes or the equivalent per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Not willing to refrain from smoking and use of nicotine substitute products during the in-house period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (as declared by subject or reported in the medical records).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "Presence or history (as declared by subject or reported in the medical records) of pancreatitis (acute or chronic).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04513704",
    "statement": "History (as declared by subject or reported in the medical records) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "No previous history of treatment for type 2 diabetes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Diagnosis of :",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Impaired Glucose Tolerance (IGT) based on one oral glucose tolerance test (OGTT) and defined as a 2 hour post-challenge glucose (after a 75-g Oral Glucose Tolerance Test) > 140 mg/dL (7.8 mmol/L) but < 200 mg/dL (11.1 mmol/L), at the screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "And / or impaired fasting glucose (IFG) based on a Fasting Plasma Glucose (FPG) ³ 100 mg/dL (5.6 mmol/L) and < 126 mg/dL (7.0 mmol/L), at the screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Absence of effective contraceptive method for females of childbearing potential.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Presence of any clinically significant endocrine disease according to the Investigator.Note: euthyroid patients on replacement therapy will be included if the dosage of thyroxine is stable for at least 3 months prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the patient's safety or successful participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Presence or history of cancer within the past five years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Related to laboratory findings:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "positive test for hepatitis B surface antigen and/or hepatitis C antibody;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Positive urine pregnancy test in females of childbearing potential ;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Thyroid-stimulating hormone (TSH) and free T4 outside central laboratory normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Related to previous or concomitant medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "Within 3 months prior to screening visit and/or during the screening period:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "anti-obesity drugs (e.g., sibutramine, orlistat, herbal preparations, etc),",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00325650",
    "statement": "systemic long-acting corticosteroids; prolonged use (more than 10 days) of systemic corticosteroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Subjects have diagnosed with type 2 diabetes according to the Guidelines for prevention and treatment of type 2 diabetes in China (2020 Edition), T2DM was diagnosed at least 8 weeks before screening;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Aged 18 to 75 years (inclusive), no gender limitation;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Body Mass Index (BMI): 18.5≤BMI≤40;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Received stable dose of metformin hydrochloride monotherapy for ≥8 weeks before screening and metformin dose ≥1500 mg/ day ;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "HbA1c must meet the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Screening: 7.5% ≤ HbA1c ≤ 11.0% (Local laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Baseline: 7.0% ≤ HbA1c ≤ 10.5% (Central laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Subjects of childbearing potential must use reliable methods of contraception throughout the study period and at least 3 months after the last dose to avoid pregnancy in female subjects or pregnancy in the male subject's partner;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Willing and able to accurately use home glucose meter for self-glucose monitoring;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Be able to understand and follow the trial procedure, voluntarily participate in the trial and sign the informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Type 1 diabetes;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Body weight change more than 5% within 1 month prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Received any of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Prior discontinuation of DPP-4 inhibitors or GLP-1 receptor agonists for efficacy, tolerability, and safety reasons;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Systemic glucocorticoid and growth hormone,or other drugs affecting glucose metabolism have been used within 8 weeks before screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "History of ≥2 episodes of grade 3 hypoglycemia within 6 months prior to screening, or grade 3 hypoglycemia between screening to randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Acute complications of diabetes, such as diabetic ketoacidosis and hyperglycemic hyperosmolar status, occurred ≥1 time within 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Severe chronic complications of diabetes (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "History of acute or chronic pancreatitis prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Subjects with clinically significant gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., gastroparesis, inflammatory bowel disease, or intestinal obstruction) within 6 months prior to screening, or who have undergone gastrointestinal surgery that affects gastric emptying;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Any of the following cardiovascular events within 6 months prior to screening: decompensated cardiac insufficiency (NYHA class III or IV); history of unstable angina pectoris, myocardial infarction, coronary artery bypass grafting, or coronary stent implantation; or long QT syndrome or prolonged QTcF interval (QTcF: male >450 ms, female >470 ms) on 12-lead ECG; severe arrhythmias that are evaluated by the investigator to be inappropriate for participation in this clinical trial;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Hemorrhagic stroke or acute ischemic stroke disease occurred within 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "History of psychiatric diseases (such as depression, anxiety, etc.) during screening; or symptomatic gallbladder disease; or history of other diseases that may endanger the safety of the subject and that the investigator deems inappropriate for enrollment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Any type of malignant tumor treated or untreated within 5 years prior to screening (except for clinically cured basal cell carcinoma or carcinoma in situ);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Severe infection within 4 weeks prior to screening, or refractory urinary tract or genital infection within 6 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Having a significant blood system disease (e.g., aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or red blood cell instability (e.g., malaria) at screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Subjects with thyroid dysfunction that cannot be controlled by a stable drug dose at screening, or with clinically significant abnormalities in thyroid function examination results requiring drug treatment at screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Personal or family history of medullary thyroid cancer (MTC) or type 2 multiple endocrine tumor syndrome at screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Any of the indicators meet the following criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "i. Systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 100mmHg at screening or before randomization;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "ii. Laboratory tests show any of the following abnormalities:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "FPG≥13.9 mmol/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "ALT or AST≥2.5×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Total bilirubin (TBiL) ≥2.0×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Triglyceride >5.7 mmol/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "eGFR<45 mL/(min*1.73 m^2);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Serum amylase and/or lipase ≥3×ULN;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Hemoglobin <100 g/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Calcitonin≥50 ng/L(pg/mL);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "iii. Serological examination:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Human immunodeficiency virus antibody or treponema pallidum antibody is positive;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Hepatitis C antibody is positive, and HCV RNA was higher than the lower limit of the detection reference range;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Hepatitis B surface antigen is positive, and the quantitative detection result of HBV DNA was higher than the lower limit of the detection reference range;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Known allergy to the test drug, Dulaglutide, Empagliflozin, or related excipients;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Subjects who have lost more than 400 mL blood due to blood donation or other reasons within 3 months prior to screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Average alcohol intake more than 21 units of alcohol (male)/14 units of alcohol (female) per week within the 3 months prior to screening (1 unit ≈360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Subject participated in any drug or medical device clinical study within 3 months prior to screening (except for screening failure);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Pregnant or lactating female;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06235086",
    "statement": "Not suitable for this study in the investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Adults (18 to 75 years old) who are diagnosed with essential hypertension and type 2 diabetes mellitus with or without hypercholesterolemia (defined as taking statin therapy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Both hypertension and diabetes are suboptimally controlled at Screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "SBP is ≥ 140 mm Hg (and his/her BP goal is < 140/90 mm Hg).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "A1C is ≥ 7% and ≤ 11% at Screening (A1C is above goal by ≥ 0.5%).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "On a stable anti-hypertensive regimen (on current regimen for at least 30 days) with at least 2 anti-hypertensive medications",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Ability to manage the subject during the 12-week study with anti-hypertensive medication(s) and dose forms (or same drug classes and comparable doses for Usual Care subjects) used within the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Currently on metformin and/or glipizide for diabetes for at least the past 60 days prior to Screening. Subjects can be managed on other noninsulin diabetes medicines (including sulfonylureas other than glipizide) during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Subjects must have a Proteus test pill (IS used to test that the Proteus Patch is correctly placed on the body and paired with the mobile device) detected as part of onboarding on the Proteus device (during the Proteus Onboarding Visit).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "In the Investigator's opinion inadequate medication adherence is a potential factor in the subject's uncontrolled hypertension or diabetes.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "BMI > 40 kg/m2 as subjects may be more likely to have secondary reasons for out of control blood pressure (BP) and/or diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "History of skin sensitivity to adhesive medical tape or metals for subjects in the Intervention Arms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "History of acute or chronic dermatitis for subjects in the Intervention Arms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Any condition that in the investigator's opinion could preclude safe participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Secondary cause for hypertension (eg, renal impairment or renal artery stenosis) or uncontrolled diabetes (eg, corticosteroid use).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Mean SBP ≥ 180 mm Hg and/or DBP ≥ 110 mm Hg, if associated with evidence of hypertensive emergency..",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02827630",
    "statement": "Current or recent (within past year) treatment with insulin or other injectables for diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Provision of signed and dated, written informed consent prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Healthy male and female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of non-childbearing potential, confirmed at the Screening Visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Have a BMI between:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Part 1: 18 to 32 kg/m2 inclusive,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Part 2 and Part 3: 18 to 32 kg/m2 inclusive,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "and weigh at least 50 kg (males and females).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Provision of signed, written, and dated informed consent for optional genetic/biomarker research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "For the healthy Japanese cohort (Part 2): healthy subjects are to be Japanese (eg, natives of Japan or Japanese Americans), defined as having both parents and 4 grandparents who are Japanese.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "For the healthy Chinese cohort (Part 3): healthy male and female (of non-childbearing potential) healthy Chinese subjects for whom both parents and all grandparents are Chinese and not lived outside of China for more than 10 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History of any clinically important disease or disorder which may either put the healthy subject at risk because of participation in the study,or influence the results or the healthy subject's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Presence of any retinal (including intraretinal) abnormality detected by ophthalmological examination including indirect ophthalmoscopy, fundoscopy or OCT.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Presence of any factors that predispose to retinal detachment including lattice degeneration, retinal hole, or high myopia (-10 diopters or higher) found on ophthalmological examination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History of retinal detachment in either eye.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History of treated or untreated retinal holes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any clinically important abnormalities across the ophthalmological examinations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any laboratory values with the following deviations:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Alanine aminotransferase > ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Aspartate aminotransferase > ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "eGFR < 90 mL/minute/1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology Collaboration formula)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "White blood cell count < LLN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Hemoglobin < LLN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any clinically important abnormalities in clinical chemistry, hematology or urinalysis results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Systolic BP < 90 mmHg or > 140 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Diastolic BP < 50 mmHg or > 90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Heart rate < 45 or > 85 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG that may interfere with the interpretation of QTc interval changes, including abnormal ST and T-wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Known or suspected history of drug abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Current smokers or those who have smoked or used nicotine products within the previous 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History of alcohol abuse or excessive intake of alcohol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Positive screen for drugs of abuse or cotinine at screening or admission to the Clinical Unit or positive screen for alcohol on admission to the Clinical Unit prior to the first administration of the IMP.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to GLP-1 RA.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Any condition that would have interfered with the evaluation of the IMP or interpretation of subject safety or study results.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Lifetime history of schizophrenia or other psychosis or bipolar disorder or suicide attempts, major depressive disorder, or self-reported suicidal ideation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Healthy subjects with a history of MTC, multiple endocrine neoplasia syndrome type 2, or healthy subjects with a screening/baseline serum calcitonin ≥ 50 pg/mL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "History of gastrointestinal abnormality that could affect gastrointestinal motility.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Excessive intake of caffeine containing drinks or food.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Has received another new chemical entity within 30 days or 5 half-lives of the first administration of IMP in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Previous bone marrow transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05694741",
    "statement": "Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Male or female.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Age 18-75 years (both inclusive) at the time of signing the informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Body mass index between 18.0 and 38.0 kilogram per meter^2 (kg/m^2) (both inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Glycated hemoglobin (HbA1c) less than or equal to (<=) 9 percent (75 millimoles per mole [mmol/mol]) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Treated with basal insulin with or without any of the following anti-diabetic drugs/regimens with stable doses >= 90 days prior to the day of screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Metformin,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Dipeptidyl peptidase 4 (DPP-4) inhibitors,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Oral combination products (for the allowed individual oral antidiabetic drugs), Injectable and oral glucagon-like peptide 1 (GLP-1) Receptor Agonists.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Physically active >= 300 metabolic equivalent of task (MET) minutes/week as determined by an International Physical Activity Questionnaire (IPAQ) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Mass-specific oxygen volume (VO2) peak greater than (>) 25 milliliters per kilogram per minute (mL/kg/min) as determined by cardiopulmonary testing (CPX) test at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Known or suspected hypersensitivity to study intervention(s) or related products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06288412",
    "statement": "Presence or history of cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischaemic attack, stroke, cardiac decompensation, clinically significant arrhythmias or clinically significant conduction disorders within 180 days prior to the day of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Diagnosed with type 2 diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Men and women (non-pregnant and using a medically approved birth-control method) aged at least 18 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "T2D patients treated with stable metformin monotherapy for at least 8 weeks prior to screening. Metformin dose should be ≥ 1500 mg/day (or individual maximally tolerated dose), but not more than the maximum dose specified in the label",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "HbA1c ≥ 7.5% and ≤ 11.0% at screening or within 4 weeks prior to screening (by local laboratory) and HbA1c ≥ 7.0% and ≤ 11.0% at pre-randomization visit (by central laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "FPG ≤ 13.3 mmol/L (≤ 240 mg/dL) at pre-randomization visit (by central laboratory)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Able and willing to provide written informed consent and to comply with the study protocol",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Women who are pregnant, intending to become pregnant during the study period, lactating females, or women of child-bearing potential not using highly effective, medically approved birth control methods.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Diagnosis or history of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Type 1 diabetes mellitus, diabetes resulting from pancreatic injury or secondary forms of diabetes, eg, acromegaly or Cushing's syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Previous treatment with any dipeptidyl peptidase-4 (DPP4) inhibitor or GLP-1 receptor agonists within the past one year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "History of hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to dipeptidyl peptidase-4 inhibitor (DPP4) or Acarbose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02243176",
    "statement": "Treatment with any anti-diabetic medication for more than 7 consecutive days other than metformin in the last 8 weeks prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Diagnosed with type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have suboptimal glycemic control as evidenced by an HbA1c measurement at study start 7.1% and 11.0%, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have a body mass index (BMI) ≤45 kg/m^2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have been treated with lifestyle modification (diet and exercise) and with one of the following single oral antidiabetic agents (OADs) or combinations of OADs administered at maximum tolerated dose:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "metformin plus an SU",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "metformin plus pioglitazone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have any contraindication, allergy, or hypersensitivity for the study drug (exenatide once weekly or liraglutide), exenatide twice daily, the OAD(s) being used, or the excipients contained in these agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "If taking metformin and have a contraindication to metformin use",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have been treated within 8 weeks of study start with systemic glucocorticoid therapy by oral, intravenous, intra-articular, or intramuscular route",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have been treated with drugs that promote weight loss (e.g., Xenical® [orlistat], Meridia® [sibutramine], Acomplia® [rimonabant], Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3 months of study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have taken any of the following excluded medications for more than 1 week within the 3 months prior to study start, or have taken any of the following excluded medications within 1 month prior to study start:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Alpha-glucosidase inhibitors (e.g., Glyser® [miglitol] or Precose® [acarbose])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Meglitinides (e.g., Prandin® [repaglinide] or Starlix® [nateglinide])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Avandia® (rosiglitazone)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Dipeptidyl peptidase (DPP)-4 inhibitors (e.g., Januvia™ [sitagliptin], Galvus® [vildagliptin], Onglyza™ [saxagliptin])",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Symlin® (pramlintide acetate)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have donated blood within 30 days prior to study start or have had a blood transfusion or severe blood loss within 3 months prior to study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have at any time, including a clinical trial, taken exenatide once weekly, exenatide twice daily, liraglutide, or any other GLP-1 receptor agonist or GLP-1 analog",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Are currently enrolled in, or discontinued within the last 3 months or longer if required by local guidelines, from a clinical trial involving use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "Have previously been screen-failed from this study for any reason",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01029886",
    "statement": "If a subject discontinues metformin, sulfonylurea, or pioglitazone prior to screening, the subject can be included if they discontinued the medication (whether alone or as component of combined medication) according to a specific schedule.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Healthy male subjects at age between 20 and 45 at the screening test",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects with a body weight of 55kg or more but less than 90kg and a Body Mass Index (BMI) of between 18.0 or more but less than 27.0",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "BMI (kg/m2) = Weight (kg) / {Height (m)}2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who show the blood glucose level within the range of 70-125 mg/dL at the fasting plasma glucose (FPG) test conducted at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who fully understand this clinical trial after hearing a detailed explanation about it, make a decision to participate in it by his/her own free will, and sign an informed consent form to comply with the precautions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have a present condition or past history of any disease involving liver, kidney, nervous system, immune system, respiratory system, or endocrine system, hematologic and oncologic disease, cardiovascular disease, or psychiatric disorder (mood disorder, obsessive-compulsive disorder, etc.) (including subjects carrying hepatitis virus in case of liver disease)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects with a past history of a gastrointestinal system disease (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or a gastrointestinal system surgery (however, subjects with a history of appendectomy or hernioplasty are not excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects with a medical history of allergic reaction to drugs (aspirin, antibiotics, etc.) or clinically significant hypersensitivity reaction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who show one of the following results at screening test:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "QTc > 450 ms in ECG or clinically significant abnormal rhythm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "In the vital signs measured in sitting position after a rest for 3 minutes or longer, subjects who showed a systolic blood pressure of ≤ 100 mmHg or ≥ 150 mmHg, or a diastolic blood pressure of ≤ 60 mmHg or ≥ 95 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have a past history of drug abuse or have shown a positive reaction to drugs that are used in abusive manner or cotinine at a urine drug screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have taken any ethical drug or an herbal medication within 2 weeks before the date of first administration or have taken any over-the-counter (OTC) drug or vitamin preparation within 1 week (however, they can be included as subjects if considered appropriate at the investigator's discretion judgment)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subject who have already participated in other clinical trials within 2 months before the date of first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subject who have had whole blood donation within 2 months or component blood donation within 1 month before the date of first drug administration, or transfusion in 1 month before the date of first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Subjects who have been drinking alcohol continuously (more than 21 units/week, 1 unit = 10 g of pure alcohol) or can't refrain from drinking alcohol during the clinical trial period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "Smokers (however, if the subject stopped smoking more than 3 months before the date of the first drug administration, he/she can be selected as a subject)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03310749",
    "statement": "12) Subjects who have had grapefruit/ any food containing caffeine within 3 days before the date of the first drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "A patient must meet all of the following criteria to be in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "A patient will not be eligible if any of the following criteria apply:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Age between 18 to 65 years inclusive at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Diagnosis of T2D:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "For Part I:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Treated with any diet and exercise, with or without metformin (stable for ≥ 2 months).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "HbA1c ≥ 7.0% and ≤ 10.0% if on diet and exercise alone, or ≥6.5 % and ≤ 9.0% if on metformin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "For Part II: • Stable on metformin for ≥ 2 months with HbA1c ≥ 7.0% and ≤ 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Satisfies one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Females not of childbearing potential: non-pregnant and non-lactating; surgically sterile or postmenopausal for 2 years or at least 1 year with a follicle stimulating hormone assessment (FSH) greater than or equal to 40 IU/L; OR",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Males: surgically sterile, abstinent, or patient or partner is utilizing an acceptable contraceptive method during and 3 months after the last study dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "On a stable diet with body mass index (BMI): 25 to 40 kg/m2 inclusive at Screening with weight stable (± 4 kg) for > 6 weeks prior to Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Use of prescription medications other than allowed medications within 30 days of planned admission to the clinic. Allowed medications include metformin, anti-hypertensives, lipid-lowering medications, thyroid replacement therapy, low-dose aspirin (81 mg/day), proton pump inhibitors and anti-depressants. Prescribed doses of these medications must have been stable for 2 months at the time of first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Clinically significant abnormalities in physical examination or vital signs at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Clinically significant electrocardiogram (ECG) abnormalities as assessed by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Clinically significant laboratory result as assessed by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "The patient has a history of clinically significant medical disease including significant allergies (except for untreated, asymptomatic seasonal allergies at the time of dosing), or hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological disease, other than T2D, hypertension, dyslipidemia, hypothyroidism or depression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "History or presence of malignancy within the past 5 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "History of Type 1 diabetes or clinically significant cardiovascular disease (including a history of unstable angina, acute myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention, or New York Heart Association Class III or IV congestive heart failure within 6 months prior to screening) or clinically significant renal disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "History of alcohol or substance abuse or eating disorder within 2 years, OR regular use of alcohol within 6 months (>14 units of alcohol per week; 1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01511900",
    "statement": "Use of any investigational drug or participation in any investigational study within 30 days prior to screening or 5 half-lives of the study agent, whichever is longer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Is female and has not experienced menses for at least 5 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a body mass index greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and wash-out periods.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis [fasted for at least 8 hours]) within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator or sponsor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a fasting triglyceride level greater than 500 mg/dL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a hemoglobinopathy causing anemia or interfering with glycosylated hemoglobin assays.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has an alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease or jaundice.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has Vitamin D (25-OH-D) less than 20 ng/mL.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has any of the following disorders:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Rheumatoid Arthritis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, autoimmune, or renal or other disease known to affect bone metabolism.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "A personal history of kidney stones.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a clinical history after age 45 of wrist, hip, or leg fractures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has signs and/or symptoms of heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Is currently participating in another investigational study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has a history of breast cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Is taking or has ever taken pioglitazone or other Thiazolidinediones.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00708175",
    "statement": "Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Have T2DM (per World Health Organization [WHO] Classification of Diabetes) not treated with insulin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Have had diabetes for at least 1 year.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Have been receiving at least 2 oral antihyperglycemic medications (OAMs) for at least 3 months prior to the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Have hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to central lab at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Have body mass index (BMI) ≤40 kilogram/square meter (kg/m^2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "This inclusion criterion applies to females of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopausal) only: are not breastfeeding, test negative for a serum pregnancy test, intend not to become pregnant during study or willing to have a reliable method of birth control.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Insulin therapy: have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks. Insulin use of any duration during pregnancy is not considered an exclusion criterion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Concomitant medications: rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1) receptor agonist (for example, exenatide, exenatide once weekly, or liraglutide) used concurrently or within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Local OAM restrictions: for participants on OAMs, restrictions for cardiac, renal, hepatic diseases and maximum dose, local product regulations must apply.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Weight loss medications: are currently taking, or have taken within the 3 months preceding screening, prescription or over-the-counter medications to promote weight loss.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Severe hypoglycemia history: have had any episodes of severe hypoglycemia within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar nonketotic coma (HHNKC): have had 1 or more episodes of DKA or hyperosmolar state/coma in the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Cardiovascular: have cardiac disease with functional status that is New York Heart Association Class III or IV (per New York Heart Association [NYHA] Cardiac Disease Classification).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Renal: have a history of renal transplantation, or are currently receiving renal dialysis or have serum creatinine ≥2 milligram/deciliter (mg/dL) (177 micromole/liter [mol/L]).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Hepatic: have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic fatty liver disease [NAFLD]), acute or chronic hepatitis, non-alcoholic steatohepatitis (NASH), or elevated liver enzyme measurements.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Lipid-lowering medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Are using niacin preparations as a lipid-lowering medication or bile acid sequestrants within 90 days prior to screening; or,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02106364",
    "statement": "Are using lipid-lowering medication at a dose that has not been stable for ≥90 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have inadequate overall glycemic control (hemoglobin A1c greater than or equal to 7.0% and less than or equal to 12.0%) at or within 4 weeks prior to Visit 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have used:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "single or multiple OAMs for at least 3 months immediately prior to entering the study, including metformin, sulfonylurea, meglitinides (repaglinide, nateglinide), or alpha glucosidase inhibitors (acarbose, miglitol); or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "insulin (once or twice daily) for at least 3 months immediately prior to entering the study; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "a combination of the above.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Are greater than or equal to 21 and less than 80 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "As determined by the investigator, are capable and willing to:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "comply with their prescribed diet and medication regimen,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "perform self blood glucose monitoring,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "use the patient diary as required for this protocol,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "participate in two 24 hour inpatient assessments",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have used a thiazolidinedione (pioglitazone or rosiglitazone) during the 3 months prior to entry into the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Are currently treated with a meglitinide without sulfonylurea",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have a known allergy or intolerance to insulin lispro mix 75/25, insulin glargine, or metformin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have plasma creatinine greater than or equal to 1.5 mg/dL (for males) or greater than or equal to 1.4 mg/dL (for females) for patients who will be treated with metformin or; greater than 2 mg/dL for patients treated with other OAMs, as determined by a local laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00551538",
    "statement": "Have received chronic (lasting longer than 2 weeks), systemic glucocorticoid therapy (excluding topical and inhaled preparations) within 4 weeks immediately prior to Visit 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have type 2 diabetes mellitus (T2DM).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to screening, with or without basal insulin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "If currently on basal insulin, must be taking LANTUS® QD or NPH or insulin detemir either QD or twice a day for at least 90 days prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have an HbA1c ≥7.0% and ≤11.0% if insulin naïve; if previously on basal insulin, then HbA1c ≤11.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Body mass index (BMI) ≤45 kilograms per meter squared (kg/m^2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "As determined by the investigator, are capable and willing to do the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "perform self monitored blood glucose (SMBG)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "complete participant diaries as instructed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "are receptive to diabetes education",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "comply with required study treatment and study visits",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have been on LANTUS® more than once daily within the previous 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have used any other insulin except the entry insulin [LANTUS®, insulin detemir, or NPH] including commercial (includes any premixed insulins) and investigational insulins within the previous 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have been exposed to a biosimilar insulin glargine within the previous 90 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have participated in a LY2963016 study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have taken basal plus mealtime insulin (basal bolus therapy) within the last year for greater than 4 continuous weeks.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have used pramlintide within the previous 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have excessive insulin resistance at study entry (total insulin dose ≥1.5 units/kg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have more than 1 episode of severe hypoglycemia within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have known hypersensitivity or allergy to LANTUS® or its excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy or have received such therapy within 4 weeks immediately preceding screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have obvious signs or symptoms, or laboratory evidence, of liver disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have one of the following concomitant diseases: significant cardiac (e.g., congestive heart failure Class III or IV) or gastrointestinal disease (e.g., significant gastroparesis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have a history of renal transplantation or are currently receiving renal dialysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have a serum creatinine greater than 2.0 milligrams/deciliter (177 micromoles/liter).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Participants with active cancer or personal history of cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have a history or diagnosis of Human Immunodeficiency Virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Have any other condition (including known drug or alcohol abuse or psychiatric disorder including dementia) that precludes the participant from following and completing the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Are pregnant or intend to become pregnant during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Women who are breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02302716",
    "statement": "Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device other than LY2963016, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have, within the last 4 years, been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have HbA1c ≥7% to ≤9.5% as determined by the central laboratory.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have been on a stable treatment of metformin only at least 90 days preceding baseline",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "with the minimum effective dose of ≥1500 mg/day, but not higher than the maximum approved dose per country-specific label, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "<1500 mg/day in case of intolerance of full therapeutic dose.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have a history of chronic or acute pancreatitis any time prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have a history of",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "proliferative diabetic retinopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "diabetic macular edema, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "no proliferative diabetic retinopathy requiring immediate or urgent treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Are at high risk for cardiovascular disease (CVD) in the investigator's opinion or have a history of any of these CV conditions prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "percutaneous coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "carotid stenting or surgical revascularization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "nontraumatic amputation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "peripheral vascular procedure (e.g., stenting or surgical revascularization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "cerebrovascular accident (stroke), or congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have within 90 days prior to screening received treatment with medications intended to promote weight loss. This includes prescribed, over the counter, or alternative remedies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by chronic kidney disease-epidemiology equation as determined by central laboratory at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Have been treated with any injectable glucagon-like peptide-1 (GLP-1) receptor agonists and insulin prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05433584",
    "statement": "Exception: use of insulin for gestational diabetes or short-term use (<14 days) for acute conditions such as acute illness, hospitalization, or elective surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Male and female participants aged >= 18 years at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Provision of signed and dated informed consent form (ICF) prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Body mass index between 25 kg/m^2 and 40 kg/m^2 (inclusive) at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Hemoglobin A1c range between 7.0% and 10.0% (inclusive) at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Diagnosed with T2DM and treated with of metformin monotherapy (MTD > 1 g) at least 8 weeks prior to screening or treated with stable, oral doses of dapagliflozin 10 mg and metformin (MTD > 1 g) for at least 3 months prior screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Participants prescribed oral dual therapy with sulphonylurea, glitinide, or dipeptidyl peptidase-4 inhibitor (in addition to metformin) may be eligible to enter the study following a washout period of these medications totaling at least 28 days before initial screening evaluations have been completed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Participants treated with stable doses of metformin (MTD > 1 g) with canagliflozin (maximum dose of 300 mg/day), or metformin (MTD > 1 g) with empaglifozin (maximum dose of 25mg/day) for at least 3 months prior to screening may be eligible to enter the study after switching to dapagliflozin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Female participants of childbearing potential must have a negative pregnancy test at screening and randomization and must not be lactating.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions through to the end of the study. It is strongly recommended for the male partner of a female participant to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "History of, or any existing condition that in the opinion of the investigator would interfere with evaluation of the investigational product, put the participant at risk, influence the participant's ability to participate, or affect the interpretation of the results of the study and/or any participant unable or unwilling to follow study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Any participant who has received another investigational product not included in the protocol as part of a clinical trial or a glucagon-like peptide-1 (GLP-1) analogue or sodium-glucose cotransporter-2 (SGLT2)-containing preparation (excluding dapagliflozin, canagliflozin, empagliflozin) within the last 30 days or 5 half-lives of the drug (whichever is longest) at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Any participant who has received any of the following medications prior to the start of the screening period (Visit 1) or prior to the study start period (Visit 4):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent use of any medicinal products, or herbal or over-the-counter (OTC) preparations licensed for control of body weight or appetite at the time of screening (Visit 1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent or previous use of drugs approved for weight loss (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within the last 30 days or 5 half-lives of the drug (whichever is longest) at the time of screening (Visit 1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent use of aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily and within the last 72 hours prior to the start of the study (Visit 4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent use of paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg and within the last 72 hours prior to the start of the study (Visit 4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent use of ascorbic acid (vitamin C) supplements at a total daily dose greater than 1000 mg and within the last 72 hours prior to the start of the study (Visit 4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent use of opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying and within the last 72 hours prior to the start of the study (Visit 4)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Concurrent participation in another study of any kind and repeat randomization in this study is prohibited.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Severe allergy/hypersensitivity to any of the proposed study treatments or excipients.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Diagnosis of type 1 diabetes mellitus, maturity-onset diabetes of the young, or latent autoimmune diabetes of adulthood or presence of anti-glutamic acid decarboxylase, anti-islet cell, or anti-insulin antibodies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Symptoms of acutely decompensate blood glucose control (eg, thirst, polyuria, weight loss) at screening or randomization, a history of diabetes ketoacidosis (DKA), or hyperosmolar nonketotic coma or treatment with daily subcutaneous insulin within 90 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Fasting hyperglycemia (> 250 mg/dL/ > 13.9 mmol/L) prior to randomization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "C-peptide level < lower limit of normal (LLN).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "History of acute or chronic pancreatitis or pancreatectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Hypertriglyceridemia (> 400 mg/dL) at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Significant inflammatory bowel disease, gastroparesis, or other severe disease or surgery affecting the upper gastrointestinal (GI) tract (including weight-reducing surgery and procedures) which may affect gastric emptying or could affect the interpretation of safety and tolerability data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Significant hepatic disease (except for nonalcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Aspartate transaminase (AST) >= 3 × upper limit of normal (ULN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Alanine transaminase (ALT) >= 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Total bilirubin (TBL) >= 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Impaired renal function defined as estimated glomerular filtration rate (eGFR) <= 60 mL/minute/1.73m^2 at screening (eGFR according to Modification of Diet in Renal Disease [MDRD] using the isotope dilution mass spectrometry-traceable MDRD Study Equation (SI units).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Use of loop diuretics within 1 month prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Poorly controlled hypertension as defined below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Systolic blood pressure (BP) > 160 mm Hg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Diastolic BP or >= 100 mm Hg After 10 minutes of supine rest and confirmed by repeated measurement at screening (Visit 1 for all participants).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Severe congestive heart failure (New York Heart Association Class III and IV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration < 11.5 g/dL [115 g/L] for males and < 10.5 g/dL [105 g/L] for females) at screening or any other condition known to interfere with interpretation of HbA1c measurement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Any positive results for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Recent viral infection or illness requiring the use of antibiotics in the month prior to screening (Visit 1) for participants on dual therapy or prior to run-in period (Visit 2) for participants on monotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "History of recurrent (at least 2) urinary tract and/or genital tract infections (including mycotic infections such as thrush) within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Substance dependence likely to impact participant safety or compliance with study procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03444584",
    "statement": "Involvement of any AstraZeneca, MedImmune, contract research organization, or study site employees and their close relatives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "American Diabetes Association (ADA) diagnostic criteria for Type 2 Diabetes (T2D)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "HbA1c >7.0% and ≤ 10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Current T2D duration > 3 months at Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "T2D and other diseases must be stable. Stable disease is defined as disease which did not require a change in medication or dosing level on 4 or more consecutive days or 7 days in total within 28 days prior to Day 0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Age ≥ 18 and ≤ 70 at Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "BMI ≥ 23 and ≤ 40 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "For female patients of child-bearing age, a negative serum pregnancy test. For patients with reproductive potential, a willingness to utilize adequate contraception (oral contraception plus a mechanical barrier) and not become pregnant (or have their partner[s] become pregnant) during the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Agrees not to change diet and exercise regimen during the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Signed and dated Ethics Committee (EC) approved informed consent before any protocol-specific screening procedures are performed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Use of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Daily use of steroids or aspirin ≥ 700 mg per week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Immunosuppressive treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Thiazolidinediones",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Concomitant treatment with any other therapeutic antibody, or treatment with any biologic agent that blocks the IL-1 or TNFα signaling pathway",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Change in medication for diabetes within 28 days prior to Day 0, defined as a change in dosing level on 4 or more consecutive days or 7 days in total",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Hemoglobin <10.0 g/dL, WBC <3.0 x 103/mm3 , platelet count <125 x 103/mm3, creatinine > 1.5mg/dL, AST/ALT >2 x ULN, alkaline phosphatase >2 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Abnormal, untreated T3, T4, thyroglobulin, or TSH levels or history of Grave's disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Known HIV antibody, hepatitis B surface antigen and/or hepatitis C antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, nonmetastatic squamous or basal cell carcinoma of the skin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Infectious disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "CRP >30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "History of recurrent infection or predisposition to infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Active leg or foot ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Immunodeficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Female patients who are pregnant, planning to become pregnant during the course of the study, or breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Receipt of a live (attenuated) vaccine within 3 months prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Major surgery within 28 days prior to Day 0",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01427699",
    "statement": "Participation in an investigational drug or device trial within 30 days prior to Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Healthy adult older than 19 years and less than 45 years at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "BMI 18.5~29.9 kg/m2 and body weight more than 50kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have consented to the use of appropriate double- pregnancy contraceptive methods up to one months after the last investigational product and not to provide sperm for men.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who sign on an informed consent form willingly.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have a clinically significant disease or medical history such as respiratory, hepatic, kidneys, blood, gastrointestinal, endocrine, immune system, skin, nervous and mental disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have acute disease within 28 days prior to the first administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have history that may affect the ADME.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have medical history or medical abuse history of hypersensitivity from SGLT inhibitors or Biguanides including Metformin or other medications(Aspirin, Antibiotics etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have clinically significant chronic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose mal-absorption.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects whose laboratory test result are same as below;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "AST,ALT > UNL(Upper Normal Limit)x3",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Fasting glucose level out of 70-125mg/dl",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Creatinine clearance is lower than 80mL/min which is calcuated by Cockcroft-Gault formulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "QT>450msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Positive urine hCG(female).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects whoes blood pressure exceeds out of normal range as below at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "SBP : over 100mmHg, under 160mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "DBP : over 60mmHg, under 100mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have been found to be positive in serological tests(HBs antigen, HCV antibody and HIV antibody).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who took ETC(Ethical Drug), oriental medicine within 2 weeks prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who took OTC(Over-the-counter Drug, including korean galenical drug) within 10 days prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have allergic disease which has clinical significance(But, light allergic rhinitis and ligth allergic dermatitis which do not need medication is exceptional).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who can not eat standard meals provided by the institution.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who donated whole blood within 60 days, donated the blood components within 20 days prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who received blood transfusion within 30 days prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who were participated in the other clinical trial within 90 days prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who took medication for the induction and inhibition of metabolizing enzymes such as barbiturate drugs within 6months prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have had abnormal diets that can affect the ADME of the drug within 30 days prior to the first administration of investigational products. (Ingestion of grapefruit juice>1L/day or Caffein>5Cups/day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who have took regular alcohol(alcohol>30g/day) prior to the first administration of investigational products.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who smoked more than 10 cigarettes per day prior 3months to the first administration of investigational products or cannot discontinue smoking during the clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Subjects who is determined unsuitable to participate in this clinical trial by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04156685",
    "statement": "Lactating Women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Be able to give written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Have type 2 diabetes treated with diet and exercise alone or in combination with metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If treated with metformin, must have been on a stable dose of the drug for a minimum of 3 months with a stable A1c value",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If treated with diet and exercise alone, must have A1c value ≥6.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If treated with diet and exercise + metformin, must have a stable A1c between 7.0% and 8.5% for at least 3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "BMI >25 but <45",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If female, must meet all the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Not pregnant or breastfeeding",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control during the entire duration of the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Must be able to communicate with the investigator, and understand and comply with protocol requirements",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have received an antibiotic, antifungal, antiparasitic, or antiviral treatment within 30 days prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who plan to use antibiotic, antifungal, antiparasitic, or antiviral treatment during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects using a proton pump inhibitor must be on a consistent dose that will be maintained throughout the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Present use of probiotics/nutritional supplements. (Note: The use of replacement doses of Vitamin D, calcium supplements, and a single daily multi-vitamin tablet is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have participated in a structured weight-loss program within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have changed body weight ≥3% within the past month",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Excess alcohol consumption; with an alcoholic drink defined as 284 ml of beer, lager, stout , 100 ml of wine or 35.5 ml spirits",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Women: More than 11 standard drinks/week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Men: More than 17 standard drinks/week",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects who have received an experimental drug within 30 days prior to study entry",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Hospitalization for any reason within the 3 months prior to study entry (Same day surgery centre visits/procedures allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Active GI disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "History of any surgery on the gastrointestinal tract except appendectomy and cholecystectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Cystic fibrosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Significant renal Impairment defined as estimated Glomerular Filtration Rate <45 ml/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects receiving systemic corticosteroid therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects receiving Immunosuppression therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04047537",
    "statement": "Subjects with any condition that the investigator deems as a sound reason for disqualification from enrollment into the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Adults aged 30 to 65 years, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Males and females",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Diagnosis of type 2 diabetes mellitus prior to screening meeting the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Body mass index <45 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "HbA1c value of > 6.5 to <9.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "C-peptide ≥1.0 ng/mL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "On a stable dose of metformin for 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Ability to provide written informed consent and be willing to comply with scheduled visits, treatment plan, laboratory tests and other study procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of any of the following: type 1 diabetes mellitus, diabetic ketoacidosis, an episode of severe hypoglycemia (defined as a change in mental status requiring assistance) during the prior 30 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "FPG >260 mg/dL at time of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Current or chronic use (within past 12 weeks) of insulin, or insulin secretagogues including: sulfonylureas, GLP-1 analogs, DPP-4 inhibitors, meglitinides, α-glucosidase inhibitors, pioglitazone, or rosiglitazone",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Glomerular filtration rate (GFR) <60 as calculated using the Modified Diet in Renal Disease equation at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "ALT, AST or total bilirubin > 2 X ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Serum amylase concentration > 1.5XULN or serum lipase concentration >2XULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Positive test result for glutamic acid decarboxylase antibodies (GADA).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "The presence of a clinically significant abnormality on resting electrocardiogram (ECG)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Positive HIV, hepatitis B (HBsAg), or positive hepatitis C (HCV Ab) test at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of clinically significant renal, hepatic, cardiovascular, neurological, or gastrointestinal disease that could impact patient safety in the investigator's opinion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Serum triglycerides >500 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Presence or history of cancer within the past 5 years with the exception of adequately treated localized basal cell skin cancer or in situ uterine cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of weight loss > 5% in the 8 weeks prior to randomization or subject is on a weight loss program and is not in the maintenance phase",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Use of any weight loss medication within 8 weeks of randomization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Uncontrolled hypertension defined as blood pressure >160/100 mmHg, using an appropriately sized cuff, at rest",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History or evidence of multiple organ autoimmune disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of thyroid dysfunction other that hypothyroidism treated with stable dose of thyroid hormone and euthyroid at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History or presence of acute or chronic pancreatitis or symptomatic recurrent gallstones",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Has undergone surgery within 6 months of screening or plans to undergo surgery during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Use of parenterally administered proteins or antibodies within 12 weeks of screening. (Note: Influenza vaccine will be allowed.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Prior exposure to any investigational agent or participation in an investigational trial within 30 days prior to Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Blood loss or blood donation >500 ml in the 2 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Use of systemic long-acting corticosteroids within two months or prolonged use (more than one week) of other systemic corticosteroids or inhaled corticosteroids (if daily dosage is >1000 mcg equivalent beclomethasone) within 30 days prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "Drugs with the potential to affect (either increasing or decreasing) endogenous insulin secretion or insulin sensitivity including corticosteroids (as detailed above), β-adrenergic blockers, beta-adrenergic agonists, quinine, thiazide or thiazide-like diuretics, calcineurin inhibitors, niacin, anti-psychotic or antidepressant drugs, somatostatin analogs, growth hormone, weight-reducing drugs (e.g. orlistat, phentermine and topiramate extended-release, lorcaserin). Stable doses of agents commonly required by subjects with T2DM including angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, statins, fibrates, and aspirin (<100 mg daily) will be permitted at the discretion of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "A serious adverse reaction or hypersensitivity to any drug, unless reaction deemed irrelevant to the study by the investigator and sponsor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of alcohol abuse or drug abuse within the previous 12 months. No history of medical or recreational use of marijuana within previous 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "A history of smoking more than one-half a pack of cigarettes per day within last 12 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of stroke, transient ischemic attack or myocardial infarction within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01933256",
    "statement": "History of New York Heart Association Class II-IV heart failure prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with basal insulin and up to 3 of the following oral antihyperglycemic medication (OAM):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "dipeptidyl peptidase-4 (DPP-4) inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "sodium-glucose cotransporter (SGLT-2) inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "biguanides",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "alpha-glucosidase inhibitors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "sulfonlyureas",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "HbA1c value of 6.5% to 10%, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m2), inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Type 1 diabetes mellitus or latent autoimmune diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 m2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Active or untreated malignancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03736785",
    "statement": "Chronic (>14 days) systemic glucocorticoid therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Impaired Hepatic Function Participants:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Both Impaired Hepatic Function and Healthy Participants:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Healthy Participants:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Both Impaired Hepatic Function and Healthy Participants:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "discontinued at least 14 days prior to the study start and throughout the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "A diagnosis of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Chronic (> 6 months) hepatic insufficiency",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Score on the Child-Pugh Scale of 7 to 9 (moderate hepatic insufficiency)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Estimated creatinine clearance (CLCr) > 60 mL/min or glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m^2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "In general good health",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Continuous non-smokers or moderate smokers for at least 3 months prior to study start",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Body Mass Index ≤39 kg/m^2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Females of reproductive potential must have a negative pregnancy test and agree to use acceptable birth control method(s) or remain sexually inactive throughout study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Non-vasectomized male patients must agree to use acceptable birth control method(s) or abstain from sexual intercourse during the trial and for 3 months after the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "History or presence of alcoholism within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Presence of hepatitis B virus (HBV) or hepatitis virus C (HVC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "History or presence of drug abuse within the past 2 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "History or presence of human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "History or presence of significant cardiovascular, pulmonary, renal, hematologic, gastrointestinal (other than hepatic impairment), endocrine, immunologic, dermatologic, or neurological disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Use of any medication or substance (including prescription or over the counter, health supplements, natural or herbal supplements) which cannot be",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Has been on a special diet within 28 days prior to the study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Blood donation within 56 days or plasma donation within 7 days prior to study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Participation in another clinical trial within 28 days of study start",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01767688",
    "statement": "Women who are pregnant or nursing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Patient with stable type 2 diabetes mellitus or healthy subject",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Subject must have pre-dose estimated Glomerular filtration rate (GFR) values (Modification of diet in renal disease (MDRD) method) at screening of:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": ">90 (normal renal function)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "60-90 (mild renal impairment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "30-60 (moderate renal impairment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "15-30 (severe renal impairment)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "BMI between 25.0-40.0 kg/m2, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Fasted plasma glucose (FPG) <11.5 mmol/l (type 2 DM patients) or >5.6 mmol/l (Healthy volunteers)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Patients with Type 1 diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Pulse <40 or >90; SBP >160 mmHg; DBP > 100 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "T2DM patients who are not on a stable regimen for their current medication (1 month or 5 half lives, whichever is longer) to control their disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Healthy Volunteers: Any of the liver function tests above the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "T2DM: The liver function tests should be within the following ranges:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "AST/ALT: <2 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Bilirubin: <1.5 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Alk Phos: < 1.5 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Patients with renal impairment who have a history of a clinically significant illness (other than renal diseases and T2DM and associated clinical symptoms), medical condition, or laboratory abnormality within 3 months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Patients with renal impairment who have not been on a stable dose of concomitant medications for at least 2 weeks for at least 2 weeks (or 5 halflives, whichever is longer) and/or for whom dose changes are likely to occur during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "Patients with T2DM treated with a diet only",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "T2DM patients with recent evidence (e.g within the last 6 months) of severe hypoglycemia, for example plasma glucose < 3mmol/l (<55 mg/dl), help from others to resolve the hypo or requiring hospitalization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01302028",
    "statement": "T2DM patients with a Hemoglobin value < 9 g/dl (5.6 mmol/l)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Eighteen (18) years of age or older, of either sex, and of any race or skin type.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Willing and able to make all required study visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Willing to use an appropriate off-loading device to keep weight off of foot ulcers.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "An ulcer present on any part of the plantar surface of the neuropathic foot or hallux which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit using the ARANZ Silhouette imaging device). The target ulcer duration must be ≥ 6 weeks but not more than 52 weeks (12 months) as documented in the subject's history or by subject report of onset, and which requires debridement.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.70 and ≤ 1.20. If ABI > 1.2, perfusion at or near the site of the ulcer should be confirmed; the foot is warm to the touch and has palpable pulses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Separation of at least 5 cm (closest ulcer edge to other closest ulcer edge) if ≥ 2 ulcers are present as measured using the ARANZ Silhouette imaging device.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Diabetes mellitus (Type 1 or 2) requiring insulin or oral/injectable medications to control blood glucose levels.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Target ulcer is not infected based on clinical assessment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Contraindications or hypersensitivity to the use of clostridial collagenase or products containing silver.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Participation in another clinical trial within thirty (30) days of Visit 1, or planned participation overlapping with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Bleeding disorder that would preclude sharp debridement during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Active cellulitis of the target ulcer, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "A target ulcer which involves the underlying tissues of tendon, muscle, or bone.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Current treatment (at the time of the Screening Visit) with any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Systemic corticosteroids. If corticosteroid treatment was for ≥ 10 days, there must be a 1 week interval between discontinuation and screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Immunosuppressive agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Chemotherapeutic agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Antiviral agents",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Systemic antibiotic therapy (for any reason) or topical antibiotic treatment of the target ulcer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Treatment of target ulcer with bioactive therapies within 1 month of screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Platelet-derived growth factor (e.g., Regranex®)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Living skin equivalent (e.g., Apligraf®)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Dermal substitute (e.g., Dermagraft®, Integra®, Oasis®, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Amniotic membrane products (e.g., EpiFix®, Grafix®, etc.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Prior treatment of target ulcer for any length of time with clostridial collagenase ointment (SANTYL®).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Radiation therapy to the target lower extremity within 30 days prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Blood counts and blood chemistry values as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Alanine aminotransferase (ALT) > 3x upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Aspartate aminotransferase (AST) > 3x upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Gamma Glutamyl Transferase (GGT) > 2.5x upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Serum albumin < 2.0 g/dL • Pre-albumin levels of < 10 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Alkaline phosphatase > 500 U/L • Serum total bilirubin > 3.0 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Serum BUN > 75 mg/dL • Serum creatinine > 4.5 mg/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "HbA1c > 12% • Hemoglobin (Hgb) < 8.0 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "WBC < 2.0 x 109/L • Absolute neutrophil count < 1.0 x 109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02581488",
    "statement": "Platelet count < 50 x 109/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Outpatients who are able to visit the study site throughout the run-in period",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Aged 30 and 74 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Type II diabetes mellitus",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Patients with urinary albumin to creatinine ratios within the following ranges at 2 measuring points during the run-in period 1) the first-morning voided urine, iin the range of 100 to 300 mg/g Creatinine 2) < 100 mg/g Creatinine at either point of Visit 2 or 3, but in the range of 100 to 300 mg/g Creatinine at follow-up",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Serum creatinine level of < 1.5 mg/dL in male and < 1.3 mg/dL in female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Normotensive or hypertensive patients",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Patients taking AT1 antagonists or ACE inhibitors at screening, but are able to stop those drugs during the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Patients who are able to provide written informed consent in accordance with the Good Clinical Practice (GCP) and other relevant laws such as the Pharmaceutical Affairs Law",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Age of onset of type 2 diabetes is < 30 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Type I diabetes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Urinary albumin to creatinine ratio of > 300 mg/g Creatinine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "HbA1c 9%",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Seated SBP 180 mmHg or DBP 110 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Findings suggesting a renal disease other than diabetic nephropathy; such as post renal transplantation, history of non-diabetic renal disease, marked haematuria, complication of urinary tract infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Cardiovascular diseases:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Patients with unstable angina, myocardial infarction, CABG, PTCA within 6 months before",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "CHF with NYHA III-IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "TIA within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Stroke within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "AV block (grade II-III) or AF",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Serious arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Known or suspected secondary HT",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "History of angioedema during administration of ARB/ACE-i",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Hypersensitivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "History of sudden exacerbation of renal function due to ARB/ACE-i",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Markedly poor bile secretion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Hepatic dysfunction: SGPT (ALT) or SGOT (AST) 100 IU/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Serum potassium level < 3.5 mEq/L or 5.1 mEq/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Unable to discontinue ARB/ACE-i",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Require prolonged administration of any medications affecting blood pressure, except diuretics, or blockers, and CCB",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Untreated sodium depletion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Pre-menopausal females who meet any one of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Pregnant or possibly pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Breast-feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Hope to be pregnant during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Even when a patient is confirmed not to meet the above criteria at the start of the study, a female patient who has the potential to be pregnant during the study is to undergo pregnancy tests. If the result turns positive, the study medication should be discontinued.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Malignant tumour or other diseases requiring oral or injection immunosuppressants",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Non-compliance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "History of drug or alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Participated in other clinical studies within 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00153088",
    "statement": "Any other conditions investigators judged as ineligible",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Males or females aged 18 or older.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects diagnosed with type 2 diabetes mellitus (DM) according to the American Diabetes Association (ADA) criteria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for type 2 diabetes mellitus for at least 2 months prior to randomization and who agree to stay on stable doses of anti-diabetes agents during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects whose fasting blood glucose levels are reasonably stable for at least 2 months prior to randomization and during the 2-week screening period.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening and a fasting plasma glucose less than 310 mg/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who can give written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who are willing and able to monitor their blood glucose concentrations with a home glucose monitor (before breakfast and 2 hours after dinner).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Female subjects must be either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) at least 6 months before randomization, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Post-menopausal for at least 12 months prior to Screening, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "If of childbearing potential and sexually active, must agree to use adequate contraception from Screening to completion of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have any significant DM-related end-organ damages.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have any disease likely to limit life span and/or increase risks of interventions such as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Carotid B-mode ultrasound test results indicating clinically significant stenosis in the common carotid arteries requiring intervention by angioplasty or resection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Cancer treatment in the past 5 years, with the exception of cancers which have been cured, and carry a good prognosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Infectious disease: HIV positivity, active tuberculosis, or pneumonia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects with evidence of clinically significant cardiovascular or cerebrovascular disease, including (but not limited to):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Hospitalization for the treatment of heart disease in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "New York Heart Association Functional Class > 2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Left bundle branch block on ECG at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Third degree atrioventricular block on ECG at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Stroke or transient ischemic attack in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects with uncontrolled hypertension with average systolic blood pressure of ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg at Screening and Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects with pulse rate ≥ 95 beats per minute at Screening and Baseline.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have or had any of the following conditions related to gastrointestinal disease:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Chronic hepatitis or cirrhosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Episode of alcoholic hepatitis or pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Inflammatory bowel disease or irritable bowel syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Serum creatinine ≥ 1.5 mg/dL for males or ≥ 1.4 mg/dL for females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Hemoglobin ≤ 12 g/dL for males or ≤ 10 g/dL for females.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have chronic obstructive airway disease or asthma requiring daily inhaled corticosteroid therapy or home use oxygen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who have any of the following conditions or behaviors likely to affect the conduct of the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Weight loss of > 10% in the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Unable to walk without assisted device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Major psychiatric disorder which would impede conduct of the research.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Excessive alcohol intake (i.e., more than 2 drinks/day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Use of illicit drugs or drugs of abuse.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects who take any of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Psychoactive agents such as monoamine oxidase inhibitors and antidepressants (e.g., lithium, Prozac, Zoloft, Serzone, Paxil, Effexor).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Any insulin sensitizers (thiazolidinediones - TZDs) such as Avandia, Actos or Duvie, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Subjects with any other clinically significant and/or unexplained abnormalities that, in the opinion of the Investigator, could impact the subject's ability to fully participate in or complete the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03560271",
    "statement": "Female subjects who have a positive serum pregnancy test at Screening, plan a pregnancy during study period, or are breast feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Male.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Aged 18-55 years (both inclusive) at the time of signing informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Body mass index between 20.0 and 27.0 kilogram per meter square (kg/m^2)(both inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Glycated haemoglobin (HbA1c) greater than or equal to (>=) 6.5 percent (%) (48 millimoles per moles [mmol/mol]) at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Use of tobacco and nicotine products, defined as any of the below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Smoking more than 5 cigarettes or the equivalent per day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Not willing to refrain from smoking and use of nicotine substitute products during the inpatient periods.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "History of major surgical procedures involving the stomach potentially affecting absorption of trial products (example: subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Presence or history of pancreatitis (acute or chronic).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Any of the below laboratory safety parameters at screening outside the below laboratory range, see \"Log of laboratory ranges used for laboratory parameter exclusion criterion\" for specific values:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Alanine Aminotransferase (ALT) greater than (>) upper normal limit (UNL)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Aspartate aminotransferase (AST) > UNL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Bilirubin > UNL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Creatinine > UNL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "International normalized ratio (INR) > UNL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05521256",
    "statement": "Precence or history of hepatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "[Part 1 and Part 2] Subjects/Patients who meet the following criteria will be considered eligible to participate in Part 1 or Part 2 of the clinical study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "1. Subject voluntarily/Patient agrees to participate in this study and signs an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to performing any of the Screening Visit procedures.\n2. Subject/Patient is able to understand the nature of the clinical study.\n3. Subject/Patient is able to read and speak German.\n4. Subject/Patient is able to communicate satisfactorily with the Investigator and study team and follow the entire requirements of the clinical study.\n[Part 1] Subjects who meet the following criteria will be considered eligible to participate in Part 1 of the clinical study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "[Part 2] Patients who meet the following criteria will be considered eligible to participate in Part 2 of the clinical study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "[Part 1 and Part 2] Subjects/Patients who meet one or more of the following criteria will not be considered eligible to participate in Part 1 or Part 2 of the clinical study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Healthy male subjects aged 19 to 55 years at the time of Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject weighs at least 60 kg and has a body mass index (BMI)between 18.5 and 29.9 kg/m2, inclusive, at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who is healthy and judged to be eligible to participate in the study at the Screening test (based on medical history, physical examination, vital sign, 12 lead ECG, and laboratory test including serology test).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Male patients aged 18 to 70 years at the time of Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Patient with T2DM who is taking metformin monotherapy as their only anti hyperglycemic treatment. Metformin dose must be stable, defined as no change in the treatment, including dose, for at least 2 months prior to the screening visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a HbA1c level at Screening between 7.5% and 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a fasting plasma glucose level less than 13.3 mmol/L at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a fasting C-peptide concentration greater than or equal to 0.8 ng/mL at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "If patient takes any chronic medications, the dose of these medications must have been stable (no change in dose or drug) for at least 4 weeks prior to Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Is able and willing to monitor glucose with a home glucose monitor and consistently record his blood glucose concentrations.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Patient weighs at least 60 kg and has a BMI between 18.5 and 35 kg/m2, inclusive, at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject/Patient is an employee or a family member of the Sponsor or the involved CRO.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Vulnerable subject (i.e., persons under any administrative or legal supervision or persons kept in detention).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject/Patient who has a positive reverse transcription polymerase chain reaction (RT PCR) test for SARS-CoV-2 prior to randomisation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject/Patient who has clinical signs and symptoms consistent with SARS-CoV-2 infection; eg, fever, dry cough, dyspnea, sore throat, fatigue, or positive SARS-CoV-2 test result within 2 weeks prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject/patient who had a severe course of COVID-19 (extracorporeal membrane oxygenation, mechanically ventilated).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Recent (within previous 14 days) exposure to someone who has COVID-19 symptoms or positive test result.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who has currently acute disease with active symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "History of clinically significant hypersensitivity reaction to any drugs or additives.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subjects who have a history of any gastrointestinal disease (Crohn's disease, ulcerative colitis, acute or chronic pancreatitis) or gastrointestinal surgery (excluding simple appendectomy or herniotomy) which can affect the absorption of drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who has participated in a clinical trial or bioequivalence test and have been administered in a product within 60 days or within 5 halflives of the drug, whichever is longer before the first study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who have taken inducer or suppressor of metabolic enzymes such as barbiturates in 30 days before the first study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who have donated whole blood in 60 days or who have donated plasma in 20 days before the first study drug administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subjects who have had any prescribed medicine or herbal medicine or who have had non-prescription medicine or vitamins within 7 days or 5 half lives before the first study drug administration, whichever is longer, except for occasional intake of paracetamol. Subjects who have received a SARS-CoV-2 vaccination within 4 weeks prior to screening or plan to be vaccinated during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a history of drug abuse or a history of alcohol abuse within 2 years prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who do not agree to be sexually abstinent or to use a condom with spermicide when engaging in sexual activity and to not donate sperm from the first administration of study drug, during the study, and for 14 days following completion of the study (Section 5.4.4).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who is judged to be not eligible by the Investigator for any other reason.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a positive test result for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a total bilirubin > 1.5 × ULN at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has abnormal thyroid-stimulating hormone levels. [Part 1] Subjects who meet one or more of the following criteria will not be considered eligible to participate in Part 1 of the clinical study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Subject who has abnormal vital signs, confirmed by repeat measurement at screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "systolic blood pressure (SBP) outside 90 - 139 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "diastolic blood pressure (DBP) outside 50 - 89 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "pulse rate outside 50 - 90 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Abnormal 12-lead ECG, confirmed by repeat measurement, unless considered not clinically significant by Investigator. QTcF > 450 ms, QRS ≥ 120 ms, PR > 220 ms at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has an estimating glomerular filtration rate (eGFR) less than or equal to 80 mL/min using the chronic kidney disease epidemiology collaboration (CKD EPI) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "History of clinically significant gastrointestinal, renal, hepatic, neurologic, haematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, musculoskeletal, or cardiovascular disease or any other condition. [Part 2] Patients who meet one or more of the following criteria will not be considered eligible to participate in Part 2 of clinical study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has systolic blood pressure (BP) greater than 160 mm Hg or diastolic pressure greater than 100 mm Hg at Screening or baseline, confirmed by repeat measurement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has history of cancer. A history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a creatine phosphokinase level ≥ 5 × upper limit of normal (ULN) at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≥ 2 × ULN at Screening, confirmed by repeat measurement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has a haemoglobin level ≤ lower limit normal (LLN) for men of the local laboratory at Screening, confirmed by repeat measurement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "The subject has a serum triglyceride level ≥ 1.5 × ULN at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04982705",
    "statement": "Has an eGFR less than or equal to 60 mL/min using the CKD EPI at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Subject with a historical diagnosis of type 2 diabetes mellitus who is currently treated with diet and exercise only or one OAD",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "BMI ≥18 kg/m2 and <35 kg/m2 at Screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "HbA1c between 7.0% and 10.0%, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Fasting C-peptide ≥0.8 ng/mL (≥0.26 nmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Female subjects of childbearing potential must be practicing adequate contraception .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Able and willing to provide written informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Diagnosis of type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Uncorrected thyroid dysfunction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Previous use of insulin within one month prior to screening, or more than seven total days of insulin treatment within three months prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Clinically significantly cardiovascular and/or cerebrovascular disease including, but not limited to the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Previous history of stroke or transient ischemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Active, unstable coronary heart disease within the past six months before Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Documented myocardial infarction within one year before Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within one year before Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Unstable angina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Clinically significant arrhythmia or valvular heart disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Current heart failure NYHA class II to IV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Resting systolic pressure >160 mm Hg or diastolic pressure >95 mm Hg at Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "ECG criteria at Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Heart rate: <40 and >110 bpm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "PR interval: <120 and > 210 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "QRS interval: <70 and >120 msec",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "QTc interval (Bazett): >450 msec or >480 msec with bundle branch block",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Fasting triglyceride level >400 mg/dL at Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "AST or ALT >2xULN, ALP and bilirubin >1.5xULN (except known Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin <35% of total bilirubin)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "If female, is currently lactating, within 6 weeks post-partum, pregnant, or actively trying to become pregnant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Has significant renal disease as manifested by one or more of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Creatinine clearance at screening <60 mL/min (calculated by Cockcroft-Gault formula) at Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Known loss of a kidney either by surgical ablation, injury or disease level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "A hemoglobinopathy that may affect determination of HbA1c level",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "History of treated diabetic gastroparesis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "History of significant gastrointestinal surgery, including gastric bypass and banding, or surgeries thought to significantly affect upper gastrointestinal function",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Current ongoing symptomatic biliary disease or history of acute/chronic pancreatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Lipase and amylase at Screening > ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Severe diabetic neuropathy, preproliferative retinopathy or proliferative retinopathy, history of ketoacidosis or hyperosmolar coma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening. (A history of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Acute or chronic history of liver disease, positive hepatitis B surface antigen (HBsAg) or positive hepatitis C testing at Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Current and history of alcohol or substance abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Clinically significant anaemia or any other abnormal haematological profile that is considered by the investigator to be clinically significant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Prior use of a GLP-1 analog",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Known allergy to any formulation excipients, or Baker's yeast, or history of drug, or other allergy which, in the opinion of the responsible study physician, contradicts participation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "History of or family history of medullary carcinoma of the thyroid.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "History of or family history of multiple endocrine neoplasia type 2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01098461",
    "statement": "Receipt of any investigational drug within the 12 weeks before Screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Able to comprehend and willing to sign an informed consent form approved by the IRB before Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Adult volunteers between 19 and 50 years of age at Screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Body mass index (BMI) between 18.0 and 24.9. ☞ BMI (kg/m^2) = body weight (kg) / (height [m])^2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "In good health, determined by no clinically significant findings from medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory tests at Screening, or subjects who are deemed acceptable by the Investigator regardless of the test results.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Significant history or clinical manifestation of any hepatic, kidney, neurological, immune, respiratory, endocrine, hematological, neoplastic, or cardiovascular disease, or psychiatric disorder (e.g., mood disorder, obsessive-compulsive disorder).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "History of stomach or intestinal disorders (e.g., Chron's disease, ulcer) or surgeries - not including appendectomy, hemorrhoidectomy, or herniotomy - which may affect the safety or pharmacokinetic/pharmacodynamic evaluation of the investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Significant history or clinical manifestation of hypersensitivity to any drug including licorice or other drug (e.g., aspirin, antibiotics).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "One or more of the following laboratory test results at Screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "ANC < 1000",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "AST, ALT, GGT, total bilirubin > 1.5x upper limit normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Fasting glucose ≥ 126 mg/dL or HbA1c ≥ 6.5% despite two retests",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "eGFR < 60 (CKD-EPI).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Systolic blood pressure < 90 mmHg or > 150 mmHg, or diastolic blood pressure < 60 mgHg or > 100 mmHg as determined by vital signs monitored after resting in sitting position for at least 3 minutes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "History of drug/chemical abuse or tested positive in urine drug screen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Used or intend to use any prescription medications/products or phytotherapeutic/herbal/plant-derived preparations within 14 days prior to dosing, or any nonprescription medications/products (i.e., over-the-counter (OTC) drugs), health products, or vitamins within 7 days prior to dosing, unless deemed acceptable by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Participation in any clinical study or bioequivalence study within 6 months prior to dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Whole blood donation within 2 months prior to dosing, plasma/platelet donation within 1 month prior to dosing, or receipt of blood products within 1 month prior to dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Alcohol consumption > 21 units/week (1 unit = 10 g of pure alcohol) or unable to abstain from consuming alcohol 3 days prior to first dosing until the last pharmacokinetic blood sampling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "History of smoking within 90 days prior to dosing (however, participation is acceptable if the subject has quit at least 90 days prior to dosing) or unable to abstain from smoking 90 days prior to dosing until the last pharmacokinetic blood sampling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Ingestion of grapefruit-containing foods or beverages 24 hours 3 days prior to dosing until the last pharmacokinetic blood sampling, or unable to abstain from ingesting such foods or beverages during the same period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Unable to abstain from ingesting caffeine-containing foods or beverages (e.g., coffee, tea [e.g., black tea, green tea], soft drinks, coffee milk, energy drinks, sports drinks) 3 days prior to dosing until the last pharmacokinetic blood sampling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Females, excluding those who have amenorrhea for at least 12 months or have been surgically sterilized (e.g., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), who are pregnant or lactating, evidenced by a positive urine hCG pregnancy test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Subject or subject's partner is unable or unwilling to use a medically acceptable means of contraception during and for 90 days following the last dosing or willing to donate sperm during the same period. - Acceptable contraceptive methods include:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Use of an intrauterine device that has been proven highly effective",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Male or female physical contraceptive used with chemical sterilization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Surgical sterilization of the subject or the subject's partner (e.g., vasectomy, hysterectomy, tubal ligation, salpingectomy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Subjects who, in the opinion of the Investigator, should not participate in in this study based on other reasons.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05642377",
    "statement": "Subject who is confirmed as the CYP2C19 poor metabolizer (e.g., *2/*2, *2/*3, *3/*3) by exploratory genotyping test at Screening in MAD group.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Have T2DM",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Meet all of following criteria at Week -2 of pre-randomization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "On diet and exercise therapy for 6 weeks or longer, AND",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Have been on a stable dosage and administration of insulin (8 to 40 units/day) for 10 weeks or longer, AND.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Have not been on any additional anti-hyperglycemic agent (AHAs, except for insulin monotherapy) for 8 weeks or longer, AND",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "HbA1c ≥7.5% and ≤10.0%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Fasting Plasma Glucose (FPG) ≥126 mg/dL and ≤230 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Have a body mass index (BMI) >18 kg/m^2 and <40 kg/m^2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "A male or female not of reproductive potential or a female of reproductive potential and agrees to remain abstinent from heterosexual activity, or agrees to use acceptable contraception to prevent pregnancy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has type 1 diabetes mellitus or has a history of diabetic ketoacidosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has a history of being administered any of the following AHAs including fixed dose combination (FDC) containing the following ingredients:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Thiazolidinediones within 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Glucagon-like peptide 1 (GLP-1) receptor agonists within 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Omarigliptin at any time",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has history of severe hypoglycemia with coma or loss of consciousness, or for whom hypoglycemia was observed greater or equal to two times per week within 8 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Is currently participating in or has participated in another study with an investigational compound or device within the prior 12 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has undergone a surgical procedure within 8 weeks or has planned major surgery during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Receives a lipid-lowering medication or thyroid replacement therapy at unstable dosage and administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has poorly controlled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has a medical history of active liver disease, including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has human immunodeficiency virus (HIV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has had new or worsening signs or symptoms of coronary heart disease or congestive heart failure within the past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder within the past 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has severe peripheral vascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has a history of malignancy ≤ 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has a clinically important hematological disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "(For women of childbearing potential) has a positive urine pregnancy test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Is pregnant or breast feeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Is expected to conceive during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Is expected to undergo hormonal therapy in preparation to donate eggs during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Routinely consumes >14 alcoholic drinks per week or engages in binge drinking",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has donated or plans to donate blood products of >300 mL within 8 weeks or during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02906709",
    "statement": "Has received or plans to receive blood products within 12 weeks or during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Diagnosed with type 2 diabetes mellitus (T2DM).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "HbA1c ≥7.5% and ≤12.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Body mass index ≥25 but ≤50 kilograms per meter squared.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have a history of stable body weight.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Concomitant antihyperglycemic agent (AHA) therapy may include metformin (MET), dipeptidyl peptidase-4 inhibitors and/or pioglitazone.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Approximately 64 to 96 subjects using glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitors will be enrolled in Study Group B.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Diagnosed with type 1 diabetes mellitus (T1DM) or other types of diabetes apart from T2DM.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have obvious clinical or radiographic signs or symptoms of liver disease (except nonalcoholic fatty liver disease), cirrhosis, acute or chronic hepatitis, or alanine aminotransferase (ALT/SGPT) and/or aspartate aminotransferase (AST/SGOT) levels ≥2.5X upper limit of normal (ULN), alkaline phosphatase ≥2X ULN or total bilirubin ≥2X ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have chronic kidney disease Stage 4 and higher or history of renal transplantation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have received U-500R insulin by CSII in the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Are taking chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have an irregular sleep/wake cycle.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have used any weight loss drugs in the 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have a history of bariatric surgery including Roux-en-Y gastric bypass surgery, gastric banding, and/or gastric sleeve.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have a history of an active or untreated malignancy, or in remission from a clinically significant malignancy during the last 5 years before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Significant hearing loss and/or vision impairment deemed by the investigator to interfere with the safe use of OmniPod U-500 system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Have cardiac disease with functional status that is New York Heart Association (NYHA) Class III or IV per New York Heart Association Cardiac Disease Functional Classification or have congestive heart failure requiring pharmacologic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02561078",
    "statement": "Are women breastfeeding or pregnant, or intend to become pregnant during the course of the study; are men who intend to impregnate their partners; or are sexually active of procreation potential not actively practicing birth control by a method determined by the investigator to be medically acceptable. Are investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subjects must satisfy the following criteria to be enrolled in the study:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "The presence of any of the following will exclude a subject from enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with histological or cytological confirmation of extensive stage Small Cell Lung Cancer (ES SCLC) or Stage IIIb or IV squamous Non-Small Cell Lung Cancer (sqNSCLC)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has received 1 or 2 prior lines of therapies, defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cohort A (SCLC, Immune Checkpoint Inhibitor naïve):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A minimum of 3 cycles of platinum-based chemotherapy in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cohort B (SCLC, ICI progressors):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior first or second line treatment includes an ICI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A minimum of 3 cycles of platinum-based chemotherapy, with or without ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cohort C (sqNSCLC, ICI progressors):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior first or second line treatment includes an ICI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "If treatment includes an ICI as maintenance therapy, at least 1 cycle of ICI in maintenance should have been completed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "At least 1 prior treatment including a platinum-based chemotherapy doublet",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A minimum of 3 cycles of platinum-based chemotherapy, with or without an ICI, in first line treatment, unless stopped at 2 cycles due to treatment-related toxicity",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must have progressed during ICI therapy, defined as unequivocal progression on or within 3 months of the last dose of ICI therapy (if no subsequent therapy)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has progressed at the last line of therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has a measurable disease defined by RECIST v1.1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject agrees to provide a tumor biopsy from primary or metastatic site prior to first dose and at a pre-specified timepoint during treatment. Core biopsy is required however, in the event a core biopsy may not otherwise be feasible in the opinion of the treating physician, an endobronchial ultrasound-guided fine needle aspirate [EBUS-FNA]) biopsy, using the largest gauge needle, may be performed instead.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has ECOG Performance Status of 0 to 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must have the following laboratory values:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Absolute neutrophil count (ANC) ≥ 1.5 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Hemoglobin (Hgb) ≥ 9 g/dL (one-time blood transfusion is allowed)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Platelet (Plt) Count ≥ 150 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "White blood cells (WBC) ≥ 2 x 109L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Serum AST/serum glutamic oxaloacetic transaminase (SGOT) or ALT/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x upper limit of normal (ULN) or ≤ 5 x ULN if presence of liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Total serum bilirubin ≤ 1.5 x ULN (≤ 3 x ULN, if Gilbert's syndrome or if indirect bilirubin concentrations are suggestive of extrahepatic source of the elevation)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Creatinine clearance (CrCl) ≥ 60 mL/minute based on Cockcroft-Gault or modification of diet in renal disease (MDRD) or ≥ 60 mL/min/1.73 m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has not recovered to Grade 2 or lower clinically significant toxicities related to the prior therapy (alopecia excluded).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has received prior LSD1 therapies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has a history of severe hypersensitivity reactions to other monoclonal antibodies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with symptomatic and untreated or unstable central nervous system (CNS) metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has recently been treated with whole brain radiation or stereotactic radiosurgery for CNS metastases must have completed therapy at least 2 weeks prior to Cycle 1 Day 1 and has a follow-up brain computed tomography (CT) or magnetic resonance imaging (MRI) demonstrating either stable or improving metastases 2 or more weeks after completion of radiotherapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject must be asymptomatic and off steroids or on stable dose of steroids for at least 2 weeks (≤ 10 mg daily prednisone or equivalent) prior to first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or any other significant gastrointestinal (GI) disorder that could affect the absorption of the study treatments.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and GI tract hemorrhages.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject with any hemorrhage/bleeding event > NCI CTCAE Grade 2 or haemoptysis > 1 teaspoon within 4 weeks prior to the first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has any of the following cardiovascular criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Evidence of acute or ongoing cardiac ischemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Current symptomatic pulmonary embolism",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Unstable angina pectoris or myocardial infarction ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Heart failure of New York Heart Association Classification III or IV ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Persistent or clinically meaningful ventricular arrhythmias prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Cerebral vascular accident or transient ischemic attack ≤ 6 months prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "QT corrected based on Fridericia's equation (QTcF) ≥ 450 milliseconds (msec) on Screening ECG, a baseline prolongation of QTcF interval ≥ 450 msec (NCI CTCAE Grade ≥ 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A history of additional risk factors for Torsades de pointes (TdP) (eg, heart failure, hypokalemia, family history of Long QT Syndrome)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has known human immunodeficiency virus (HIV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject who is seropositive due to HBV vaccination is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject who has no active viral infection and is under adequate prophylaxis against HBV reactivation is eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has any other malignancy within 2 years prior to enrollment, with the exception of adequately treated in-situ bladder cancer, in-situ carcinoma of the cervix, uteri, nonmelanomatous skin cancer, ductal in situ breast carcinoma, thyroid cancer, or early stage prostate cancer (all treatment of which should have been completed 6 months prior to enrollment).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has medical conditions requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "A brief (≤ 7 days) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of nonautoimmune conditions (eg, delayed-type hypersensitivity reaction caused by contact allergen) is permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Adrenal replacement steroid doses > 10 mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has active autoimmune diseases or history of autoimmune diseases that may relapse. Subjects with the following diseases are allowed to be enrolled after further screening: type I diabetes, hypothyroidism managed with hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia), or diseases not expected to recur in the absence of external triggering factors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject is pregnant or nursing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has a history of persistent skin rash ≥ NCI CTCAE Grade 2 related to prior ICI therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has organ transplant history, including allogeneic stem cell transplant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has interstitial lung disease history.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has received a live/attenuated vaccine within 30 days of first dose.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04350463",
    "statement": "Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "PDL1-positive status as determined by an immunohistochemistry assay performed by a central laboratory. A positive result in chemotherapy, chemoradiation of the tumor sample biopsy will satisfy the eligibility criterion",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Eastern Cooperative Oncology group Performance Status of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Life expectancy greater than or equal to 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors Version 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Adequate hematologic and end organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed. Hormone-replacement therapy or oral contraceptives, and tyrosine kinase inhibitors approved for treatment of NSCLC discontinued greater than 7 days prior to Cycle 1 Day 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Known central nervous system disease, including treated brain metastases in the following participants:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "who will not receive prior chemotherapy for advanced disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (referred as 2L+ participants)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Participants with a history of treated asymptomatic brain metastases are allowed in the 2L+ participants and previously treated for brain metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Leptomeningeal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Uncontrolled tumor-related pain",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01846416",
    "statement": "Uncontrolled hypercalcemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Pathologically or cytologically confirmed diagnosis of Stage IIIB or Stage IV NSCLC",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Patients who have failed conventional treatment (at least 1 prior treatment line), or for whom no therapy of proven efficacy exists",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Patients whose tumors:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "are EGFR mutation-positive or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "are EGFR mutation-negative or unknown provided they had disease progression after achieving either response or stable disease for at least 6 months from a previous treatment with erlotinib (Tarceva®) or gefitinib (Iressa®)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Patients aged 18 years or older",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Life expectancy of at least three (3) months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score 0-2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Written informed consent that is consistent with ICH-GCP guidelines",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Prior major surgery, chemotherapy or radiation therapy within 4 weeks before start of therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Prior treatment with an mTOR inhibitor within the past 4 weeks before start of therapy or concomitantly with this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Use of erlotinib (Tarceva®) or gefitinib (Iressa®) within 14 days of run-in treatment with Sirolimus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Active CNS metastases (defined as stable for <4 weeks and/or symptomatic and/or requiring treatment with anticonvulsants or steroids)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Severe alteration in serum fasting cholesterol (equal or more than 350 mg/dL) or triglycerides (equal or more than 400 mg/dL). Patients may be allowed to enrol on the trial after initiation of lipid lowering agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Requirement for treatment with any of the prohibited concomitant medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Concomitant CYP3A4 inhibitors within the past 7 days before start of therapy or concomitantly with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Concomitant CYP3A4 inducers within the past 14 days before start of therapy or concomitantly with this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Any contraindications for therapy with Sirolimus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Known hypersensitivity to BIBW 2992, Sirolimus or other rapamycin analogues (everolimus, temsirolimus, deforolimus, etc.) or the excipients of any of the trial drugs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00993499",
    "statement": "Use of any investigational drug within 4 weeks before start of therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Histologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Prior therapy must meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Subject has experienced disease progression or unacceptable toxicity/intolerance after receiving at least 1 systemic platinum-containing regimen;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Subject with a tumor of non-squamous histology must be tested for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement. Subject with EGFR activating mutation or ALK rearrangement must have experienced disease progression or unacceptable toxicity/intolerance after receiving at least one EGFR tyrosine kinase inhibitor or ALK inhibitor;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Subject has received PD-1/PD-L1 blockade or has been informed of the results of relevant positive Phase 3 trials with these agents.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 at baseline;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Minimum life expectancy of 3 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Agrees to use a medically effective method of contraception. Male subjects and women of child-bearing potential (WOCBP) must agree to use effective contraception, e.g., oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide), or practice true abstinence from sexual intercourse during the study and for 3 months after the last dose. Women of child-bearing potential include female subjects who have experienced menarche and have not undergone surgical sterilization or are not postmenopausal (defined as amenorrhea ≥ 12 consecutive months without an alternative medical cause);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "WOCBP must have a negative serum pregnancy test within 7 days prior to receiving investigational product and a negative urine pregnancy test on Day 1 of each Cycle;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Recovered (i.e., Grade ≤ 1 or to a baseline level) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer (with the exception of alopecia for which no resolution is required and peripheral neuropathy which must have resolved to Grade ≤ 1 for subjects receiving prior taxane-based chemotherapy);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Adequate organ function defined as below:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Total bilirubin ≤ upper limit of normal (ULN);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Hemoglobin (Hgb) ≥ 9.0 g/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Serum creatinine (sCr) ≤ 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Absolute neutrophil count (ANC) ≥ 1500 cells/mm3;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Platelets ≥ 100 × 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Sufficient archived tumor samples (if taken within 6 months prior to treatment may be submitted) available for PD assessments, or willingness to undergo a pre-treatment core needle biopsy, preferably of the primary tumor, in order to obtain such tissue;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Willing and able to undergo a post-dose core needle biopsy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Prior treatment with docetaxel or mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Requires administration of a prohibited medication or treatment;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Has a significant uncontrolled intercurrent illness including, but not limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Ongoing or active infection requiring antibiotics;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Clinically significant cardiac disease (class III, or IV of the New York Heart Association classification; unstable angina pectoris, myocardial infarction within 6 months or is post angioplasty or stenting within 6 months; clinically significant cardiac arrhythmia, or uncontrolled hypertension (i.e., systolic blood pressure > 150 mm Hg, diastolic blood pressure > 90 mmHg) despite anti-hypertensive medication;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Uncontrolled diabetes, active liver disease, poorly controlled chronic obstructive pulmonary disease, serious or non-healing wound, ulcer, or fracture;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Known or tests positive for human immunodeficiency virus, hepatitis B, or hepatitis C",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Active known auto-immune disease with the exception of autoimmune thyroiditis, vitiligo, and alopecia;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Pleural effusion requiring repetitive drainage, i.e., an indwelling catheter or 2 thoracenteses with 6 weeks of the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Received monoclonal antibodies (for any reason), chemotherapy, surgery, investigational therapy, or radiotherapy within 14 days of the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Received live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Use of immunosuppressive medication within 14 days before the first dose of mogamulizumab. Note: Inhaled, intranasal, intra-articular, or topical corticosteroids are allowed. Non-immunosuppresive doses of systemic steroids for adrenal replacement or for contrast allergy are allowed;;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Any history or signs of central nervous system metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Any history or signs of pulmonary lymphangitic spread;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Experienced a Grade 3 or higher hypersensitivity reaction to monoclonal antibodies or other therapeutic proteins, and the reaction could not be controlled or prevented on subsequent infusion with standard therapies such as antihistamines, 5-hydroxytryptamine (5-HT3) receptor antagonists, or corticosteroids;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "The subject has a history of severe hypersensitivity reactions to drugs formulated with polysorbate 80;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "History of second primary cancer within the past 5 years, with the exception of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Curatively resected non-melanomatous skin cancer;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "Curatively treated ductal carcinoma in situ of the breast;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "The subject is pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02358473",
    "statement": "The subject has aspartate aminotransferase and/or alanine aminotransferase > 1.5 × ULN, with concomitant alkaline phosphatase > 2.5 × ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses. Procedures performed for routine clinical practice up to 2 weeks before the provision of written consent are acceptable if not intentionally done for study purposes. If a patient declines to participate in any voluntary exploratory research and/or genetic component of the study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Male or female aged at least 18 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Histological or cytological confirmation of diagnosis of NSCLC.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR-TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) or T790M EGFR resistance mutation as assessed by local laboratory/or central laboratory via tissue/cytology or in plasma.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Mandatory provision (if available) of formalin fixed, paraffin embedded tissue and blood for central confirmation of EGFR mutation status. Please refer to the Laboratory Manual for details.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "In all patients enrolled, confirmed BM as having at least one non-measurable and/or measurable brain lesion at baseline as per CNS RECIST 1.1 via MRI imaging.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "World Health Organisation (WHO) performance status 0 to 2 and a minimum life expectancy of 4 weeks.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Females should be using adequate contraceptive measures (up to 6 months after the last administration), should not be breastfeeding and must have a negative serum pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential by fulfilling 1 of the following criteria at screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Women under 50 years old would be consider postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Male subjects should be willing to use barrier contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Have a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 inclusive and weigh at least 40.0 kg and no more than 100.0 kg, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete all required tests and procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Participation in another clinical study with an IP during the previous 14 days (or longer, depending on characteristics of agents used).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Treatment with any of the following: EGFR-TKI (e.g. erlotinib, gefitinib or afatinib) within 10 days or at least 5x the half-life, whichever is the longer; any cytotoxic chemotherapy, investigational agents or other anticancer drugs within 14 days of start of IP; osimertinib in the present or other studies; major surgery (excluding placement of vascular access) within 4 weeks of start of IP; radiotherapy (including brain) with a limited field of radiation within 1 week of start of IP, except in patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first administration of the IP; current receipt (or inability to stop at least 3 weeks before study start) medications or herbal supplements known to be potent inducers of CYP3A4.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting the IP with the exception of alopecia and grade 2, prior platinum therapy-related neuropathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "History of brain surgery or major brain trauma in the last year (if the surgery is in the same hemisphere as the brain metastasis).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses or active infection including hepatitis B, hepatitis C and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Any of the following cardiac criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Mean resting corrected QT interval (QTc) >470 msec obtained from 3 ECGs, using the screening clinic ECG machine derived QTc value.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third degree heart block, second degree heart block).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as electrolyte abnormalities including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Serum/plasma potassium <lower limit of normal (LLN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Serum/plasma magnesium <lower limit normal (LLN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Serum/plasma calcium <lower limit normal (LLN)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Heart failure, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "ANC <1.5 × 109/L; Platelets <100 × 109/L; Haemoglobin <90 g/L;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Alanine aminotransferase (ALT) >2.5x ULN or >5x ULN in the presence of liver metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Aspartate aminotransferase (AST) >2.5x ULN or >5x ULN in the presence of liver metastases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Total bilirubin >1.5x ULN or >3x ULN in the presence of liver metastases or Gilbert's Syndrome;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Creatinine >1.5xl ULN concurrent with creatinine clearance <50 mL/min (using Cockcroft-Gault formula).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the tablet or previous significant bowel resection that would preclude adequate absorption of osimertinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "History of hypersensitivity to active or inactive excipients of osimertinib or drugs with a similar chemical structure or class to osimertinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "In addition, the following is considered a criterion for exclusion from the exploratory genetic research:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Previous allogenic bone marrow transplant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Patients on anticoagulant treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Absence of collateral flow between ulnar and radial artery as assessed by the Allen´s test\".",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Suffering from claustrophobia and/or having implanted metal devices or implants such as pacemaker, vascular or heart valves or metal deposits such as bullets, shells, metal grains in the eyes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Previous participation in a research PET or PET/CT study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "The following are exclusion criteria for contrast enhanced MRIs:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Glomerular filtration rate <30 ml/min",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "History of renal insufficiency",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Pregnancy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03463525",
    "statement": "Women who are breast-feeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Signed informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Age ≥18 years and able to tolerate the EBUS-TBNI procedure;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Histologically/cytologically confirmed lung cancer. Eligible subjects may include, for example: primary or recurrent non-resectable disease, locally advanced stages II and III with nodal disease, stage IV advanced disease;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "At least one lesion documented via imaging (within 4 weeks of Screening) which can be accessed using EBUS-TBNI;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Subject is not a candidate for surgery;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Has received or plans to receive SOC chemotherapy; adequate hematologic recovery must be confirmed according to the institution's SOC;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Performance Status (ECOG) 0-2 at study entry;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Life expectancy of at least 6 months;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Adequate marrow, liver, and renal function at study entry;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "ANC ≥ 1.5 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Hemoglobin ≥ 9.0 grams/dL;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Platelets ≥ 75 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Total bilirubin ≤ 1.5x institutional ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "AST/ ALT ≤ 2.5x institutional ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Creatinine ≤ 1.5x institutional ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Significant cardiac disease (Class III or IV per New York Heart Association guidelines);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Active bacterial, viral, or fungal infections (including active AIDS, hepatitis B or hepatitis C);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Symptomatic central nervous system (CNS) metastasis which are neurologically unstable, or CNS disease requiring increase in steroid dose (treated metastatic disease and stable steroid use are not excluded)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Known hypersensitivity to study agent;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04314895",
    "statement": "Pregnant or breastfeeding women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Men and women greater than or equal to 18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "A diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Nucleoside analog, including gemcitabine and fluorouracil;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Carboplatin or cisplatin;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Anthracycline; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Alkylating agent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant experienced severe thrombocytopenia, defined as 2 platelet counts <50 x 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "ECOG performance status <=2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant has experienced >=Grade 2 CIT other than during the current chemotherapy treatment regimen within 6 months of Screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant has any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant has received >2 previous lines of chemotherapy or is receiving whole brain radiation during the study treatment period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant has a known medical history of genetic prothrombotic syndromes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant has a history of arterial or venous thrombosis within 3 months of screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Use of vitamin K antagonists;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03471078",
    "statement": "Participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of CIT within 3 months of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subjects with any of the following characteristics/conditions will not be included in the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Evidence of histologically or cytologically confirmed diagnosis of locally advanced or metastatic ALK positive NSCLC where ALK status has been previously established by the Ventana ALK (D5F3) CDx Assay (Roche Diagnostics), the Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular), or the EML4 ALK Fusion Gene Detection Kit (AmoyDx).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subject should have:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "(in Cohort 1) Disease progression after crizotinib as the only ALK inhibitor;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "(in Cohort 2) Disease progression after one ALK inhibitor other than crizotinib, with or without prior crizotinib.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Prior treatment with an ALK inhibitor must have completed 5 half lives prior to study entry.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "All Subjects must have at least 1 measurable extracranial target lesion according to RECIST v1.1 that has not been previously irradiated. CNS metastases are allowed if:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Asymptomatic: either not currently requiring corticosteroid treatment, or on a stable or decreasing dose of 10 mg QD prednisone or equivalent; or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Previously diagnosed and treatment has been completed with full recovery from the acute effects of radiation therapy or surgery prior to enrollment, and if corticosteroid treatment for these metastases has been withdrawn for at least 4 weeks with neurological stability.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1, or 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Age 18 years (or 20 years as required by local regulation).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate bone marrow functions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Absolute Neutrophil Count (ANC) 1,500/mm3 or 1.5 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Platelets 100,000/mm3 or 100 x 109/L;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Hemoglobin 9 g/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate pancreatic function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Serum total amylase 1.5 x upper limit of normal (ULN);*",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Serum lipase 1.5 x ULN. *if total amylase >1.5 x ULN, but pancreatic amylase is within the ULN, then subject may be enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate renal function: a. Serum creatinine 1.5 x ULN or estimated creatinine clearance 60 mL/min as calculated using the method standard for the institution.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Adequate liver function:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Total serum bilirubin 1.5 x ULN;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2.5 x ULN (5.0 x ULN in case of liver metastases).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Acute effects of prior radiotherapy and chemotherapy resolved to baseline severity or to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 except for AEs that in the investigator's judgment do not constitute a safety risk for the subject.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Serum or urine pregnancy test (for females of childbearing potential) negative at screening. Female subjects of non childbearing potential must meet at least 1 of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause (which may be confirmed with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state if appropriate;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Have undergone a documented hysterectomy and/or bilateral oophorectomy;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Have medically confirmed ovarian failure. All other female subjects (including female subjects with tubal ligations) are considered to be of childbearing potential.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Willing and able to comply with the study scheduled visits, treatment plans, laboratory tests, and other procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "More than 1 prior chemotherapy regimen prior to enrollment in advanced/metastatic setting. If disease recurred/relapsed within the adjuvant chemotherapy treatment or <=6 months after the completion of the adjuvant chemotherapy, then the adjuvant chemotherapy is considered as the first line systemic chemotherapy to the disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Systemic anti cancer therapy completed within a minimum of 5 half lives of study enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Prior therapy with an antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways, including, but not limited to, anti programmed cell death protein 1 (anti PD 1), anti programmed cell death protein ligand 1 (anti PD L1), anti PD L2, anti cluster of differentiation 137 (anti CD137), or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known epidermal growth factor receptor (EGFR) activating mutations; known prior therapy with EGFR TKI(s) (the prior treatment with brigatinib is allowed as an ALK TKI).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Major surgery within 4 weeks prior to enrollment. Minor surgical procedures (eg, port insertion) are not excluded, but sufficient time should have passed for adequate wound healing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Radiation therapy within 2 weeks prior to enrollment. Palliative radiation must have been completed at least 48 hours prior to enrollment. Stereotactic or partial brain irradiation must have completed at least 2 weeks prior to enrollment. Whole brain irradiation must have completed at least 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Spinal cord compression unless the subject has good pain control attained through therapy, and there is complete recovery of neurological function for the 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Gastrointestinal abnormalities, including inability to take oral medication; requirement for intravenous alimentation; prior surgical procedures affecting absorption including total gastric resection or lap band; active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease; treatment for active peptic ulcer disease in the past 6 months; malabsorption syndromes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known prior or suspected severe hypersensitivity to lorlatinib or any component in the formulation; known prior therapy with lorlatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Clinically significant cardiovascular disease (both arterial and venous) and non vascular cardiac conditions, (active or within 3 months prior to enrollment, which may include, but not are limited to:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Arterial disease such as cerebral vascular accident/stroke (including transient ischemic attack -TIA), myocardial infarction, unstable angina;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Venous diseases such as cerebral venous thrombosis, symptomatic pulmonary embolism;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Nonvascular cardiac disease such as congestive heart failure (New York Heart Association Classification Class ≥ II), second degree or third degree atrioventricular block (unless paced) or any AV block with PR interval >220 msec; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Ongoing cardiac dysrhythmias of CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, bradycardia defined as <50 bpm (unless subject is otherwise healthy such as long distance runners, etc.), machine read electrocardiogram (ECG) with QTc >470 msec, or congenital long QT syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subject with predisposing characteristics for acute pancreatitis according to investigator judgment, including but not limited to uncontrolled hyperglycemia, current gallstone disease, in the last month prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "History of extensive, disseminated, bilateral or presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis and pulmonary fibrosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Evidence of active malignancy (other than NSCLC, non melanoma skin cancer, or localized and presumed cured prostate cancer or any in situ cancer which does not currently require treatment) within the last 3 years prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Concurrent use of any of the following food or drugs (consult the sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days prior to the first dose of administration of lorlatinib:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known strong CYP3A inhibitors (eg, strong CYP3A inhibitors: grapefruit juice or grapefruit/grapefruit related citrus fruits [eg, Seville oranges, pomelos], boceprevir, cobicistat, conivaptan, itraconazole, ketoconazole, posaconazole, ritonavir alone and with danoprevir or elvitegravir or indinavir or lopinavir or paritaprevir or ombitasvir or dasabuvir or saquinavir or tipranavir, telaprevir, troleandomycin, and voriconazole). The topical use of these medications (if applicable), such as 2% ketoconazole cream, is allowed;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known CYP3A substrates with narrow therapeutic index, such as astemizole*, terfenadine*, cisapride*, pimozide, quinidine, tacrolimus, cyclosporine, sirolimus, alfentanil, fentanyl (including transdermal patch) or ergot alkaloids (ergotamine, dihydroergotamine) (*withdrawn from US market);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known strong CYP3A inducers (eg, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's Wort);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Known P glycoprotein (P gp) substrates with a narrow therapeutic index (eg, digoxin).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator and/or the sponsor, would make the subject inappropriate for entry into this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Subject who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03909971",
    "statement": "Pregnant female participants; breastfeeding female participants; fertile male participants and female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 97 days if male or 35 days if female, after the last dose of investigational product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting capmatinib was allowed.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Subjects with Stage IIIB or IV NSCLC (any histology) at the time of study entry",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Subjects with histologically or cytologically confirmed diagnosis of NSCLC that is:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "EGFR wt status (for exon 19 deletions and exon 21 L858R substitution mutations)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "and ALK rearrangement-negative",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "and MET-mutation and/or amplification status (as defined in the protocol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "For Cohorts 1a, 1b, 2, 3, 4 subjects must have failed one or two prior lines of systemic therapy for advanced disease (stage IIIB or IV NSCLC). For Cohort 6, subjects must have failed one prior line of systemic therapy for advanced disease (stage IIIB or IV NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "For Cohorts 5a, 5b, and 7, subjects must not have received any systemic therapy for advanced disease (stage IIIB or IV NSCLC).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Subjects with at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there was clear sign of progression since the irradiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Subjects who recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (Common Terminology Criteria for Adverse Events [CTCAE] v 4.03). Subjects with any grade of alopecia were allowed to enter the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Subjects with adequate organ function",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Prior treatment with crizotinib, or any other MET or HGF inhibitor",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Characterized ALK-positive rearrangement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Clinically significant, uncontrolled heart diseases",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting capmatinib or subjects who had not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy ≤ 2 weeks prior to starting capmatinib or subjects who had not recovered from radiotherapy-related toxicities.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Receiving treatment with strong inducers of CYP3A4 and/or any enzyme-inducing anticonvulsant and could not be discontinued ≥ 1 week prior to the start of treatment with capmatinib and for the duration of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Receiving treatment with unstable or increasing doses of corticosteroids.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of capmatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Applicable to Cohorts 1-4 and Cohort 6 only: previous anticancer and investigational agents within 4 weeks or ≤ 5 × half-life of the agent (whichever was longer) before first dose of- capmatinib. If previous treatment was a monoclonal antibody, then the treatment must have been discontinued ≥ 4 weeks before first dose of capmatinib. If previous treatment was an oral targeted agent, then the treatment must have been discontinued ≥ 5 × half-life of the agent before the first dose of capmatinib.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Pregnant or nursing (lactating) women.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 7 days after stopping treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Sexually active males unless they used a condom during intercourse while taking drug and for 7 days after stopping treatment and should not father a child in this period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02414139",
    "statement": "Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Provision of informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Male or female ≥18 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Histologic or cytologic confirmed diagnosis of small cell lung cancer, either limited or extensive disease at initial presentation is allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Evidence of progressive disease during or following 1 or 2 prior chemotherapy regimens",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "At least 1 prior regimen must have contained a platinum salt",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "'Adjuvant therapy' will constitute a prior treatment regimen",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "No more than 2 prior regimens are allowed",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Measurable disease (only for the phase II portion)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Eastern Cooperative Oncology Group (ECOG) Performance status 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "A minimum life expectancy of 12 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Adequate bone marrow, hepatic and renal function as evidenced by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Absolute neutrophil count (ANC) ≥ 1.5 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Platelet count ≥ 100 x 109/L",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Hemoglobin ≥ 9.0 g/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Serum bilirubin < 1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Serum creatinine < 1.5 x ULN",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "No 'active' CNS metastases. Prior CNS metastases are allowed, provided adequate palliative therapy has been administered and CNS disease control has been established prior to study entry. • A brain MRI scan, ≤ 28 days from day 1, is required",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures and who have a negative serum pregnancy test within 1 week prior to initial study treatment. (See Appendix B)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Male patients willing to use adequate contraceptive. (See Appendix B)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "At least 21 days must have elapsed prior to day 1 cycle 1, from chemotherapy, radiotherapy, immunotherapy or following major surgery and any surgical incision should be completely healed. At least 14 days must have elapsed prior to Day 1 Cycle 1 for \"limited palliative radiotherapy\", defined as a course of therapy encompassing < 25% total bone marrow volume and not exceeding 30 Gy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "At least 14 days must have elapsed for chemotherapy regimens, biologic, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Patients who are pregnant or breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Active involvement of the Central Nervous System (CNS).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Uncontrolled infection or systemic disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Clinically significant cardiac disease not well controlled with medication (e.g., congestive heart failure, symptomatic coronary artery disease e.g. angina, and cardiac arrhythmias) or myocardial infarction within the last 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Chemotherapy regimens within the last 21 days (or within 6 weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens, biologic, and targeted therapy given continuously or on a weekly basis with limited potential for delayed toxicity within the last 14 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "No concurrent systemic chemotherapy or anticancer biologic therapy is allowed. Note: Patients on hormonal treatment for breast cancer or prostate cancer may continue on treatment and enter into study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Known hypersensitivity to any components of SC16LD6.5 study drug product.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Patients with known human immunodeficiency virus (HIV) or Hepatitis B or C (active, previously treated or both), a history of solid organ or bone marrow transplantation would generally be considered to have met exclusion criteria, however exceptions may be considered on a case-by-case basis by the medical monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "Psychiatric disorder or social or geographic situation that would preclude study participation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01901653",
    "statement": "QT interval measurement corrected by Fridericia's formula (QTcF) interval of >450 msec (males) or >470 msec (females)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Adult male or female participants aged >=20 years (Japan) or >=18 years (United States).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Has pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed after, at least, a first line of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed metastatic adenocarcinoma of the colon or rectum who have progressed to at least 2 lines of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed locally advanced or metastatic sqEC that has progressed after at least a first line of standard systemic therapy for metastatic disease. First-line participants can be enrolled if a platinum doublet is contraindicated or refused by the participants, OR pathologically confirmed locally advanced or metastatic sqNSCLC that has progressed after at least 2 lines of standard systemic therapy for metastatic disease.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "For the Western safety cohort only: participants with locally advanced or metastatic solid tumor for whom no standard treatment with an established survival benefit is available or if the participant refuses other standard therapy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "For disease-specific cohort participants: measurable disease per RECIST v. 1.1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Left ventricular ejection fraction greater than (>) 50% as measured by ECHO or MUGA scan within 4 weeks before receiving the first dose of study drug.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Recovered to Grade 1 or baseline from all toxic effects of previous therapy (except alopecia or neuropathy).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Suitable venous access for the study-required blood sampling.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "For the Western safety cohort only: willingness to undergo serial skin tissue biopsies.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "For disease-specific cohort participants: Must have an archival (banked) tumor sample or agree to have a new (fresh) tumor biopsy during the screening period. If a new tumor sample is needed, the disease should be accessible for a nonsignificant risk biopsy procedure (those occurring outside the brain, lung/mediastinum, and pancreas, or obtained with endoscopic procedures not extending beyond the stomach or bowel). For participants in the Western safety cohort, this biopsy is optional.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Participants who require continuous use of proton pump inhibitors (PPIs) or histamine-2 (H2) receptor antagonists and participants who are taking PPIs within 5 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Treatment with clinically significant enzyme inducers, such as phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, or Saint John's wort within 14 days before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Treatment with any systemic anticancer treatment (including investigational products) within 30 days or 5 half-lives, whichever is shorter, before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "History of any of the following within the last 3 months before administration of the first dose of study drug:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Ischemic myocardial event including angina requiring therapy and artery revascularization procedures, myocardial infarction, and unstable symptomatic ischemic heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Ischemic cerebrovascular event, including transient ischemic attack and artery, revascularization procedures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Significant, uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "New York Heart Association Class III to IV heart failure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Any other cardiac condition that, in the opinion of the investigator, could pose an additional risk for participation in the study (example, pericardial effusion or restrictive cardiomyopathy).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Baseline prolongation of the QT interval corrected for heart rate (HR) using Fridericia's formula [QT interval corrected for heart rate using Fridericia's formula (QTcF); example, repeated demonstration of QTcF interval >480 millisecond (ms), history of congenital long QT syndrome, or torsades de pointes].",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Hypertension that is unstable or not controlled by medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "History of uncontrolled brain metastasis unless:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery, and",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Stable disease (SD) for >=30 days, without steroid use (or stable steroid dose established for >=14 days before the first dose of TAK-931).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Known history of human immunodeficiency virus infection.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C virus (HCV) infection viral load. Note: Participants who have positive HBV core antibody or HBV surface antigen antibody can be enrolled but must have an undetectable HBV viral load.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Prior treatment with radiation therapy involving >=25% of the hematopoietically active bone marrow within 3 months before the first dose of study drug.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Participants with known microsatellite instability-high (MSI-H) genotype or known wild type tumor protein 53 (TP53) per local testing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03261947",
    "statement": "Western Safety Cohort Only: Participants with Japanese heredity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Healthy men and women aged 18-45 years.\nSigning freely and voluntary informed consent , accompanied by two witnesses who also sign.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Not have a history of malaria infection.\nFor women, use of adequate contraception from the star restriction to be lifted by a doctor for contraception study.\nAccept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco ,Urabá and Bajo Cauca) .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Be reachable by phone throughout the study period.\nBeing Duffy positive ( Fy +) .\nLevels of hemoglobin ( Hb) > 11 g / dl.\nAvailability to participate during the period in which they develop the study.\nDo not be participating in another clinical study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "2. Preimmune group",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Healthy men and women aged 18-45 years.\nSigning freely and voluntary informed consent , accompanied by two witnesses who also sign .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Having a history of infection (s ) and serological tests for malaria positive for P. vivax.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "For women, use adequate contraception from the start restriction to be lifted by a doctor for contraception study .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Accept not to travel to areas considered endemic for malaria during Trophies infectious period (1 month ) ( Buenaventura , Tierralta , Pretoria , Tumaco Urabá and Bajo Cauca) .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Be reachable by phone throughout the study period.\nAvailability to participate during the period in which they develop the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "3. Voluntary blood donors",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Step 2 Patients that have chronic or acute disease, different from malaria by P. vivax.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Having a history of disease or clinical conditions that according to medical criteria might increase significantly the risk related with participation on this study Hemoglobin levels <9 g/dL at the time of recruitment Have received antimalarial treatment before the diagnosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Naïve group",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Healthy men and women aged 18-45 years.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Be positive diagnosis of P. vivax determined by thick smear examination .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "The patient must not have circulating malaria parasites such as P. falciparum or P. malariae .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Have a parasitemia ≥ 0.1 %. by thick smear .",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Hb ≥ 9 g / dL at the time of diagnosis of malaria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "The patient must have the capacity to provide informed consent freely and voluntarily . Should be illiterate may assert its decision to participate by putting their fingerprint in the format consent. Minors who are between 15 and 17 and wishing to participate must sign the informed consent and one of its Parents must sign the informed consent, accompanied by 2 witnesses who also sign",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Step 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Negative IFAT (< 1:20) for P. vivax on screening tests",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02083068",
    "statement": "Other criteria used in the case of naive volunteers, except a history of having lived in an endemic area for the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Adult (male and female) subjects between 18 and 55 years of age inclusive, who do not live alone (from inoculation day until at least the end of the Riamet® treatment) and will be contactable and available for the duration of the trial and contactable up to 2 weeks following the End of Study visit (approximately 8.5 weeks).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Body weight minimum 50 kg, body mass index between 18 and 32 kg/m2, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Certified as healthy by a comprehensive clinical assessment (detailed medical history, complete physical examination and special investigations).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Vital signs after 5 minutes resting in supine position:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "90 mmHg ≤ systolic blood pressure (SBP) ≤ 140 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "40 mmHg ≤ diastolic blood pressure (DBP) ≤ 90 mmHg,",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "40 bpm ≤ heart rate (HR) ≤ 100 bpm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Must have QTcF ≤450 ms, QTcB ≤450 ms for male subjects, QTcF ≤470 ms, QTcB ≤470 ms for female subjects and PR interval ≤210 ms at screening and at pre-inoculation on inoculation day.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Heterosexual women of childbearing potential should be surgically sterile or using an insertable, injectable, transdermal or combination oral contraceptive approved by the TGA combined with a barrier contraceptive for the duration of the study, and have negative results on a urine pregnancy test done before inoculation. Abstinent, heterosexual female subjects must agree to start a double method if they start a sexual relationship during the study. Adequate contraception does not apply to subjects of childbearing potential with same sex partners (abstinence from penile-vaginal intercourse), when this is their preferred and usual lifestyle. Female subjects with same sex partners must not be planning in vitro fertilisation within the required contraception period. Women of non-childbearing potential who will not require contraception during the study are defined as: post-menopausal (spontaneous amenorrhoea for ≥ 12 months, or spontaneous amenorrhoea for 6-12 months and follicle-stimulating hormone (FSH) ≥ 40 IU/mL; either should be together with the absence of oral contraceptive use for > 12 months). Male subjects participating must agree to use a double-barrier method of contraception including condom plus diaphragm or condom plus intrauterine device or condom plus stable oral/transdermal/injectable hormonal contraceptive by the female partner from the time of informed consent through to 90 days after the last dose of OZ439 and PQP. Abstinent male subjects must agree to start a double-barrier method if they begin sexual relationships during the study and up to 90 days after the last dose of study drug. Male subjects with female partners that are surgically sterile, or male subjects who have undergone sterilisation and have had testing to confirm the success of the sterilisation may also be included.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Having given written informed consent prior to undertaking any study-related procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Must be willing and able to communicate and participate in the whole study. -",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Haematology, clinical chemistry, coagulation or urinalysis results at screening or on admission prior to Inoculation or IMP administration that are outside of Sponsor-approved clinically acceptable laboratory ranges documented in the laboratory manual or are considered clinically relevant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any history of malaria or participation in a previous malaria challenge study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Must not have travelled to or lived (>2 weeks) in a malaria-endemic region during the past 12 months or planned travel to a malaria-endemic region during the course of the study (for endemic regions see https://map.ox.ac.uk/country-profiles/#!/). Bali is not considered a malaria-endemic region.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Participation in any investigational product study within the 12 weeks preceding IMP administration.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Has evidence of increased cardiovascular disease risk (defined as >10%, 5-year risk for those greater than 35 years of age, as determined by the Australian Absolute Cardiovascular Disease Risk Calculator (http://www.cvdcheck.org.au/)). Risk factors include sex, age,systolic blood pressure (mm/Hg), smoking status, total and HDL cholesterol (mmol/L), and reported diabetes status.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Symptomatic postural hypotension at screening on two consecutive readings, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 2-3 minutes when changing from supine to standing position.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History of splenectomy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History or presence of diagnosed (by an allergist/immunologist) or treated (by a physician) food or known drug allergies (including but not limited to allergy to any of the antimalarial rescue medications to be used in the study), or history of anaphylaxis or other severe allergic reactions. Note. Subjects with seasonal allergies/hay fever, house dust mite or allergy to animals that are untreated and asymptomatic at the time of dosing can be enrolled in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History of convulsion (including intravenous drug or vaccine-induced episodes) Note. A medical history of a single febrile convulsion during childhood is not an exclusion criterion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease (HIV or other immuno-deficiencies), insulin-dependent and non-insulin dependent diabetes (excluding glucose intolerance if exclusion criterion 4 is met), progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, porphyria, psoriasis, rheumatoid arthritis, asthma, epilepsy, or obsessive-compulsive disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History of malignancy of any organ system (other than localised basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within 5 years of screening, regardless of whether there is evidence of local recurrence or metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Subjects with history of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis including depression or receiving psychiatric drugs or who has been hospitalised within the past 5 years prior to enrolment for psychiatric illness, history of suicide attempt, or confinement for danger to self or others.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History of serious psychiatric condition that may affect participation in the study or preclude compliance with the protocol, including but not limited to past or present psychoses, disorders requiring lithium, a history of attempted or planned suicide, more than one previous episode of major depression, any previous single episode of major depression lasting for or requiring treatment for more than 6 months, or any episode of major depression during the 5 years preceding screening.The Beck Depression Inventory (Appendix 4) will be used as an objective tool for the assessment of depression at screening. In addition to the conditions listed above, subjects with a score of 20 or more on the Beck Depression Inventory and/or a response of 1, 2 or 3 for item 9 of this inventory (related to suicidal ideation) will not be eligible for participation. These subjects will be referred to a general practitioner or medical specialist as appropriate. Subjects with a Beck score of 17 to 19 may be enrolled at the discretion of the Investigator if they do not have a history of the psychiatric conditions mentioned in this criterion and their mental state is not considered to pose additional risk to the health of the subject or to the execution of the study and interpretation of the data gathered.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History of recurrent headache (e.g. tension-type, cluster or migraine) with a frequency of ≥2 episodes per month on average and/or severe enough to require medical therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Presence of acute infectious disease or fever (e.g. sublingual temperature ≥38.5°C) within the 5 days prior to inoculation with malaria parasites.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Evidence of acute illness within the 4 weeks prior to screening that the Investigator deems may compromise subject safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Significant inter-current disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Subject has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion (e.g. gastrectomy, diarrhoea).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Blood donation of any volume within 1 month before inclusion, or participation in any research study involving blood sampling (more than 450 mL/unit of blood), or blood donation to Australian Red Cross Blood Service (Blood Service) or other blood bank during the 8 weeks prior to the treatment drug dose in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Subject unwilling to defer blood donations to the Blood Service for at least 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Medical requirement for intravenous immunoglobulin or blood transfusions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Subject who has ever received a blood transfusion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History or presence of alcohol abuse (alcohol consumption more than 40 g per day) or drug habituation, or any prior intravenous usage of an illicit substance.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Tobacco use of more than 5 cigarettes or equivalent per day, and unable to stop smoking for the duration of the clinical unit confinement.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Female subject who is breastfeeding.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any vaccination within the last 28 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any corticosteroids, anti-inflammatory drugs, immunomodulators or anticoagulants. Any subject currently receiving or having previously received immunosuppressive therapy (including systemic steroids, adrenocorticotrophic hormone or inhaled steroids) at a dose or duration associated with hypothalamic-pituitary-adrenal axis suppression (e.g. 1 mg/kg/day prednisone, chronic use of inhaled high potency corticosteroids such as budesonide 800 μg/day or fluticasone 750 μg, or equivalent).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any recent (<6 weeks) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (e.g. chloroquine, piperaquine phosphate, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, doxycycline etc.).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Ingestion of any poppy seeds within the 24 hours prior to the screening blood test (subjects will be advised by phone not to consume any poppy seeds in this time period).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Excessive consumption of beverages or food containing xanthine bases including Red Bull, chocolate, coffee etc. (more than 400 mg caffeine per day, equivalent to more than 4 cups of coffee per day).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Unwillingness to abstain from consumption of grapefruit or Seville oranges from inoculation day until end of Riamet® treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Unwillingness to abstain from consumption of quinine containing foods/beverages such as tonic water and lemon bitter, from inoculation day until end of Riamet® treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Use of prescription drugs or non-prescription drugs or herbal supplements (such as St John's Wort), within 14 days or 5 half-lives (whichever is longer) prior to the malaria inoculation. As an exception, ibuprofen (preferred) may be used at doses of up to 1.2 g/day or paracetamol at doses of up to 4 g/day after discussion with the Investigator. Limited use of other non-prescription medications or dietary supplements, not believed to affect subject safety or the overall results of the study, may be permitted on a case-by-case basis following approval by the Sponsor in consultation with the Investigator. Subjects are requested to refrain from taking non-approved concomitant medications from recruitment until the conclusion of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or is unable to cooperate because of a language problem or poor mental development.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any subject in the exclusion period of a previous study according to applicable regulations.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any subject who is the Principal Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, or other staff thereof, directly involved in conducting the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Any subject without a good peripheral venous access. Biological status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Positive result on any of the following tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Positive urine drug test. Any drug listed in Section 7.2.1 in the urine drug screen unless there is an explanation acceptable to the Investigator (e.g., the subject has stated in advance that they consumed a prescription or over-the-counter product which contained the detected drug) and/or the subject has a negative urine drug screen on retest by the pathology laboratory. Any subject testing positive for acetaminophen (paracetamol) at screening may still be eligible for study participation, at the Investigator's discretion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Positive alcohol breath test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Cardiac/QT risk:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia, or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "ECG abnormalities in the standard 12-lead ECG (at screening or at pre-inoculation on inoculation day) which in the opinion of the Investigator is clinically relevant or will interfere with the ECG analyses.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03542149",
    "statement": "Known hypersensitivity to artesunate or any of its excipients, artemether or other artemisinin derivatives, piperaquine phosphate, proguanil/atovaquone, primaquine, or 4-aminoquinolines. -",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Healthy adults (male or non-pregnant, non-lactating female) 18 to 55 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Able to provide free and willing written informed consent to participate;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "A score at least 80% correct on a 10 question Assessment of Understanding;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "No plans to travel to a malaria endemic area during the course of the study;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Duffy positive phenotype;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Normal (non-deficient) G6PD phenotype (range : 4.6 to 13.5 u/gm hemoglobin);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Free of significant health problems as established by medical history and clinical examination completed prior to the study;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Available to participate and reachable by phone for duration of study (approximately 9 months starting from screening).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Only subjects with no or low cardiac risk factors according to the Gaziano study and a normal EKG will be included in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Pregnant or nursing at screening or plans to become pregnant or nurse from the time of enrollment until 6 months after sporozoite challenge;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Duffy negative phenotype;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "G6PD deficiency or have any hemoglobinopathy by history;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Past infection with any species of malaria (as demonstrated by a positive thick smear) in the last 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of receipt of treatment or prophylaxis for malaria during the previous 6 months;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of receipt of malaria vaccine within the previous 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of receipt of malaria challenge (being bitten by experimentally infected mosquitoes) within the previous 5 years;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Plans to travel to malarious areas during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Allergy to antimalarials or significant (e.g. systemic) hypersensitivity reactions to mosquito bites (local hypersensitivity reactions at the site of a mosquito bite are not an exclusion criterion);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "History of psoriasis (given its interaction with chloroquine);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Use of any investigational or non-registered drug or vaccine within 30 days preceding the challenge or planned use during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Use or planned use of any drugs with significant anti-malarial activity, such as doxycycline, clindamycin, azithromycin, during the study period (volunteers can withhold the use of these medications during the study period, at the minimum starting from 4 weeks before the challenge until 4 weeks after becoming parasitemic);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection and history of splenectomy;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of challenge;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "For corticosteroids, this is defined as prednisone, or equivalent, 0.5 mg/kg/day;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Inhaled and topical steroids are allowed;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "A family history of congenital or hereditary immunodeficiency;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Chronic or active neurologic disease including seizure disorder;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by medical history, physical examination, or abnormal baseline laboratory screening tests:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "ALT above normal range (table 9);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Creatinine above normal range (table 9);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Hemoglobin below normal range (table 10);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Platelet count below normal range (table 10);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Total white cell count below normal range (table 10);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Acute disease at the time of enrollment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Acute disease is defined as the presence of a moderate or severe illness with or without fever;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Challenge can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever (i.e., oral temperature < 38°C/100.4°F);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Hepatomegaly, right upper quadrant abdominal pain or tenderness;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Seropositive for HIV, hepatitis C virus (antibodies to HIV and HCV), and/or HBsAg;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Administration of immunoglobulins and/or any blood products within the 3 months preceding challenge or planned administration during the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Suspected or known current alcohol abuse/drug abuse as obtained by history and physical examination;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Inability to make follow-up visits;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00935623",
    "statement": "Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have a diagnosis of NSCLC with at least 1 measurable lesion assessable using standard techniques by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have T790M-positive status using a test validated and performed locally after disease progression on EGFR tyrosine kinase inhibitor (TKI) treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 at the time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have serum albumin that is ≥25 grams per liter at the time of enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have adequate organ function, with all screening labs performed within 7 days of treatment initiation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have a life expectancy of ≥3 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have resolution, except where otherwise stated in the inclusion criteria, of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Previous treatment with an EGFR monoclonal antibody (except for past treatment for squamous cell carcinoma of head and neck or metastatic colorectal cancer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Previous treatment with osimertinib or third generation EGFR TKIs.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Participants with symptomatic or growing brain metastases less than 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "History of drug-induced interstitial lung disease (ILD), ILD, or radiation pneumonitis requiring treatment with steroid prior to study enrollment, or any evidence of clinically active ILD.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have a significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment. Participants with a history of gross hemoptysis (defined as bright red blood of ≥1/2 teaspoon) within 2 months prior to enrollment are excluded.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have experienced any arterial thrombotic event or arterial thromboembolic event, including myocardial infarction, unstable angina (history or evidence of current clinically relevant coronary artery disease of current ≥Class III as defined by Canadian Cardiovascular Society Angina Grading Scale or congestive heart failure of current ≥Class III as defined by the New York Heart Association), cerebrovascular accident, or transient ischemic attack, within 6 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have a history of deep vein thrombosis, pulmonary embolism, or any other significant venous thromboembolism (venous catheter thrombosis or superficial venous thrombosis not considered \"significant\") during the 3 months prior to study enrollment. Participants with venous thromboembolism occurring 3 to 6 months prior to study enrollment are allowed, if being treated with low molecular weight heparin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have a history of gastrointestinal perforation and/or fistula within 6 months prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have uncontrolled hypertension, as defined in CTCAE Version 4.0, prior to initiating study treatment, despite antihypertensive intervention. CTCAE Version 4.0 defines uncontrolled hypertension as Grade >2 hypertension; clinically, the participant continues to experience elevated blood pressure (systolic >160 millimeters of mercury [mmHg] and/or diastolic >100 mmHg) despite medications.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Are receiving chronic therapy with any of the following medications within 7 days prior to enrollment:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "nonsteroidal anti-inflammatory agents (NSAIDs; such as indomethacin, ibuprofen, naproxen, or similar agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "other anti-platelet agents (such as clopidogrel, ticlopidine, dipyridamole, or anagrelide).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have radiologically documented evidence of major blood vessel invasion or encasement by cancer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have radiographic evidence of pulmonary intratumor cavitation, regardless of tumor histology.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Are receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have abnormal cardiac findings.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02789345",
    "statement": "Have undergone chest irradiation within 2 weeks prior to study drug administration, have not recovered from all radiation-related toxicities, or requires corticosteroids. A 2-week washout is permitted for focal palliative radiation to non-central nervous system disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "The participant is eligible to enter the study if all of the following apply:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "The following criteria should be checked at the time of study entry.\nIf ANY exclusion criterion applies, the subject must not be included in the study:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Exceptions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "a Inhaled and topical steroids.\nb Participation in hepatitis C vaccine study with confirmed negative HCV antibodies prior to participation in that study, and negative HCV RNA PCR at screening for this study c The following vaccinations may be administered more than 7 days before or after a study vaccination: polio, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, Bacillus Calmette-Guérin (BCG vaccine), measles, influenza, pneumococcal disease, COVID-19 or yellow fever",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Participant is a healthy adult, aged 18 to 55 years (inclusive), of Thai origin.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Participant is willing and able to give informed consent to participate in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Able, in the investigator's opinion, and willing to comply with the study requirements and follow-up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Women of childbearing potential: must agree to practice continuous, effective contraception for the duration of the trial, and have a negative pregnancy test before each vaccination. (Costs for contraceptives will be reimbursed by the trial.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Pregnancy or breastfeeding, or planned pregnancy during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Presence of any medical condition (physical or mental) which, may place the participant at undue risk or interfere with the results of the study*. Including: serious cardiac, renal, hepatic or neurological disease, severe malnutrition",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Any confirmed or suspected immunosuppressive or immunodeficient condition. Including: history of splenectomy, human immunodeficiency virus (HIV) infection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Chronic administration (>14 days in total) of immunosuppressants or other immune-modifying drugs within six months of enrollment. Including: oral corticosteroids equivalent to prednisone > 20 mg/day (a)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of an autoimmune disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody(b) detected in serum.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Screening electrocardiogram (ECG) demonstrating a QTc interval ≥ 450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Seropositivity for hepatitis C virus (antibodies to HCV) at screening (b)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Finding on safety laboratory values as defined below:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "AST > 2 x upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "ALT > 2 x upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Anaemia (Hb < 10 g/dL),",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Platelets < 150,000",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Total bilirubin > 2 x upper normal limit",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Abnormalities of examination or investigations at screening. Including: hepatomegaly, right upper quadrant abdominal pain or tenderness, abnormal blood tests (as defined in the protocol which are not listed above)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Positive malaria parasitaemia (RDT) at screening or baseline (Month 0, Day 0).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Receipt or planned receipt of an investigational medical product or participation in an interventional clinical trial during the study period",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Contraindications to the use of artemisinins, piperaquine or primaquine*. Including: use of medications with known potential interactions, prior allergic reactions to one or more components of the drug regimen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg products)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of clinically significant contact dermatitis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Contraindication to intramuscular (IM) injection*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Administration of a vaccine not included in the study protocol within 30 days of a study vaccine (c).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "History of anaphylaxis post-vaccination.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "Administration of immunoglobulins and/or any blood products during the period starting three months before the first dose of study vaccine or planned administration during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05252845",
    "statement": "subject to the investigator's judgement",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Malaria infection (either locally transmitted or imported) detected at a health facility via passive surveillance, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Resides in a study Enumeration Area (EA), and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "RACD Intervention Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case resides in study EA, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Residents of the six houses closest to the index case, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "rfMDA Intervention Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case resides in study EA, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Residents of the six houses closest to the index case, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Artemether/Lumefantrine (A-L) (combination medication) Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Consent to take A-L medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Does not meet A-L Exclusion Criteria under item #4 below",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Pill count Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "People who receive any number of RACD or rfMDA drug dose(s)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Reactive Vector Control Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Informed consent provided by head of household or person in otherwise in charge of household, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case resides in study EA, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index household and 6 non-index households closest to index household",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Endline Survey, Individual, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Resides or spent at least 1 night in the EA in the preceding 4 weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with study participants, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Resident of index household or of neighbouring households",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with key stakeholders, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "In leadership position within Zambezi region, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interview with refusers, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refused to participate in rfMDA, RACD, and/or RAVC, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent to take part in the anonymous survey",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Focus group discussions with study participants, Inclusion Criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Provides informed consent, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Was eligible to be enrolled in the study in participant's Target Area, and",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Either took part in RACD or rfMDA intervention (+/- RAVC), OR refused these interventions",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Malaria infection identified through active case detection",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "RACD Intervention Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case does not reside in study EA, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in RACD, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household received the intervention in the previous 5 weeks, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household > 500 m from the index case, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "rfMDA Intervention Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Index case does not reside in study EA, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in rfMDA, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household received the intervention in the previous 5 weeks, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household > 500 m from the index case, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Artemether/Lumefantrine (combination medication) Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Pregnancy in first trimester, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Previous regular menstruation, with no menstruation for most recent 4 weeks, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Weight < 5 kg*, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Severe malaria, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Known allergy to A-L, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal of the offered A-L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Note regarding A-L weight exclusion: Because of the pre-set required field at the top of the Eligibility section of this Application, the investigators have indicated a 6 month minimum age limit, primarily to note to the reader that there will be a lower age limit to infants enrolled. Yet during the actual conduct of this trial the investigators will utilize 5 kg weight as the cutoff, rather than using age. A lower weight cutoff of 5 kg is in accordance with A-L's manufacturer (Novartis)'s guidance on supporting pediatric data.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Pill count Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in pill count, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Individuals who did not receive any drug doses through RACD or rfMDA",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Reactive Vector Control Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal by head of household to participate in RAVC, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Already received RAVC during current transmission season, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Household is > 500 m from index case household (note: refusal to participate in RACD or rfMDA is not an exclusion criterion for RAVC)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Endline Survey, Individual, Exclusion Criteria: • Refusal to participate in Endline Survey (note: lack of participation in rfMDA or RACD is not an exclusion criterion)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with study participants, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Key stakeholder [see below]",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Age < 15 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interviews with key stakeholders, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Not in leadership position",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Individual Interview with refusers, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Age < 15 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Acceptability Assessment: Focus group discussions with study participants, Exclusion Criteria:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Refusal to participate in Acceptability Assessment, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Speaks language not understood or able to be translated, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Key stakeholder or in another leadership position, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02610400",
    "statement": "Age < 15 years",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "The patient's parent or attendant relative has provided informed consent and the patient has assented (where relevant) to participation in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "The patient is a child that weighs between 5 and 15 kg (kilogram)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "The patient has falciparum malaria as evidenced by",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Thick or thin blood smears of > 500 P falciparum per mcl (microlitre)(patients with mixed infections may be included provided >500 P Falciparum /mcl) and /or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Positive RDT (rapid diagnostic test)for malaria",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "The patient has either",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "severe or complicated malaria as determined by the Investigator based on the WHO criteria for severity, or",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "the patient has uncomplicated malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Attending relative or parent does not provide informed consent for participation, or the child if capable does not assent to participation in the trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Ability to tolerate oral therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Patient has received any treatment with an artemisinin or quinine in the last 24 hours",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01047436",
    "statement": "Patient is allergic or intolerant to artemisinins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Healthy adults (males and non-pregnant, non-lactating females) between the ages of 18 and 45 years, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Able and willing to participate for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Able and willing to provide written (not proxy) informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Provides informed consent before any study procedures, correctly answers >/= 70% of questions on the post consent quiz and is available for all study visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Women of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each vaccination and on the day of malaria challenge.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Not sterilized via bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or menopausal and still menstruating or < 1 year of the last menses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Women of childbearing potential must have used an acceptable method of contraception* in the 30 days prior to enrollment and must agree to continue use of the same method throughout the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes, but is not limited to, abstinence from sex with men, monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to enrollment, barrier methods such as condoms or diaphragms with spermicide or foam, effective intrauterine devices, NuvaRing, successful Essure placement (permanent, non-surgical, non-hormonal sterilization) with documented confirmation test at least 3 months after the procedure, and licensed hormonal methods such as implants, injectables, or oral contraceptives.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Is in good health, as judged by the investigator, and determined by vital signs (heart rate, blood pressure, and oral temperature), medical history and physical examination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Able to understand and comply with planned study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Reachable (24/7) by mobile phone during the whole study period and willing to provide two close contacts to assist with making contact.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Lives in the greater Seattle area and within an approximately one hour commute to the study research clinic.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Willing to avoid non-study related blood donation for 3 years following P. falciparum challenge.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Agrees not to travel to a malaria endemic region during the entire course of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Agrees not to travel away from the greater Seattle area from the day of first study immunization through 20 days after the last study immunization, and during the 29 days after CHMI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of malaria infection or vaccination, residence in a malaria-endemic area for > / =5 years, travel to a malaria-endemic area in the past 6 months, or participation in a malaria research study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Is breastfeeding or plans to breastfeed at any time throughout the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Plans to become pregnant at any time throughout the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Use of any antimalarial antibiotic or drug within 28 days prior to Study Day 1 or planned use during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Any clinically significant acute or chronic medical condition* or need for chronic medications** that, in the opinion of the investigator, will interfere with immunity or affect safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes, but is not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt of systemic, prescription medications for the treatment of chronic medical conditions or variations of normal physiologic functions are permissible if, in the opinion of the investigator, they are used for conditions that are not clinically significant and would not impact the effectiveness of the vaccine or the safety of the subject or the safety and immunogenicity outcomes of the protocol. Use of systemic, over-the-counter medications and PRN systemic, prescription medications are allowed if, in the opinion of the investigator, they pose no additional risk to subject safety, vaccine efficacy or assessment of immunogenicity/reactogenicity. Topical (except corticosteroid) medications, nasal (including corticosteroid) medications, vitamins, and supplements are permissible. Any drug with antimalarial properties is not permissible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Asthma, other than mild, well-controlled asthma*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Cold or exercise induced asthma controlled with inhaled medications other than inhaled corticosteroids is permissible. Subjects should be excluded if they require daily bronchodilator use, or have had an asthma exacerbation requiring oral/parenteral steroid use or have used theophylline or inhaled corticosteroids in the past year.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of a psychiatric condition that may make study compliance difficult, such as schizophrenia, or unstable bipolar disorder*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes persons with psychoses or history of suicide attempt or gesture in the 3 years before study entry or an ongoing risk for suicide.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Any history of non-febrile seizures or complex febrile seizures*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of simple febrile seizures or a family history of seizure disorder is not exclusionary",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Autoimmune disease (autoimmune thyroid disease is permissible and vitiligo or mild eczema not requiring chronic therapy is permissible).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Known or suspected congenital or acquired immunodeficiency including anatomic or functional asplenia* or immunosuppression as a result of underlying illness or treatment. *Any splenectomy is exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Abuse of alcohol or drugs that, in the opinion of the investigator, may interfere with the subject's ability to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Body mass index (BMI) > / = 35 kg/m^2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Active neoplastic disease*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Chronic topical or systemic corticosteroid use*.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons using a topical corticosteroid for a limited duration for mild uncomplicated dermatitis such as poison ivy or contact dermatitis may be enrolled the day after their therapy is completed. Oral or parenteral (IV, SC, or IM) corticosteroids given for non-chronic conditions not expected to recur are permissible if, within the year prior to enrollment, the longest course of therapy was no more than 14 days and no oral or parenteral corticosteroids were given within 30 days prior to enrollment. Intraarticular, bursal, tendon, or epidural injections of corticosteroids are permissible if the most recent injection was at least 30 days prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt or planned receipt of inactivated vaccine or allergy desensitization injection from 14 days before the first immunization through 14 days after the last immunization.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Planned receipt of inactivated vaccine or allergy desensitization injection from 14 days prior to CHMI through 28 days after CHMI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt or planned receipt of live attenuated vaccine 30 days before or at any time during the study up to 28 days after CHMI.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt of any experimental agent* within 30 days prior to enrollment or planned receipt prior to the end of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Vaccine, drug, biologic, device, blood product, or medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Plans to enroll in another clinical trial* that could interfere with safety assessment of the investigational product at any time during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Includes trials that have a study intervention such as a drug, biologic, or device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Receipt of blood products or immunoglobulin within six months prior to Study Day 1 or donation of a unit of blood within two months before Study Day 1.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Systolic blood pressure > / = 161 mm Hg or diastolic blood pressure > / = 96 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Resting heart rate < 55 or > 100 beats per minute.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Oral temperature > / = 38 degrees C (100.4 degrees F).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Positive serology for HIV 1/2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Positive hepatitis B surface antigen (HBsAg).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Positive antibody to hepatitis C virus (HCV).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Any Grade 1 or higher screening clinical lab value* (see Toxicity Tables Section 9.2.3).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Screening clinical labs include blood tests (white blood cells [WBC], hemoglobin, platelets, creatinine, non-fasting glucose, potassium, alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) and urine dipstick tests (protein, glucose, hemoglobin). Any Grade 1 or higher value for any screening test will exclude the subject from enrollment with the exception of hematuria > / = 1 + detected during menses or other endometrial bleeding for females. In this situation, the test can be repeated if clinically warranted but is not considered an indicator of poor health status or increased risk and so is not a contraindication to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Acute febrile illness (oral temperature > / = 38 degrees C [100.4 degrees F]) or other acute illness within 3 days prior to vaccination (subject may be rescheduled).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "A screening ECG with abnormalities consistent with underlying heart disease.*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has a history of psoriasis or porphyria.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has a known allergy to chloroquine, 4-aminoquinoline derivatives, atovaquone, proguanil,artemether-lumenfantrine, 8-aminoquinoline derivatives, non-steroidal anti- inflammatory drugs, or acetaminophen.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Antacids and kaolin can be administered at least 4 hours from intake of chloroquine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Does not apply to infectivity controls",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "History of retinal or visual field changes, clinically significant auditory damage, or G6PD deficiency.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has history of or a positive test for sickle cell disease or trait or other hemoglobinopathy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Plans to undergo surgery (elective or otherwise) between enrollment and the end of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Known hypersensitivity to PfSPZ or its components.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02773979",
    "statement": "Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "All of the following criteria must be fulfilled for a volunteer to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "EXCEPTIONS to required pregnancy prevention includes the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "7. Willing to have blood samples stored for future research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "INCLUSION CRITERIA FOR GROUP 4:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "All of the following criteria must be fulfilled for a volunteer to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Inclusion Criteria for Groups 1, 2, 3, (Year 2)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "All of the following criteria must be fulfilled for a volunteer to continue to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "1. Previously enrolled in the study and has received at least 1 vaccination.\n2. Available for the duration of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "3. In good general health and without clinically significant medical history in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "4. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to scheduled vaccine dose #4 and until 1 month after the 4th vaccination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "-A reliable method of birth control includes one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "EXCEPTIONS to required pregnancy prevention includes the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Inclusion Criteria for Group 4 (Year 2):",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "All of the following criteria must be fulfilled for a volunteer to continue to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "EXCLUSION CRITERIA FOR GROUPS 1, 2, 3:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Co-enrollment guidelines: Co-enrollment in other trials is restricted, other than enrollment on observational studies.\nConsideration for co-enrollment in trials evaluating the use of a licensed medication will require the approval of the PI.\nStudy staff should be notified of co-enrollment on any other protocol as it may require the approval of the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Exclusion Criteria for Group 4:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Exclusion Criteria for Groups 1, 2, 3 (Year 2):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Exclusion Criteria for Group 4 (Year 2):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "1. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "2. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "3. History of adverse reactions to artemether/lumefantrine in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "4. History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "5. Current or planned participation in an investigational vaccine study until the last required protocol visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "6. Receipt of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "INCLUSION CRITERIA FOR GROUPS 1,2,3:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Meets age requirements for Arm currently being enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Available for the duration of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "In good general health and without clinically significant medical history in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Females of childbearing potential must be willing to use reliable contraception from 21 days prior to Study Day 0 and until 1 month after the last vaccination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "A reliable method of birth control includes one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Confirmed pharmacologic contraceptives (parenteral) delivery;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Intrauterine or implantable device",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Postmenopausal state: defined as no menses for 12 months without an alternative medical cause",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Surgical sterilization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Unmarried AND not sexually active AND menstruating OR not menstruating females 12-17 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become >=18 years of age, married, or sexually active), the female will be required to start reliable contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Meets age requirements for Arm currently being enrolled.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Available for the duration of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "In good general health and without clinically significant medical history in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Willing to have blood samples stored for future research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Confirmed pharmacologic contraceptives (parenteral) delivery;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Intrauterine or implantable device",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Postmenopausal state: defined as no menses for 12 months without an alternative medical cause",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Surgical sterilization",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Unmarried AND not sexually active AND menstruatingOR not menstruating females 12-17 years of age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become greater than or equal to 18 years of age, married, or sexually active), the female will be required to start reliable contraception",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Willing to have blood samples stored for future research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Previously enrolled in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Available for the duration of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "In good general health and without clinically significant medical history in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Willing to have blood samples stored for future research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (beta-hCG) test (if female). NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Menstruating females 11 years of age and younger. (In order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory defined limits of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and <= Grade 2.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory defined upper limit of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and <= Grade 2.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Infected with HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Clinically significant prolonged QTc (>450 milliseconds) on screening EKG",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Current or planned participation in an investigational vaccine study until the last required protocol visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Known:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sj(SqrRoot)(Delta)gren s syndrome, or autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Seizure disorder (exception: history of simple febrile seizures)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Asplenia or functional asplenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Use of chronic (>=14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Allergy to latex or neomycin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Adverse reaction to hepatitis A and/or typhoid and/or meningococcal vaccine in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Adverse reaction to artemether/lumefantrine in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Receipt of: -Live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Immunoglobulins and/or blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Investigational malaria vaccine in the last 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Clinically significant prolonged QTc (by sex/age) on screening EKG",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "History of adverse reactions to artemether/lumefantrine in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Current or planned participation in an investigational vaccine study until the last required protocol visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Receipt of: -Investigational malaria vaccine in the last 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (beta-hCG) test (if female). NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Menstruating females 11 years of age and younger. (In order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory defined limits of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and less than or equal to Grade 2.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory defined upper limit of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and less than or equal to Grade 2.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Infected with HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Known: -Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years. -Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren s syndrome, or autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Seizure disorder (exception: history of simple febrile seizures)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Asplenia or functional asplenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Use of chronic (greater than or equal to 14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Allergy to latex or neomycin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Adverse reaction to hepatitis A and/or typhoid and/or meningococcal vaccine in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Adverse reaction to artemether/lumefantrine in the past",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Receipt of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Immunoglobulins and/or blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03917654",
    "statement": "Investigational malaria vaccine in the last 2 years. 7. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Male or female aged 2 years to <13-year-old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Uncomplicated falciparum malaria as defined as:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Positive blood smear with asexual forms of P. falciparum (may be mixed with non-falciparum species)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Parasitaemia between 5,000-250,000 parasites/µL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Fever defined as tympanic temperature >37.5°C or history of fever within last 48 hours",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Ability to take oral medication",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Willingness and ability to comply with study protocol for study duration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Written informed consent given to participate in the trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Signs of severe/complicated malaria*",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Any clinical reason suggesting that the child's treatment should be given immediately and not delayed during the transfer to Kilifi County Hospital in the opinion of the treating physician.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Acute illness other than malaria requiring urgent systemic treatment as assessed by the treating physician",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Previous splenectomy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Treatment with artemisinin or ACT within the previous 7 days",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Treatment with mefloquine in the 2 months prior to presentation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Known hypersensitivity or contraindication to arterolane-piperaquine, DHA-piperaquine, artemisinin, mefloquine (epilepsy, major psychiatric illness) or primaquine",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "QTc interval >450 milliseconds at point of presentation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Known personal or family history of cardiac conduction problems",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03452475",
    "statement": "Participation within another clinical trial in the previous 3 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "All of the following criteria must be fulfilled for a volunteer to participate in this trial:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "An individual will be excluded from participating in this trial if any one of the following criteria is fulfilled:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Age: > 18 years old and < 50 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Available for the duration of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Known resident or long-term resident (more than 1 year) of Sotuba, Mali or surrounding villages.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "In good general health and without clinically significant medical history in the opinion of the investigator.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Females of childbearing potential must be willing to use reliable contraception from 21 days prior to Study Day 0 and until 1 month after the last vaccination.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "A reliable method of birth control includes one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Confirmed pharmacologic contraceptives (parenteral) delivery.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Intrauterine or implantable device.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "EXCEPTIONS to required pregnancy prevention includes the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Postmenopausal state: defined as no menses for 12 months without an alternative medical cause.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Surgical sterilization.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Willing to have blood samples stored for future research.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (β hCG) test (if female). NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject's age.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory-defined limits of normal. (Subjects may be included at the investigator's discretion for \"not clinically significant\" values outside of normal range and ≤ Grade 2.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal. (Subjects may be included at the investigator's discretion for \"not clinically significant\" values outside of normal range and ≤ Grade 2.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Infected with HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "History of receiving any investigational product within the past 30 days.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Current or planned participation in an investigational vaccine study until the time period of the last required study visit under this protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "History of a severe allergic reaction or anaphylaxis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Known:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjögren's syndrome, or autoimmune thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Immunodeficiency syndrome.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Seizure disorder (exception: history of simple febrile seizures).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Asplenia or functional asplenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Use of chronic (≥14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Allergy to latex or neomycin.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Receipt of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Live vaccine within 4 weeks prior to enrollment or a killed vaccine within 2 weeks prior to enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Immunoglobulins and/or blood products within the past 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Investigational malaria vaccine in the last 2 years.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05135273",
    "statement": "Any other condition that in the opinion of the investigator would jeopardize the safety or rights of a subject participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Subjects must meet all of the following inclusion criteria to be eligible for enrollment in this study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "A subject meeting any of the following exclusion criteria are not eligible for enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "18 through 50 years of age, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Able and willing to participate for the duration of the study and able to understand and comply with planned study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Able and willing to provide written (not proxy) informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Provides informed consent before initiation of any study procedure, correctly answers = / > 80 percent of questions* on the post consent quiz and is available for all study visits. *Subjects who score less than 80 percent may retake the quiz one time and are excluded if the second test is also less than 80 percent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Is in good health, as judged by the investigator, and determined by medical history and physical examination. *Existing medical diagnoses or conditions (except those in the Subject Exclusion Criteria) must be deemed as stable. A stable medical condition is defined as no change in prescription medication, dose, or frequency of medication in the last three months (90 days) and health outcomes of the specific disease are considered to be within acceptable limits in the last six months (180 days). Any change due to change of health care provider, insurance company, or that is done for financial reasons, as long as in the same class of medication, will not be considered a violation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a violation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of solicited events and immunogenicity.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Women of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each mosquito exposure**.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Not sterilized via bilateral tubal ligation, bilateral oophorectomy, or hysterectomy, or, if menopausal, still menstruating or < 1 year of the last menses.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Study vaccination or CHMI",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Women of childbearing potential must have used a highly effective form of contraception* in the 30 days prior to their first mosquito exposure**. *Highly effective single forms of contraception include abstinence from sexual activity that could lead to pregnancy, monogamous relationship with vasectomized partner who has been vasectomized for six months or more prior to enrollment, successful Essure (R) placement (permanent, non-surgical, non-hormonal sterilization) with documented confirmation test at least three months after the procedure, or use of effective intrauterine devices or the contraceptive implant (Nexplanon). If none of the highly effective single forms of contraception is used, a combination of an acceptable barrier method and an acceptable hormonal method must be used. Acceptable barrier methods include condom (male or female) and a spermicide (cream, film, foam, or gel), diaphragm or cervical cap with spermicide, and the birth control sponge. Acceptable hormonal methods include birth control patch, shot (Depo-Provera), and pills, and the vaginal ring (NuvaRing). **Study vaccination or CHMI.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Women of childbearing potential must agree to continue use of a highly effective form of contraception through 90 days after their last mosquito exposure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "For women, must not be breastfeeding or plan to start breastfeeding at any time before the end of study follow up.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "At low (< / = 10 percent) 5-year cardiovascular risk*. *Per the risk prediction method of Gaziano (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864150/). Risk for persons < 35 years of age will be based on the age 35-44 group.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No history of malaria infection or vaccination, residence in a malaria-endemic area for > / = 5 years, or participation in a malaria research study*. *Participation without exposure to malaria infection or to a malaria vaccine is not exclusionary.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No receipt of malaria prophylaxis or travel to a malaria-endemic area in the six months prior to first mosquito exposure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No receipt of blood products or immunoglobulin within six months prior to, or donation of a unit of blood within two months prior to, enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Weight > / = 50 kg and body mass index (BMI) < 35 kg/m^2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Negative serology for HIV 1/2*. *If the ELISA is positive, HIV confirmation should be performed. If the HIV Western Blot is not consistent with HIV infection, the subject may be enrolled. A past subject in an HIV vaccine trial who has a positive antibody ELISA may participate if the Western Blot is not consistent with pending seroconversion or positive or an HIV PCR assay result is below the level of detection of HIV.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Negative hepatitis B surface antigen and hepatitis C virus antibody.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No Grade 1 or higher screening clinical lab value*. *Screening clinical labs include blood tests (white blood count [WBC], hemoglobin, platelet count, creatinine, and alanine aminotransferase [ALT]) and urine dipstick tests (protein and hemoglobin). Any Grade 1 or higher value for any screening test will exclude the subject from enrollment with the exception of hematuria > / = 1 + detected concurrent with endometrial bleeding for females. In this situation, the test can be repeated if clinically warranted but is not considered an indicator of poor health status or increased risk and so is not a contraindication to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Screening ECG with no clinically significant abnormalities*. *Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT / QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No known allergy to mosquito bites, chloroquine, hydroxychloroquine, amodiaquine atovaquone, proguanil, non-steroidal anti-inflammatory drugs, or acetaminophen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No known sickle cell trait or other hemoglobinopathy.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Negative sickle cell screening laboratory test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Does not plan to undergo surgery (elective or otherwise) between screening and the end of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No dermatologic abnormalities in either forearm that could impair assessment of local reactions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No history of psoriasis or porphyria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No history of G6PD deficiency.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "No contraindication to repeated phlebotomy*. *Such as minimal venous access or recent history of anemia.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Reachable (24/7) by mobile phone during the duration of the study period and willing to provide two close contacts to assist with making contact.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Lives in the greater Seattle area and within an approximately one hour commute to the study research clinic.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Willing to avoid non-study related blood donation for the duration required by the blood bank* following last mosquito exposure. *Bloodworks Northwest prohibits donation from persons who have had malaria.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Agrees not to travel to a malaria endemic region during the entire course of the trial.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Agrees not to travel away from the greater Seattle area in the 14 days after a study immunization*, and from the day of CHMI until the end of malaria treatment visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Subjects in Study Arms 1 and 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Use of any antibiotic or drug with antimalarial properties within 28 days prior to first mosquito exposure or planned use during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Any clinically significant acute or chronic medical condition* or need for chronic medications** that, in the opinion of the investigator, will interfere with immunity or affect safety. *Includes, but is not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions. **Receipt of systemic, prescription medications for the treatment of chronic medical conditions or variations of normal physiologic functions are permissible if, in the opinion of the investigator, they are used for conditions that are not clinically significant and would not impact the effectiveness of the vaccine or the safety of the subject or the safety and immunogenicity outcomes of the protocol. Use of systemic, over-the-counter medications and PRN systemic, prescription medications are allowed if, in the opinion of the investigator, they pose no additional risk to subject safety, vaccine efficacy or assessment of immunogenicity/reactogenicity. Topical (except corticosteroid) medications, nasal (including corticosteroid) medications, vitamins, and supplements are permissible. Following enrollment, use of topical corticosteroid medications for treatment of GAP3KO administration reactions is permissible. Any drug with antimalarial properties is not permissible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Asthma, other than mild, well-controlled asthma*. *Cold or exercise-induced asthma controlled with inhaled medications other than inhaled corticosteroids is permissible. Subjects should be excluded if they require daily bronchodilator use, or have had an asthma exacerbation requiring oral/parenteral steroid use or have used theophylline or inhaled corticosteroids in the past year",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Known atherosclerotic cardiovascular disease or history of myocardial infarction, pericarditis, or myocarditis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Diabetes mellitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "History of a psychiatric condition that may make study compliance difficult, such as schizophrenia or bipolar disorder*. *Includes persons with psychoses or history of suicide attempt or gesture in the 3 years before study entry or an ongoing risk for suicide.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Chronic or active neurologic condition (including seizures and migraine headaches).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Autoimmune disease (autoimmune thyroid disease is permissible and vitiligo or mild eczema not requiring chronic therapy is permissible).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Known or suspected congenital or acquired immunodeficiency including anatomic or functional asplenia* or immunosuppression as a result of underlying illness or treatment. *Any splenectomy is exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Abuse of alcohol or drugs that, in the opinion of the investigator, may interfere with ability to comply with the protocol or increase risk to subject's health during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Active neoplastic disease*. *Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months). Cervical neoplasia under surveillance is acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Chronic topical or systemic corticosteroid use*. *Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons using a topical corticosteroid for a limited duration for mild uncomplicated dermatitis such as poison ivy or contact dermatitis prior to enrollment may be enrolled the day after their therapy is completed. Oral or parenteral (intravenous, intramuscular, subcutaneous) corticosteroids given for non-chronic conditions not expected to recur are permissible if, within the year prior to enrollment, the longest course of therapy was no more than 14 days and no oral or parenteral corticosteroids were given within 30 days prior to enrollment. Intraarticular, bursal, tendon, or epidural injections of corticosteroids are permissible if the most recent injection was at least 30 days prior to enrollment. Topical or systemic corticosteroid use for study related adverse events is not exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Receipt or planned receipt of inactivated vaccine or allergy desensitization injection within 14 days before or after a mosquito exposure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Receipt or planned receipt of live attenuated vaccine within 28 days before or after a mosquito exposure.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Current use of tenofovir/emtricitabine (Truvada).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Receipt of any experimental agent* within 30 days prior to screening or planned receipt prior to the end of the study. *Vaccine, drug, biologic, device, blood product, or medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Plans to enroll in another clinical trial* that could interfere with safety assessment of the investigational product at any time during the study period. *Includes trials that have a study intervention such as a drug, biologic, or device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Systolic blood pressure > / = 161 mm Hg or diastolic blood pressure > / = 96 mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Resting heart rate < / = 49 or > / = 101 beats per minute.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Oral temperature > / = 38 degree Celsius (100.4 degree Fahrenheit).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Acute febrile illness (oral temperature = / > 38 degree Celsius [100.4 degree Fahrenheit]) or other acute illness within three days prior to mosquito exposure*. *Note for afebrile, acute illness only: If a subject is afebrile, his/her acute illness is nearly resolved with only minor residual symptoms remaining, and, in the opinion of the site principal investigator or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol, the subject may receive the subsequent study vaccination or CHMI without further approval from the DMID Medical Officer.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Is using or intends to use within 28 days after a mosquito exposure a medication with a known interaction with atovaquone-proguanil* or chloroquine**. *Includes, for example, tetracycline (may reduce atovaquone concentrations), or metoclopramide (may reduce bioavailability of atovaquone). **Includes, for example, cimetidine, metoclopramide, carbamazepine, phenytoin, St. John's wort, and antidepressants. Antacids and kaolin may reduce absorption of chloroquine but can be administered if separated by at least 4 hours from intake of chloroquine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03168854",
    "statement": "Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "4. History of recurrent headache (e.g.\ntension-type, cluster or migraine), recurrent nausea, and/or vomiting with a frequency of ≥2 episodes per month on average and severe enough to require medical therapy, during the six months preceding the screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "15. Evidence of acute illness within the four weeks prior to screening that the PI/Co-investigator deems may compromise participant safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "16. Significant inter-current disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "17. Participant has a clinically significant disease or any condition or disease that might affect drug absorption, distribution or excretion (e.g.\ngastrectomy, diarrhea).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "18. Use of prescription or non-prescription drugs, herbal and dietary supplements within 14 days or five blood elimination half-lives (whichever is the longer) prior to the first dose of tafenoquine.\nThe exceptions are: Ibuprofen (preferred) may be used at doses of up to 1.2 g per day or paracetamol at doses of up to 4 g per day.\nLimited use of other non-prescription medications or dietary supplements not believed to affect participant safety or the overall results of the study may be permitted on a case-by-case basis following approval by the Sponsor in consultation with the PI or Co-investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "19. History of retinal abnormalities, diseases of the retina or macula of the eye, visual field defects, and hearing disorders like reduced hearing and tinnitus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "20.\nAny participant who, in the judgment of the PI or Co-investigator, is likely to be non-compliant during the study, or is unable to cooperate because of a language problem or poor mental development.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "21. Any participant who is directly involved in conducting the study.\n22.\nAny participant with poor peripheral venous access for blood sampling.\n23.\nKnown hypersensitivity reactions to primaquine, other 8-aminoquinolines, or any component of Arakoda™.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Male or female aged 18 to 55 years inclusive who will be contactable and available for the duration of the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Total body weight greater than or equal to 45 kg, and a body mass index (BMI) within the range of 18 to 32 kg/m2 (inclusive).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Vietnamese (Kinh people) or belonging to one of the other 53 ethnic groups in Vietnam.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "G6PD enzyme activity levels of >70% of the site median value for normal G6PD using a quantitative G6PD test.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Certified as in good health as determined by a comprehensive clinical assessment (past medical history, complete physical examination, vital signs, ECG) and laboratory tests (biochemical, hematology and urinalysis results at screening that are within the local laboratory reference range).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Vital signs at screening and throughout the study (measured after five minutes in the supine position) within the following ranges:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Systolic blood pressure (SBP) - 90-140 mmHg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Diastolic blood pressure (DBP) - 40-90 mmHg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Heart rate (HR) 40-100 bpm.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "ECG ranges at screening: Time from the start of the Q wave to the end of the T wave (QT) corrected (QTc) by Bazett's formula (QTcB)/QT interval corrected by Fridericia's formula (QTcF) ≤450 ms for male participants, QTcB/QTcF ≤470 ms for female participants, and Pulse Rate (PR) interval ≤210 ms.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "A female participant of childbearing potential is eligible to enter the study if she is non-pregnant, non-lactating, has a negative pregnancy test at the screening visit and agrees to comply with one of the following contraceptive procedures during the study and for a period of 90 days after the last dose of tafenoquine. - Use of oral contraceptive, either combined or progestogen alone used in conjunction with a double barrier method. - Use of an intrauterine device with a documented failure rate of <1% per year. - Use of depo provera injection. - Double barrier method consisting of spermicide with either condom or diaphragm. - Male partner who is sterile prior to the female participant's entry into the study and is the sole sexual partner for the female. - Complete abstinence from intercourse for two weeks prior to tafenoquine administration, throughout the study and for a period of 90 days after the last dose of tafenoquine.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Women of non-childbearing potential who will not require contraception during the study are defined as: surgically sterile or post-menopausal.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Male participants who have, or may have, female sexual partner(s) during the course of the study must agree to one of the following acceptable double methods of contraception: - Condom plus diaphragm or condom plus insertable device, or condom plus stable oral/transdermal/injectable hormonal contraceptive by the female partner. - Surgical sterilization (vasectomy) and a barrier method (condom or occlusive cap).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Abstinent male participants must agree to start a double method of contraception if they begin sexual relationships with a female during the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Willing and able to comply with all scheduled visits, physical examination, AE questionnaire, laboratory tests, and other study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Willingness to complete an acceptability questionnaire after each tafenoquine regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Completion of the written informed consent process prior to undertaking any study-related procedure.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Female participants who are pregnant or breast feeding (lactating).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Resting vital signs (measured after 5 minutes) at screening outside of the following ranges:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Body temperature (i.e. tympanic body temperature >38.0°C).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "40 ≤ PR ≥ 100 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "90 ≤ SBP ≥ 140 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "50 ≤ DBP ≥ 90 mmHg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Presence of acute infectious disease or fever (i.e. tympanic body temperature >38.0°C) within 5 days prior to the first dose of study medication.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Cardiac/QT risk: - Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Electrolyte disturbances, particularly hypokalemia, hypocalcaemia, or hypomagnesaemia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "ECG abnormalities in the standard 12-lead ECG at screening which in the opinion of the PI/Co-PI is clinically relevant or will interfere with the ECG analyses.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Positive result for any of the following serology tests: hepatitis B surface antigen (HBs Ag), anti-hepatitis B core antibodies (anti-HBc Ab), anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Any recent (<6 weeks) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (e.g. azithromycin, clindamycin, doxycycline, trimethoprim/sulfamethoxazole, hydroxychloroquine etc.) (only participants providing blood for ex vivo antimalarial studies of tafenoquine).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Participants are currently taking medications and chemicals that are commonly associated with the development of hemolytic anemia such as chloroquine, dapsone, fava beans, flutamide, methylthioninium chloride, nitrofurantoin, pegloticase, phenazopyridine, primaquine, rasburicase, and trimethoprim/sulfamethoxazole.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "History or presence of diagnosed (by an allergist/immunologist) or treated (by a physician) food or known drug allergies or any history of anaphylaxis or other severe allergic reactions including face, mouth, or throat swelling or any difficulty breathing. Participants with seasonal allergies/hay fever can be enrolled in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Presence of current or suspected serious chronic diseases such as cardiac or autoimmune disease, insulin-dependent and non-insulin dependent diabetes, progressive neurological disease, severe malnutrition, acute or progressive hepatic disease, acute or progressive renal disease, porphyria, psoriasis, rheumatoid arthritis, asthma (excluding childhood asthma, or mild asthma with preventative asthma medication required less than monthly), epilepsy, or obsessive-compulsive disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within five years of screening, regardless of whether there is evidence of local recurrence or metastases.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Participants with history of schizophrenia, bi-polar disease, psychoses, disorders requiring lithium, attempted or planned suicide, or any other severe (disabling) chronic psychiatric diagnosis.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "Participants who have received psychiatric medications within one year prior to screening, or who have been hospitalized within five years prior to screening for either a psychiatric illness or due to danger to self or others.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05203744",
    "statement": "History of an episode of minor depression that required at least six months of pharmacological therapy and/or psychotherapy within the last five years; or any episode of major depression. The Beck Depression Inventory (BDI) will be used as an objective tool for the assessment of depression at screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one or more of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "fever at the time of evaluation (axillary temperature greater than or equal to 37.5 degrees Celsius by digital thermometer)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "report of fever within the last two days",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "clinically profound anemia (conjunctival or palmar pallor)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "headache",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "body aches",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "abdominal pain",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "decreased intake of food or fluids",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "weakness",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Weight greater than or equal to 5kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Positive malaria smear for P. falciparum mono-infection with parasite density 2,000-200,000/mm^3.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Planning to remain in the study area for 1 year.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Willingness to return for four-weekly routine visits, as well as unscheduled sick visits.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Parental/guardian consent for each participant.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Signs of severe malaria: One or more of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "hemoglobin less than or equal to 5 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "prostration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "respiratory distress",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "bleeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "recent seizures, coma or obtundation (Blantyre coma score < 5)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "inability to drink",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "persistent vomiting",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Known allergy or history of adverse reaction to chloroquine (CQ), artesunate, azithromycin, erythromycin or atovaquone-proguanil (AP)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Chronic medication with any antibiotic or anti malarial medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Previous enrollment in this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Alanine aminotransferase (ALT) more than 5x the upper limit of normal or creatinine greater than 3x the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00379821",
    "statement": "Evidence of chronic disease or physical stigmata of severe malnutrition (i.e., loss of muscle mass or subcutaneous tissue, edema, or skin or hair findings consistent with severe malnutrition)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Are 18-70 years of age, inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Can understand and sign an informed consent, communicate with the investigator, and understand and comply with the protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have had a diagnosis of type 1 or type 2 diabetes for a period of at least 1 year.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Use insulin injections at home for glucose control and are on a stable insulin regimen without more than a 20% change in their total daily insulin dose during the previous 3 months. Their total daily insulin dose during the previous 3 months will be confirmed through a review of the subject's electronic health record, insulin prescriptions, and insulin pump settings (if applicable).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a hemoglobin A1c (HbA1c) in the range of 7.0 - 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a hemoglobin in the normal range for sex:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Females: 12-15.5 grams/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Males: 13.5-17.5 grams/dl.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have adequate venous access sites in upper extremities.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Body weight between 40 - 150 kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have participated in an interventional medical, surgical, or pharmaceutical study within 30 days of screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a known hypersensitivity to any of the components of study treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have skin disease/injury at Dexcom G6 CGM insertion site(s) that would prevent insertion of the CGM.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a medical condition that in the opinion of the investigator could affect study participation and/or personal well-being.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a clinically significant history or presence of any of the following conditions:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Hepatic failure or has alanine aminotransferase (ALT) greater than 3 times the upper limit of normal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Has an estimated glomerular filtration rate (GFR) <60 ml/min/1.73 m2 or End Stage Kidney Disease on renal replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Type 2 diabetic subjects who have a C-peptide level less than 0.2 nmol/L (these subjects will be referred to their primary care doctor or endocrinologist for further work up).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have congestive heart failure of class 1 or greater on the New York Heart Association (NYHA) classification system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a history of seizures.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a history of cerebrovascular accident.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a history of ischemic heart disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "For female subjects of potential childbearing age (age 18 to 55) they will be excluded if:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Pregnant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Refuse to agree to a pregnancy test at the time of enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a positive urine pregnancy test at the time of enrollment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a positive COVID-19 test within 14 days of visit 3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have any COVID-19 related symptoms in the 14-day period prior to visit 3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05644730",
    "statement": "Have a known unprotected COVID-19 exposure in the 14-day period prior to visit 3.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "Patients with type 2 diabetes mellitus who have not adequately responded to any one of the following therapies:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "Diet therapy and exercise therapy alone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "In addition to diet therapy and exercise therapy, use of α-glucosidase inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "Patients contraindicated for Nesina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes mellitus (these patients require prompt adjustment of hyperglycemia by fluid infusion and insulin, and hence use of Nesina is not appropriate.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "Patients with severe infection, pre- or post-operative patients, or patients with serious traumatic injury (blood glucose control by insulin injection is desirable for these patients, and hence use of Nesina is not appropriate.)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01945216",
    "statement": "Patients with a history of hypersensitivity to any ingredient of Nesina",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Female age 18 to 55 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Healthy as determined by laboratory results and medical history",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Waist circumference > 87 cm",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Stable weight defined as < 4.5 kg gained or lost in past year",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Agreement to maintain current level of physical activity throughout the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Diagnosed with Type II diabetes mellitus with fasting blood glucose 100 - 250 mg/dl (5.6 - 13.9 mmol/L)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Ability to comprehend and complete the questionnaires and forms",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Agreement to comply with study procedures, test article consumption, and has access to a microwave oven",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Voluntary, written, informed consent to participate in the study",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Pregnant, breastfeeding, or planning to become pregnant during the course of the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Use of prescription or over the counter products known to effect weight including but not limited to the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "megestrol acetate;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "somatropin;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "sibutramine;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "orlistat;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "paroxetine;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "dextroamphetamine;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "methylphenidate;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "atomoxetine;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "quetiapine;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "olanzepine;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "risperidone, within 4 weeks of randomization and during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Unstable medication for diabetes mellitus (Dosage must be stable for 90 days prior to randomization), use of insulin is exclusionary",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Alcohol use > 2 standard alcoholic drinks per day",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Significant cardiac history defined as a history of:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "myocardial infarction (MI);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "coronary angioplasty or bypass graft(s);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "valvular disease or repair;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "unstable angina pectoris;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "transient ischemic attack (TIA);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "cerebrovascular accidents (CVA);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "congestive heart failure; or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "coronary artery disease (CAD)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission for more than 5 years are acceptable.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Uncontrolled hypertension defined as untreated systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Unstable renal and/or liver disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "History of alcohol or drug abuse within the past year",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Unstable psychiatric disorder requiring hospitalization within the past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic anemia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Participation in another clinical research trial within 30 days prior to randomization and during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Significant abnormal liver function as defined as AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Serum creatinine > 125 umol/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Anemia of any etiology defined as hemoglobin < 110 g/L",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Uncontrolled and/or untreated thyroid disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Unstable medications (Dosage must be stable for 90 days prior to randomization)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "History of food allergies or sensitivities, including lactose intolerance",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Vegetarians",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Cognitively impaired and/or unable to give informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00931034",
    "statement": "Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "For subgroup 1",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Nulligravidae aged ≥ 15 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Residing within the study area and planning to stay for the study duration",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Signed or thumb-printed informed consent obtained from participant/participant legally acceptable representatives. An assent will be obtained from minors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "For subgroups 2 and 3",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Primigravidae aged ≥ 15 years at the time of enrolment",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Residing within the study area for the last three months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Signed or thumb-printed informed consent obtained from participant/participant legally acceptable representatives. An assent will be obtained from minors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Additional criteria for subgroup 3 • Third trimester of gestational age",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "For subgroup 1 only",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Women of non-childbearing potential. Non-childbearing potential is defined as current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Women reporting established use of oral, injected or implanted hormonal contraceptives; intrauterine device or intrauterine system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "For all the subgroups",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Chronic use of i) immunosuppressive drugs, ii) or other immune modifying drugs within three months prior to enrolment in the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Known history of Human Immunodeficiency Virus (HIV) (No test will be done by the study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Use of any other investigational or non-registered product (drug or vaccine) during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Any previous participation in any malaria (vaccine) study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06162078",
    "statement": "Any other condition or situation that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have Type 2 diabetes (T2D)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have an HbA1c c ≥6.5% (≥48 mmol/mol) to ≤9.0% (≤75 mmol/mol)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have a body mass index (BMI) ≥25 kilogram per square meter (kg/m²) at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have been on a stable treatment dose of 1 of the listed GLP-1 RAs for ≥3 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "No treatment with oral antidiabetic medicine (OAM) or on stable doses (for at least 3 months before screening) of up to 3 OAM. The OAM may include metformin, sodium-glucose linked transporter-2 inhibitor (SGLT-2i), thiazolidinediones, or α-glucosidase inhibitors.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have Type 1 Diabetes (T1D)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have a clinical history of",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "proliferative diabetic retinopathy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "diabetic maculopathy, or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "non-proliferative diabetic retinopathy that requires acute treatment",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Are at high risk for cardiovascular disease or have a history of",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "myocardial infarction",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "percutaneous coronary revascularization procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "carotid stenting or surgical revascularization",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "nontraumatic amputation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "peripheral vascular procedure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "cerebrovascular accident",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "or hospitalization for congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have New York Heart Association (NYHA) Functional Classification Class IV congestive heart failure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have a history of ketoacidosis or hyperosmolar state or coma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05706506",
    "statement": "Have a history of severe hypoglycemia or hypoglycemia unawareness within the 6 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Between 19 aged and 50 aged healthy adult",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Body weight more than 55kg for male, more than 50kg for female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Body Mass Index over 18.5kg/m2 and under 27.0kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "if female, the subject must satisfy more than one of the following:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "subject who have reached menopause (no natural menstruation for at least 2 years.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "subject who is surgically infertile(hysterectomy or bilateral salpingo-oophorectomy, tubal ligation, or in infertile state under other method)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Subject who is currently with or have diagnosed with clinically significant hepatobiliary(severe hepatopathy, etc.), kidney(severe nephropathy, etc.), neurological, immunologic, respiratory, urinary, gastrointestinal endocrinological(diabetic ketoacidosis, diabetic coma, etc.), hematological, oncological, cardiovascular(heart failure, etc.) or metal illness",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Subject with one of the following laboratory test results",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "AST, ALT > UNLx1.5",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "eGRF < 60 ml/min/1.73 m2 (MDRD formula)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "immuno-serology test results in positive",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Systolic blood pressure > 150mmHg or <90mmHg, Diastolic blood pressure >100mmHg or <50mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "Subject who has history of the following and the history may affect safety of the subject or result of this study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "History of any prescription drug or herbal medicine within 14 days before first administration investigational products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "History of any non-prescription drug including health food, vitamin within 7 days before first administration investigational products",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04768673",
    "statement": "History of drug-metabolizing induction/inhibition enzyme such as barbital",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Cluster eligibility",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Within 8 hours transport of Iquitos",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Incidence <250/1000 and >2 cases year prior to trial",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Population size (<650)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Chloroquine (CQ) eligibility",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Resides in neighboring household but within 200 m of Pv index case in the past 2 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Age ≥6 months old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Present for intervention",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Adult ≥18 years old that provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "A child ≥8 years and <18 years old that provides informed assent and has informed consent from their parents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "A child ≥6 months old and <8 years old that has informed consent from their parents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Tafenoquine (TQ) eligibility",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Eligible to receive CQ",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Age ≥16 years old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Adult ≥18 years old that provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "A child ≥16 years and <18 years old that provides informed assent and has informed consent from their parents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Primaquine eligibility",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Eligible to receive CQ and ineligible to receive TQ",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Age ≥6 months old",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Adult ≥18 years old that provides informed consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "A child ≥8 years and <18 years old that provides informed assent and has informed consent from their parents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "A child ≥6 months old and <8 years old that has informed consent from their parents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Baseline evaluation and informed consent -Villagers will be eligible to participate in surveys if they slept in a household in cluster randomized to control or focal mass drug administration (fMDA) for at least one night in the past four weeks",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Eligibility for fMDA",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "High-risk villagers are defined as individuals residing in households that are within 200 meters of a Plasmodium vivax index case households from the prior 2 years (including individuals in the index case household) will be eligible to receive fMDA that cycle",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Villagers that were eligible but missed in the 1st round in a cycle, or become eligible in the next two months, will not be eligible to receive fMDA in the 2nd round in a cycle.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Chloroquine eligibility",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "History of retinal or visual field changes",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Known hypersensitivity or adverse reaction to CQ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Currently taking CQ or have taken CQ in the past four weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Ineligible for TQ or PQ (see criteria below)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Hemoglobin <9 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Tafenoquine eligibility",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "G6PD deficiency or intermediate status (defined as activity ≤6.0 UI/gHb per SD biosensor)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "G6PD status unknown or refusal of G6PD status test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Acute or severe malaria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Pregnancy (known or identified by pregnancy test)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Refusal of pregnancy test if new amenorrhea in the past 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Woman breastfeeding a child that is G6PD deficient or with unknown G6PD status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Known hypersensitivity or adverse reaction to TQ or PQ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Hemoglobin < 9 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Primaquine eligibility",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "G6PD deficiency (defined as activity ≤4.0 UI/gHb per SD biosensor)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "G6PD status unknown or refusal of G6PD status test",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Acute or severe malaria",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Pregnancy (known or identified by pregnancy test)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Refusal of pregnancy test if new amenorrhea in the past 4 weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Breastfeeding child with documented or unknown G6PD deficiency status",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Known hypersensitivity or adverse reaction to TQ or PQ",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Have taken mefloquine (i.e. artesunate- mefloquine), TQ or PQ, or other antimalarial in the past four weeks",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05690841",
    "statement": "Hemoglobin < 9 g/dL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Participants diagnosed (clinically) with type 2 diabetes mellitus (T2D) for at least 1 year prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Have been treated with basal-bolus multiple daily injection (MDI) therapy for at least 90 days prior to screening including:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Basal insulin glargine U-100, in combination with bolus insulin analog (insulin lispro, insulin aspart, or insulin glulisine) with meals.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Participant must have been treated with the same type of allowed bolus insulin analog for at least 30 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Participants may be treated with up to 3 of the following oral antihyperglycemic medications (OAMs) for T2D in accordance with local regulations:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Dipeptidyl peptidase-4 (DPP-4) inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "sodium glucose cotransporter 2 (SGLT2) inhibitor",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "oral glucagon-like peptide 1 (GLP-1) agonist",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Doses of OAMs are required to have been stable for at least 90 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Participants may be treated with injectable GLP-1 receptor agonist for T2D in accordance with local regulations. The GLP-1 receptor agonist dose is required to have been stable for at least 90 days prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Have an HbA1c value ≥7.5% and ≤10% according to the central laboratory at screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Have been diagnosed at any time with type 1 diabetes mellitus or latent autoimmune diabetes in adults.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Have had any episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia) within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Have had any episode of hyperglycemic hyperosmolar state or diabetic ketoacidosis within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04605991",
    "statement": "Have hypoglycemia unawareness as judged by the investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Ability to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Age 21-80 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Clinical history of type 2 diabetes mellitus, as defined by either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Hyperglycaemia not requiring insulin (diet, oral hypoglycaemic agents and metformin if patients serum creatinine levels were within normal limits.)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Hyperglycaemia requiring insulin with: no history of diabetic ketoacidosis AND with either the period between diagnosis and insulin usage >1 year or elevated fasting or stimulated C-peptide level",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Glycosylated haemoglobin A1 (HbA1c) ≤10%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Diabetic nephropathy, as defined by:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "serum creatinine at Screening (Visit 1) ≤265 μmol/L (3.0 mg/dL) in women and ≤283 μmol/L (3.2 mg/dL) in men",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "urinary protein/creatinine ratio ≥700 mg/g (measured in spot urine) during the run-in phase (Visit 2 or Visit 5 retest)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Hypertension at screening, as defined by either:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Mean systolic blood pressure (SBP) >130 mmHg and/or mean diastolic blood pressure (DBP) >80 mmHg in untreated patients",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Patients currently receiving antihypertensive medication (i.e. medications specifically prescribed to treat hypertension)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Ability to stop current antihypertensive therapy with Angiotensin Converting Enzyme Inhibitor (ACE-Is), Angiotensin Receptor Blockers (ARBs) and direct vasodilators, and to stop chronic immunosuppressive therapy and current therapy with metformin without risk to the patient (Investigator's discretion).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "All female patients had to have negative results from the urine pregnancy test (UPT) at Visits 1 and 6 in order to be able to continue in the study.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Pre-menopausal women (last menstruation ≤1 year prior to signing informed consent) who:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "were not surgically sterile or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "were nursing or pregnant or",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "were of child-bearing potential and were not practicing acceptable methods of birth control, or did not plan to continue practicing an acceptable method throughout the study (Note: Acceptable methods of birth control included transdermal patch, intra-uterine device, oral, implantable or injectable contraceptives) AND did not agree to periodic urine pregnancy testing (UPT) during participation in the study. No exceptions were made.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Increase of serum creatinine >35% between Visit 1 (Screening) and Visit 5. If creatinine was increased >35% at Visit 5, the measurement was to be repeated within five calendar days and if the increase was confirmed, the patient had to be excluded from the trial for safety reasons.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Non-diabetic renal disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Congestive heart failure (New York Heart Association functional class III or IV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Unstable angina, myocardial infarction, coronary artery bypass graft surgery, or percutaneous coronary intervention within the last three months prior to signing the informed consent form",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Stroke or transient ischaemic attack within the last six months prior to signing the informed consent form",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00168857",
    "statement": "Further exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "A subject is eligible for the study if all of the following criteria are met:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "A subject will be excluded if any of the following criteria are met:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Provide written informed consent prior to enrollment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Is male or female between 18-70 years old.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Has been diagnosed with type II diabetes for greater than 12 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Is currently either using lifestyle modification or taking one or two of the following oral antihyperglycemic agents and has been on stable doses for 90 days prior to screening:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "metformin",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, linaglyptin)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Pioglitazone",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Has an A l c between 7.5 - 9.0% based upon point of care testing performed at visit 1.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Currently performs self-monitoring blood glucose checks at least 3 times per week.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Able to adhere to protocol requirements.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Has Type 1 Diabetes or Gestational Diabetes.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Is pregnant or planning to become pregnant during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Current use OR use in the past 6 months of sulfonylureas.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Current use OR use in the past 6 months of insulin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "History of cardiovascular disease or cerebrovascular disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Any planned surgery during the course of the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Current continuous renal replacement therapy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Current oral or injectable steroid use or use within the previous 3 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Previous or current treatment with deep brain stimulation.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Any previous known disease, injury, or surgical intervention involving the brain or central nervous system.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Moderate or greater hearing loss.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Presence of a cochlear implant.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Diagnosed vestibular dysfunction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Eye surgery within the previous three months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Any history of previous ear surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Active ear infections or a perforated tympanic membrane.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02130401",
    "statement": "Presence of a serious or unstable medical or psychological condition which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Body Mass Index (BMI): 18 to 28 kg/m2 (inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Results of Glycosylated Hemoglobin A1c (HbA1c) value are within the normal range (4.3-5.6%, inclusive)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Results of the 75 g oral glucose tolerance test (OGTT) during screening show:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Blood glucose before OGTT <110 mg/dL.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Blood glucose 1 hour after glucose loading <180 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Blood glucose 2 hours after glucose loading <140 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "A history of relevant diseases of internal organs (diabetes mellitus, Ileus, Ileus-like symptoms, diseases that may significantly jeopardize body systems",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Febrile illness within 1 week before drug administration",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Family history of diabetes (within the second degree of relationship)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Known drug hypersensitivity or idiosyncrasy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Known severe allergies, non-allergic drug reactions, or multiple drug allergies",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Habitual medication including Chinese herbal drugs",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Intake of any drugs within 2 weeks of drug administration of period 1",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Regular daily consumption of more than 1 L of usual beer or the equivalent quantity of approximately 40 g of alcohol in another form",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Donation of more than 150 mL of blood within 4 weeks before the screening examination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01728740",
    "statement": "Participation in another clinical trial within 4 weeks before the screening examination",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Subjects aged 18 to 74 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Provision of signed and dated written informed consent prior to any study specific procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "BMI between 25 and 35 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "HbA1c range of 7% to 8.5%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Willing and able to self-inject investigational product",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Diagnosed with T2DM with glucose control managed with metformin monotherapy where no significant dose change has occurred in the three months prior to screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Women of child-bearing potential who are sexually active with a male partner must be using at least one highly effective method of contraception. And must have a negative serum or urine pregnancy test within 72 hours prior to the start of IP, and must not be breastfeeding.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Any subject who has received another IP as part of a clinical study or a GLP-1 analogue containing preparation within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Concurrent participation in another randomization study of any kind; repeat randomization is prohibited",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Any subject who has received any of the following medications within the specified timeframe prior to the start of the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Herbal preparations for control of body weight or appetite",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Drugs licensed for control of body weight or appetite",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Opiates, domperidone, metoclopramide, or other drugs known to alter gastric emptying",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Antimicrobials within the quinolone (eg, ciprofloxacin), macrolide (eg, clarithromycin) or azole class (eg, ketoconazole)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Any change in antihypertensive medication",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Aspirin (acetylsalicylic acid) at a dose greater than 150 mg once daily",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Paracetamol (acetaminophen) or paracetamol-containing preparations at a total daily dose of greater than 3000 mg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Ascorbic acid (vitamin C) supplements at a total daily dose of greater than 1000 mg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Symptoms of acutely decompensated blood glucose control, recent severe hypoglycemia, a history of T1DM orDKA",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Acute pancreatitis at screening or history of acute pancreatitis or chronic pancreatitis or serum triglyceride levels > 11 mmol/L at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Significant inflammatory bowel disease, gastroparesis or other severe disease or surgery affecting the upper GI tract, which may affect gastric emptying or could affect the interpretation of safety and tolerability data",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Significant hepatic disease (except for NASH or NAFLD without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "AST ≥ 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "ALT ≥ 3 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "TBL ≥ 2 × ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Impaired renal function defined as eGFR< 30 mL/minute/1.73m2 at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Poorly controlled hypertension defined as:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "SBP > 160 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "DBP or ≥ 90 mmHg - After 10 minutes of supine rest and confirmed by repeated measurement at screening. Subjects who fail BP screening criteria may be considered for 24-hour ABPM at the discretion of the investigator. Subjects who maintain a mean 24-hour BP < 160/100 mmHg with a preserved nocturnal dip of > 15% will be considered eligible.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Any clinically important abnormalities in rhythm, conduction, or morphology of the resting 12-lead ECG or any abnormalities that may interfere with the interpretation of serial ECG changes, including QTc interval changes at screening, as judged by the investigator, and prolonged QTcF > 450 ms, or family history of long QT-segment at screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "PR (PQ) interval prolongation, intermittent second (Wenckebach block while asleep is not exclusive), or third-degree AV block, or AV dissociation",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Persistent or intermittent complete bundle branch block.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Severe congestive heart failure (NYHA Class III or IV)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Basal calcitonin level ≥ 50 ng/L at screening or history/family history of medullary thyroid carcinoma or MEN2",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Any positive results for serum hepatitis B surface antigen, hepatitis C antibody, and HIV antibody",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "History of substance dependence, alcohol abuse, or excessive alcohol intake within 3 years prior to screening and/or a positive screen for drugs of abuse or alcohol at screening or on admission to the study unit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Symptoms of depression or any other psychiatric disorder requiring treatment with medication (eg, anti-depressants, anti-psychotics) at screening. However, subjects who use benzodiazepines for chronic anxiety or sleep disorders may be permitted to enter the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "History of severe allergy/hypersensitivity, including to any component of the investigational product formulation or other biological agent, or ongoing clinically important allergy/hypersensitivity as judged by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Blood/plasma donation within 1 month of screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "Involvement of any AstraZeneca, the contract research organization, or the virtual study site employee or their close relatives",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05437848",
    "statement": "For women only- currently pregnant (confirmed with positive pregnancy test) or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Treatment with metformin for at least 2 months",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Has HbA1c 7.0% to 11.0%, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Body mass index (BMI)25 kg/m^2 to 45 kg/m^2, inclusive",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "List of medications that are not allowed or the patient has been on stable treatment for at least 2 months:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Hormone replacement therapy (female subjects)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Oral contraceptives (female subjects)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Antihypertensive agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Lipid-lowering agents",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Thyroid replacement therapy",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Has been treated with exenatide (BYETTA®) or any DPP-4 inhibitor prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Received any study medication or participated in any type of clinical trial within 30 days prior to screening",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Has donated blood within 60 days of screening visit or is planning to donate blood during the study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Treated with any of the following medications:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Sulfonylurea or Thiazolidinedione within 3 months of screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®)within 30 days of screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 6 months of screening;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Drugs that directly affect gastrointestinal motility, including but not limited to, anticholinergics, macrolide antibiotics, dopamine antagonists, opioids, and Reglan®(metoclopramide);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00477581",
    "statement": "Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Older participants, aged 70 years and above, with T2DM inadequately controlled on their current anti-diabetic pharmaceutical treatment regimen.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Signed written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "At screening HbA1c ≤7.0% or >10% (Acknowledging that the threshold of 7% may not be appropriate for all older participants and that this was the responsibility of the investigator to include the participant based on an individual evaluation of the expected benefits of better glycemic control versus risk of hypoglycemia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "At screening participants on both basal insulin and sulfonylurea or basal insulin and meglitinides.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "At screening FPG >250 mg/dL (>13.9 mmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Type 1 diabetes mellitus or history of ketoacidosis within one year prior to the screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Type 2 diabetes mellitus diagnosed less than 1 year prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Anti-diabetic treatment not at a stable regimen or initiated within the last 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Treatment within the 3 months preceding the screening with other anti-diabetic agent than allowed background therapy. Allowed therapy includes metformin, sulfonylurea (except glibenclamide >10mg, gliclazide >160mg), meglitinides (except repaglinide >6mg), pioglitazone and basal insulin and should follow local product circulars and labeling restrictions for the study population.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Participants who had been on an approved or an investigational Glucagon-like peptide 1 (GLP-1) medication (exenatide, liraglutide, lixisenatide or others).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "History of severe hypoglycemia associated with symptoms unawareness or results in unconsciousness/coma/seizure in the 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "BMI <22 or >40 kg/m^2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Malnutrition assessed clinically by the investigator or any sub-investigator and by Mini-Nutritional Assessment-Short Form (MNA-SF) score <12 in countries (the judgment of the investigator prevails on questionnaires scores).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Cognitive disorder and dementia assessed clinically by the investigator or any sub investigator and by Mini Mental State Examination (MMSE) score <24 (the judgment of the investigator prevails on questionnaires scores), or any neurologic disorder that affected the participant's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Participant who had a glomerular filtration rate (eGFR) (using the Modification of Diet in Renal Disease (MDRD) formula <30ml/min/1.73m^2).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Participant with severe or uncontrolled disease, or any clinically significant abnormality identified on physical examination or investigational clinical procedure that, in the judgment of the investigator or any sub-investigator, would preclude safe completion of the study or constrains efficacy assessment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Laboratory findings at the time of screening:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Amylase and/or lipase: >3 times the upper limit of the normal (ULN) laboratory range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 times ULN",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Calcitonin >20 pg/mL (5.9 pmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (i.e. worsening) and not controlled (i.e. prolonged nausea and vomiting) gastroesophageal reflux disease within 6 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT01798706",
    "statement": "Personal or immediate family history of medullary thyroid cancer or genetic conditions that predisposed to medullary thyroid cancer (e.g., multiple endocrine neoplasia syndromes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject is at least 18 years of age;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject has had a diagnosis of diabetes mellitus either Type I or Type II;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "For insulin-using subjects only: subject will not inject insulin or wear an insulin pump insertion set within a 10 cm distance of any Bios device;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject able to wear multiple CGM devices simultaneously;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject is either a patient diagnosed with Type I diabetes mellitus currently wearing a Dexcom CGM device or a patient diagnosed with Type II diabetes mellitus who will agree to use a Dexcom CGM device during participation in the study. There are no restrictions on the model of the Dexcom CGM device.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject agrees to provide a log of medications (prescription and over-the-counter) and dietary supplements (e.g., vitamins) taken during the study period, including dosage;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject has a smart device that complies with the requirements listed in Attachment 1 of this protocol and is willing to download and run the GraphWear Patient application on their device;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject is able to read and understand the Informed Consent Form and has voluntarily provided written informed consent;",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "In the Principal Investigator's opinion, subject is able to be compliant with provisions laid out in this protocol.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject has any of the following:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "a skin condition that precludes wearing of the device;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "a known allergy that precludes wearing of the device;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "tattoos or other skin alterations that may interfere with device placement and/or operation;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "History of substance abuse within 6 months of study start;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Use of any illicit drugs during the duration of the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Marijuana use during the duration of the study period;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "If female, subject is pregnant or nursing;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subject is on active dialysis;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT04226846",
    "statement": "Subjects whom the Principal Investigator believes may not be an appropriate candidate for this device.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Ability and willingness to participate in the study, give written informed consent, and comply with the study restrictions and all protocol procedures",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Sex: male or female",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Weight: >50 kg, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Age:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "For Part A 18 to 70 years, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "For Part B, Part B-EXT, and C 18 to 55 years, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Body Mass Index",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "For Part A:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "≥18.5 kg/m2 and ≤35.0 kg/m2, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "For Part B and Part B-EXT: ≥30.0 kg/m2 and ≤40.0 kg/m2, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "For Part C:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "≥25.0 kg/m2 and ≤40.0 kg/m2, inclusive, at screening",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Patients with T2DM for at least 6 months, having HbA1c of 6.5% to 8.5% (Part C)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "History or clinically significant active disease of the gastrointestinal, cardiovascular, hepatic, neurologic, renal, pancreatic, immunologic, dermatologic, endocrine, genitourinary, or hematologic system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Uncontrolled hypertension",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "History of type 1 diabetes mellitus",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "History or current diagnosis of acute or chronic pancreatitis or factors for pancreatitis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 or subjects with suspected medullary thyroid carcinoma",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05579314",
    "statement": "Existence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution, metabolism, or excretion of the investigational product",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Japanese male or female patients with T2DM treated with diet and exercise alone or with one hypoglycaemic drug other than glitazones.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Hemoglobin A1c (HbA1c) at screening (Visit 1)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "For patients treated with 1 other oral antidiabetic drug: HbA1c between 6.5% and 9.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "For patients not treated with any antidiabetic drug: HbA1c between 7.0% and 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Age between 20 and 70 years",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Body mass index (BMI) between18.0 and 40.0 kg/m2",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Signed and dated written informed consent before admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Antidiabetic treatment with insulin or glitazones within 3 months before obtaining informed consent or with more than 1 oral hypoglycaemic agent at the time of informed consent",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Fasted blood glucose of >240 mg/dL (>13.3 mmol/L) or a randomly determined blood glucose level of >400 mg/dL (22.2 mmol/L) on 2 consecutive days during wash-out period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Myocardial infarction, stroke, or transient ischaemic attack within 6 months before informed consent.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Clinically relevant concomitant diseases other than T2DM, hyperlipidaemia, and medically treated hypertension before the first administration such as",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Renal insufficiency (calculated estimated glomerular filtration rate <60)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Cardiac insufficiency of New York Heart Association (NYHA) II-IV or other known cardiovascular diseases including hypertension of >160/95 mmHg,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Neurological disorders (such as epilepsy) or psychiatric disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Acute or clinically relevant chronic infections (e.g., human immunodeficiency virus, hepatitis, repeated urogenital infections)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Patients under treatment with any concomitant medication except for the following drugs at the time of informed consent.:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Statins.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Antihypertensives (diuretics not allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "alpha-Blockers for benign prostate hypertrophy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Occasional use of acetylsalicylic acid, ibuprofen, or paracetamol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00885118",
    "statement": "Additional inclusion/exclusion criteria apply",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Inclusion Critieria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Patients are able to provide signed and dated written informed consent prior to any study specific procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Women are post-menopausal (defined as at least 1 year post cessation of menses) and aged ≥ 45 and ≤ 70 years. Males are aged ≥ 40 years and ≤ 70 years. Patients should have suitable veins for cannulation or repeated venipuncture.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Patients are diagnosed with T2DM for at least the last 6 months.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Patients are on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months5. HbA1c levels ≥6.0% (=42 mmol/mol) and ≤9.0% (75 mmol/mol).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Have a body mass index (BMI) ≤ 35 kg/m2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Contraindications to dapagliflozin according to the local label.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Use of antidiabetic drugs other than metformin within 3 months prior to screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "History of drug abuse or alcohol abuse in the past 12 months.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Use of loop diuretics.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Regular smoking and other regular nicotine use.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Any contra-indication to magnetic resonance imaging scanning. These contra-indications include patients with following devices:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Central nervous system aneurysm clip",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Implanted neural stimulator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Implanted cardiac pacemaker of defibrillator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Cochlear implant",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Metal containing corpora aliena in the eye or brain.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT03338855",
    "statement": "Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Drugs and Alcohol",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Healthy male subjects aged 18 to 55 years inclusive.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Body Mass Index (BMI) is between 19-35kg/m2 (inclusive), with a minimum body weight of 45kg.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject must read and write at a comprehension level that is sufficient to provide written informed consent, and be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has provided informed consent to participate in the study as indicated by providing a signed and dated written informed consent form prior to the initiation of any study procedures.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "General",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Presence of any clinically relevant abnormality identified on the screening medical assessment, laboratory examination or 12-lead ECG, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study. These include any unstable medical disorder; disorders that would interfere with the action, absorption, distribution, metabolism, or excretion of bupropion or GSK189075; disorders which may pose a safety concern or interfere with the accurate assessment of safety or efficacy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Laboratory",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Clinically significant abnormalities at Screening including:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Systolic blood pressure outside the range of 90 - 140 mmHg, diastolic blood pressure outside the range of 50 - 90 mmHg, and pulse rate at rest > 100 and < 45 bpm.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Positive tests for hepatitis B surface antigen, hepatitis C antibodies, and HIV.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Positive cotinine, drug and/or alcohol test.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Significant ECG abnormalities are defined as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Parameter Range",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Heart Rate < 40 and >100 bpm",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "PR Interval <120 and > 220 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "QRS duration < 70 and >120 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "QTC Interval (Bazett) > 450 ms",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "ALT, alkaline phosphatase, or total bilirubin ³ 1.5 times the upper limits of normal (Note: Subjects with an increased total bilirubin may enter the study only if direct bilirubin is within normal limits).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Fasting triglycerides >400 mg/dL (>11.3 mmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Clinically significant abnormalities of T3 and TSH.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Serum creatinine clearance <60ml/min (estimated from serum creatinine (SCr) and demographic data using the MDRD calculation):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "A validated web-based calculator is found at:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "http://nephron.com/cgi-bin/MDRDSIdefault.cgi",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "To calculate estimated GFR (mL/min/1.73m2) manually:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "= 186 x (SCr in mg/dL)-1.154 x (age)-0.203 x (0.742 if female) x (1.210 if African-American)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "= exp(5.228-1.154 x ln (SCr)-0.203x ln(age)-(0.299 if female) + (0.192 if African American))",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Any other clinically significant laboratory abnormality as determined by the Principal Investigator in consultation with the GSK Medical Monitor.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Central Nervous System",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Current diagnosis or a previous history of mania, psychosis, major depression, or other major psychiatric disorder.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Current or past history of seizure disorder or brain injury (traumatic or disease-related); or any condition which, in the opinion of the investigator, predisposes to seizure; those treated with other medications or treatment regimes that lower seizure threshold; those undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines or benzodiazepine-like agents).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Note: A single childhood febrile seizure is not exclusionary.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History or current diagnosis of anorexia nervosa or bulimia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subjects who, in the investigator's judgement, pose a homicidal or suicidal risk, have ever made a suicide attempt, or have ever been homicidal.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Hepatic and Gastrointestinal systems",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of hepatic disease or known hepatic or biliary abnormalities, (with the exception of previously documented diagnosis of Gilbert's syndrome) and/or a history of biliary or gastrointestinal disorder, which might affect absorption, distribution, metabolism, or excretion of drugs (except appendectomy or cholecystectomy more than 12 weeks prior to the study).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Endocrine system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Untreated or unstable thyroid disease. Subjects taking thyroid medications must be on a stable dosing regimen for at least 4 weeks prior to the first dose of study drug until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Cardiac system",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of clinically significant cardiac rhythm disorder or QTc interval ³450 milliseconds at Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has history of ischemic heart disease, including stable/unstable angina or acute myocardial infarction.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Uncontrolled hypertension with systolic blood pressure >140mm Hg and diastolic blood pressure >90mm Hg.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of alcohol abuse or an average weekly intake of greater than 21 units per week (one unit = 1 glass of wine = 1 measure of spirits = ½ pint of beer).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Unwilling or unable to abstain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of tobacco in any form (smoking cigarettes, cigars, and/or pipes, or chewing tobacco-containing products), for 4 weeks prior to Screening until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Unwilling or unable to abstain from the use of prescription or non-prescription drugs, vitamins, or dietary/herbal supplements within 1 week prior to the first dose of study drug until completion of the Follow-up visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject is currently using medications that may alter gastric/small bowel motility, result in diarrhea, or bind concomitant medications. For example, but not limited to: erythromycin, antacids, prokinetic agents and cholestyramine.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Subject has a history of drug or other allergy that, in the opinion of the Principal Investigator, contraindicates their participation in this study. • Concomitant medications usage that includes:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of agents that are known to inhibit or induce cytochrome P450 enzymes within 14 days prior to the first dose of study medication , including grapefruit-containing products and St. John's Wort.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of bupropion hydrochloride or GSK189075 within the last 6 months prior to Screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of anti-depressant medication for clinically significant depression.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose in Treatment Period 1, unless in the opinion of the Investigator and Sponsor the medication will not interfere with the study procedures or compromise subject safety.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Note: Occasional use of acetaminophen and ibuprofen according to directions provided in the product label may be acceptable during the study, at the discretion of the Principal Investigator. Acetaminophen will be limited to doses up to 2 grams/day and ibuprofen at doses up to 1.2 grams/day.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Drug hypersensitivity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of hypersensitivity to WELLBUTRIN SR, ZYBAN, GSK189075 or any of their constituents or closely related compounds.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "History of sensitivity to heparin or heparin-induced thrombocytopenia.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Other",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Past treatment with a new molecular entity (investigational drug) or any other trial during the previous 30 days, or 5 half-lives, whichever is longer. A new molecular entity is defined as any compound not in Phase 3. (The washout period of 30 days is counted from the last dose of study drug in the previous study until the first dose of study drug).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00625859",
    "statement": "Participation in the study would result in subject's donation of blood in excess of 500mL within a 56-day period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Men and women aged 19 years or older as of the date of written consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with type 2 diabetes who have been on up to 3 antidiabetic medications at a stable dosage and regimen for at least 8 weeks prior to the Pre-Baseline Visit (Visit 1-1). For insulin, a fluctuation of within 10% during the 8 weeks prior to the Pre-Baseline Visit (Visit 1-1) is allowed.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with a BMI of 18 to 45 kg/m² at the Screening Visit (Visit 1).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients whose test results from the investigational site&#39;s laboratory at the Screening Visit (Visit 1) meet all of the following criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "HbA1c: 7.0% ≤ HbA1c ≤ 10.0%",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "eGFR: 30 ≤ eGFR &lt; 60 ml/min/1.73 m² (using the CKD-EPI formula)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients who are willing to cooperate and participate in this clinical trial after understanding the explanation of the trial and who can voluntarily sign the informed consent form.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients whose central laboratory results from the sample collected at the Pre-Baseline Visit (Visit 1-1) show an eGFR of 30 ≤ eGFR &lt; 60 ml/min/1.73 m² (using the CKD-EPI formula).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients whose central laboratory results from the sample collected at the Pre-Baseline Visit (Visit 1-1) show an HbA1c of 7.0% ≤ HbA1c ≤ 10.0%.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with a medication compliance rate of 70-130% during the Run-in Period, as confirmed at the Baseline Visit (Visit 2).",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals diagnosed with renal diseases other than diabetic chronic kidney disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Patients with uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals diagnosed with type 1 diabetes (insulin-dependent diabetes) or diabetic ketoacidosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals who are undergoing dialysis at the time of the Screening Visit (Visit 1) or have a history of renal transplantation or medically significant renal disease/surgery (e.g., renal vascular occlusive disease, nephrectomy)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals who have received cytotoxic treatment, immunosuppressive therapy, or immunotherapy for renal disease within 6 months of the Baseline Visit (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals diagnosed with or treated for any of the following diseases within 3 months of the Screening Visit (Visit 1), as determined by the investigator to be clinically significant:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Severe heart disease [heart failure (NYHA class III and IV), ischemic heart disease (angina, myocardial infarction), peripheral vascular disease, individuals who have undergone percutaneous transluminal coronary angioplasty or coronary artery bypass grafting] * NYHA class:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class I: No limitation on physical activity; no symptoms during ordinary activities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class II: Slight limitation on physical activity; no symptoms at rest, but symptoms occur during ordinary activities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class III: Marked limitation on physical activity; no symptoms at rest, but symptoms occur with less than ordinary activities",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Class IV: Symptoms present even at rest, and worsened by any physical activity",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic or mitral valve stenosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter, arrhythmia",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Transient ischemic attack",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Severe cerebrovascular diseases (e.g., stroke, cerebral infarction, cerebral hemorrhage)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals requiring treatment due to dehydration from continuous diarrhea or vomiting, or those at risk of fluid volume depletion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals unable to take medications orally, or with major gastrointestinal diseases or surgeries (e.g., gastrectomy, gastrointestinal bypass) that may affect drug absorption, distribution, metabolism, or excretion",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with positive results from the serology tests at the Screening Visit (Visit 1):",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Positive for HIV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Positive for HBsAg with HBV DNA ≥ 2000 IU/mL",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Positive for Anti-HCV",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with severe liver dysfunction at the Screening Visit (Visit 1) as follows:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "AST or ALT &gt; 3 times the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Total bilirubin &gt; 2 times the upper limit of normal",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with more than a 25% change in eGFR between the Screening Visit (Visit 1) and the Baseline Visit (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with clinically significant severe infections (e.g., those requiring continuous antibiotic or immunotherapy) or severe trauma, as determined by the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with a past or present diagnosis of malignant tumors (participation allowed if cured or if there has been no recurrence in the past 5 years)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with a history of hypersensitivity to the active ingredient or components of the investigational drug",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals with a history of alcohol or drug abuse within 12 months of the Screening Visit (Visit 1)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals taking ACE inhibitors, ARBs, or renin inhibitors (allowed if taken at a stable dose and regimen for more than 8 weeks prior to the Pre-Baseline Visit (Visit 1-1))",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals requiring continuous systemic corticosteroid treatment (use of topical corticosteroids for joint, nasal, ocular, or inhalation administration, or temporary systemic corticosteroid use for contrast agent allergies or adverse event treatment/prevention is allowed)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Women of childbearing potential who do not agree to use appropriate contraception* during the trial A. Women over 50 years of age who have been amenorrheic for at least 12 months after discontinuing exogenous hormone therapy B. Women with a history of irreversible surgical infertility (e.g., hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) (tubal ligation not allowed) C. Women under 50 years of age who have been amenorrheic for at least 12 months after discontinuing exogenous hormone therapy and whose luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels are within postmenopausal ranges according to the investigational site&#39;s standards Appropriate contraception: Complete abstinence, tubal ligation, hormonal contraceptives with no known drug interactions [levonorgestrel intrauterine system (IUS) (Mirena), medroxyprogesterone injection], copper intrauterine devices, and partner's vasectomy. Periodic abstinence (e.g., calendar methods, basal body temperature method, or post-ovulation method) and withdrawal are not considered acceptable contraceptive methods.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Men who have not undergone vasectomy and who do not agree to use barrier contraception (e.g., condoms), or whose partners do not agree to use appropriate contraception during the trial",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Pregnant or breastfeeding women, or women with a positive pregnancy test result at the Screening Visit (Visit 1) or Baseline Visit (Visit 2)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Individuals who received investigational drugs within 8 weeks prior to the Screening Visit (Visit 1) (participation allowed if no investigational drug was administered or if involved in a non-interventional observational study)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT06606093",
    "statement": "Other individuals deemed inappropriate for trial participation at the discretion of the investigator",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "Before participating in the clinical trial, a person who fully explained the purpose, content, and characteristics of the clinical trial drug and signed a written consent form approved by the IRB of Chungbuk University Hospital to participate in this study according to his free will.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "Healthy adults aged 19 or older at the time of screening.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "Those who weigh more than 50.0 kg in men and women, and have a body mass index (BMI) of 18.0 kg/m2 or more and less than 30.0 kg/m2 or less in women.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "Body mass index (BMI) = Weight (kg) / [Height (m)] 2.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "A person with a clinically significant history in liver, kidney, neuropsychiatric system, respiratory system, endocrine system, blood and tumor system, cardiovascular system (including orthostatic hypotension), digestive system, musculoskeletal system, etc.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "A history of gastrointestinal diseases (e.g., esophageal diseases such as Crohn's disease, esophageal achalasia, or esophageal stenosis) or surgery (except appendectomy, hernia).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "Those who are hypersensitive to other drugs (DPP-4 inhibitors, etc.) or have a history of clinically significant hypersensitivity reactions, including DWP16001, DWC202213 and homogeneous (SGLT2 inhibitors)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "A person who shows the following results in the inspection items conducted during screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "Blood ALT, AST, Total bilirubin > twice the upper limit of the normal range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "The glomerular filtration rate (e-GFR) <90 mL/min/1.73 m2 (using the CKD-EPI method)",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT05737771",
    "statement": "After more than 3 minutes of rest, systolic blood pressure > 150 mmHg or <90 mmHg, or diastolic blood pressure > 100 mmHg or <60 mmHg, or pulse ≤ 40 bpm or ≥ 100 bpm in vital signs measured at the seat",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Exclusion Criteria for randomization at the end of the screening period:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Participants with type 2 diabetes mellitus diagnosed for at least 1 year before the screening visit, treated for at least 3 months prior to visit 1 with metformin alone or metformin and a second oral anti-diabetic treatment that could be a sulfonylurea, a glinide, a sodium glucose co-transporter-2 inhibitor or a di-peptidyl peptidase 4 (DPP-4) inhibitors, and who were not adequately controlled with this treatment.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Signed written informed consent.",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "HbA1c at screening visit:",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "less than 7.5% or more than 10% for participants previously treated with metformin alone,",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "less than 7.0% or more than 9% for participants previously treated with metformin and a second oral anti-diabetic treatment.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Use of oral glucose-lowering agents other than those stated in the inclusion criteria or any injectable glucose-lowering agents during the 3 months before screening.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Previous Treatment with insulin (except for short-term treatment due to intercurrent illness including gestational diabetes, at the discretion of the trial physician).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "History of discontinuation of a previous treatment with a glucagon-like peptide (GLP-1) receptor agonist (GLP-1 RA) due to safety/tolerability issue or lack of efficacy.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Participant who previously participated in any clinical trial with lixisenatide or the insulin glargine/lixisenatide fixed ratio combination or had previously received lixisenatide.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Any contraindication to metformin use, according to local labeling.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Use of weight loss drugs within 3 months prior to screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Within the last 6 months prior to screening visit: history of stroke, myocardial infarction, unstable angina, or heart failure requiring hospitalization. Planned coronary, carotid or peripheral artery revascularisation procedures to be performed during the study period.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy was already performed), chronic pancreatitis, pancreatitis during a previous treatment with incretin therapies, pancreatectomy, stomach/gastric surgery.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (e.g, multiple endocrine neoplasia syndromes).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Uncontrolled or inadequately controlled hypertension (systolic blood pressure above 180 mmHg or diastolic blood pressure above 95 mmHg) at screening visit.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "At screening visit, Body Mass Index (BMI) less than or equal to 20 or above 40 kg/m^2.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "At screening visit amylase and/or lipase more than 3 times the upper limit of the normal (ULN) laboratory range.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "At screening visit alanine aminotransferase (ALT) or alkaline phosphatase (AST) more than 3 ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "At screening visit calcitonin above or equal to 20 pg/mL (5.9 pmol/L).",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "HbA1c less than 7% or above 10%;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Fasting Plasma glucose above 250 mg/dL (13.9 mmol/L);",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Metformin maximal tolerated dose less than 1500 mg/day;",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT02058147",
    "statement": "Amylase and/or lipase more than 3 ULN.",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Informed Consent",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "70 years of age or less",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Have 2 or more of the following obesity-related co-morbid conditions:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Systolic blood pressure 140-160 mmHg (130-160 if diabetic);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Diastolic blood pressure 90-100 mmHg (85-100 if diabetic);",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Requirement for 2 or more medications to achieve control (<140/90 mmHg)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to achieve control (<200 mg/dL)",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "At lease one of the following metabolic criteria:",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Fasting blood glucose level > 100 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Glucose level > 140 mg/dL",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Diagnosis of type 2 diabetes",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Waist circumference ≥ 102 cm for men or ≥88 cm for women",
    "type": "Inclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Stroke/MI/unstable cardiovascular disease within 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Clinically significant renal, hepatic or psychiatric disease",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Unstable thyroid disease or replacement therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Nephrolithiasis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Obesity of known genetic or endocrine origin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Participation in a formal weight loss program or lifestyle intervention",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Glaucoma or intraocular pressure",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Pregnancy or breastfeeding",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Drug or Alcohol abuse",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Smoking cessation within previous 3 months or plans to quit smoking during study",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Eating disorders",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Cholelithiasis within past 6 months",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Excluded medications",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Type 1 diabetes or use of any antidiabetic medication other than metformin",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Previous bariatric surgery",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Bipolar disorder or psychosis",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Steroid hormone therapy",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg",
    "type": "Exclusion",
    "tags": {}
  },
  {
    "nctId": "NCT00553787",
    "statement": "Creatinine clearance < 60 mL/minute",
    "type": "Exclusion",
    "tags": {}
  }
]